

CITATION REPORT

List of articles citing

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

DOI: 10.1016/s1474-4422(09)70299-6
Lancet Neurology, The, 2010, 9, 119-28.

Source: <https://exaly.com/paper-pdf/47979620/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2264	Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. 2010 , 67, 308-16		130
2263	Evidence of syntaxin 1A involvement in migraine susceptibility: a Portuguese study. 2010 , 67, 422-7		10
2262	Geriatric medicine, Japanese Alzheimer's disease neuroimaging initiative and biomarker development. 2010 , 221, 87-95		8
2261	A mitocentric view of Alzheimer's disease suggests multi-faceted treatments. 2010 , 20 Suppl 2, S591-607		83
2260	Cerebrospinal Fluid Tau and Amyloid β Proteins Do Not Correlate With Cognitive Functioning in Cognitively Impaired Memory Clinic Patients. 2010 , 15, 588-593		4
2259	Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. 2010 , 21, 1119-28		94
2258	Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. 2010 , 119, 523-41		267
2257	Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. 2010 , 120, 385-99		65
2256	A cortical form of CADASIL with cerebral A β amyloidosis. 2010 , 120, 813-20		11
2255	The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. 2010 , 257, 2004-14		38
2254	Early Alzheimer's trials: new developments. 2010 , 14, 293		6
2253	Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer's disease. 2010 , 14, 640-7		6
2252	Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice. 2010 , 1, 305-16		6
2251	Why pleiotropic interventions are needed for Alzheimer's disease. 2010 , 41, 392-409		124
2250	Alzheimer's disease: progress in prediction. <i>Lancet Neurology, The</i> , 2010 , 9, 4-5	24.1	48
2249	Thinking outside the box about COX-1 in Alzheimer's disease. 2010 , 38, 492-4		7
2248	Inverse association between CSF A β 42 levels and years of education in mild form of Alzheimer's disease: the cognitive reserve theory. 2010 , 40, 456-9		26

2247	Diagnosis and biomarkers of predementia in Alzheimer's disease. 2010 , 8, 89	76
2246	Current awareness in geriatric psychiatry. 2010 , 25, i-viii	
2245	Beyond diagnosis: what biomarkers are teaching us about the "bio"logy of Alzheimer disease. 2010 , 67, 283-5	4
2244	Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid A β -42. 2010 , 68, 825-34	123
2243	Modeling cognitive trajectories within longitudinal studies: a focus on older adults. 2010 , 58 Suppl 2, S313-8	13
2242	Multiple myeloma presenting as hyperammonemic encephalopathy. 2010 , 58, 1620-2	7
2241	Cerebrospinal fluid biomarkers in Alzheimer's disease: are the hypotheses more dynamic than the biomarkers?. 2010 , 58, 1619-20	1
2240	Presenilin/gamma-Secretase and Inflammation. 2010 , 2, 16	15
2239	Staging anti-inflammatory therapy in Alzheimer's disease. 2010 , 2, 142	27
2238	In vivo imaging biomarkers in mouse models of Alzheimer's disease: are we lost in translation or breaking through?. 2010 , 2010,	11
2237	Preclinical diagnosis of Alzheimer's disease: Prevention or prediction?. 2010 , 4, 259-261	2
2236	Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease. 2010 , 2010,	20
2235	The effect of the APOE-epsilon4 allele and ACE-I/D polymorphism on cognition during a two-year follow-up in first-ever stroke patients. 2010 , 29, 534-42	11
2234	Errors in Table in: Evidence of Syntaxin 1A Involvement in Migraine Susceptibility: A Portuguese Study. 2010 , 67, 920	
2233	Cerebrospinal fluid tau protein levels and 18F-fluorodeoxyglucose positron emission tomography in the differential diagnosis of Alzheimer's disease. 2010 , 30, 245-53	7
2232	Challenges of High-resolution Diffusion Imaging of the Human Medial Temporal Lobe in Alzheimer Disease. 2010 , 21, 355-65	4
2231	Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. 2010 , 30, 13861-6	220
2230	Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer's disease. 2010 , 22, 971-80	37

2229	Quantitative structural MRI for early detection of Alzheimer's disease. 2010 , 10, 1675-88	45
2228	Circulating levels of brain-derived neurotrophic factor: correlation with mood, cognition and motor function. 2010 , 4, 871-87	116
2227	Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. 2010 , 133, 3336-48	377
2226	Serial MRI and CSF biomarkers in normal aging, MCI, and AD. 2010 , 75, 143-51	117
2225	Relationship of dementia screening tests with biomarkers of Alzheimer's disease. 2010 , 133, 3290-300	77
2224	Estimating and disclosing the risk of developing Alzheimer's disease: challenges, controversies and future directions. 2010 , 5, 501-517	19
2223	Tarot decks and PET scans: predicting the future of MCI. 2010 , 75, 204-5	2
2222	[Which properties are necessary for a marker in early and differential diagnosis of neurodegenerative disease?]. 2010 , 78, 443-4	
2221	Prävention von Demenzen. 2010 , 4, 361-372	
2220	Biomarkers of PD progression: is CSF the answer?. 2010 , 75, 1036-7	4
2219	The clinical use of structural MRI in Alzheimer disease. 2010 , 6, 67-77	1131
2218	Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's. 2010 , 68, 913-21	37
2217	YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. 2010 , 68, 903-12	298
2216	Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment. 2010 , 31, 1452-62, 1462.e1-2	61
2215	Boosting power for clinical trials using classifiers based on multiple biomarkers. 2010 , 31, 1429-42	133
2214	Automated MRI measures predict progression to Alzheimer's disease. 2010 , 31, 1364-74	71
2213	The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. 2010 , 31, 1263-74	105
2212	Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline. 2010 , 31, 1419-28	52

2211	Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment. 2010 , 31, 1443-51, 1451.e1	45
2210	Ventricular maps in 804 ADNI subjects: correlations with CSF biomarkers and clinical decline. 2010 , 31, 1386-400	45
2209	3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. 2010 , 31, 1284-303	114
2208	'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease?. 2010 , 33, 381-9	139
2207	Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. 2010 , 6, 239-46	308
2206	The Alzheimer's disease neuroimaging initiative: progress report and future plans. 2010 , 6, 202-11.e7	332
2205	Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. 2010 , 6, 230-8	209
2204	Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. 2010 , 6, 367-77	36
2203	Alzheimer's Disease Neuroimaging Initiative special issue. 2010 , 31, 1259-62	14
2202	Sharpen that needle. 2010 , 67, 918-20	34
2201	Role of structural MRI in Alzheimer's disease. 2010 , 2, 23	76
2200	Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. 2010 , 2, 20	54
2199	Pro: Can biomarkers be gold standards in Alzheimer's disease?. 2010 , 2, 17	9
2198	Con: Can neuropathology really confirm the exact diagnosis?. 2010 , 2, 11	16
2197	Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?. 2010 , 2, 8	16
2196	Alzheimer disease: MRI and CSF biomarkers in AD--accuracy and temporal change. 2010 , 6, 650-1	4
2195	Bapineuzumab. 2010 , 10, 1121-30	70
2194	Should olfactory dysfunction be used as a biomarker of Alzheimer's disease?. 2010 , 10, 633-5	43

2193	Amyloid imaging and memory change for prediction of cognitive impairment. 2011 , 3, 3	23
2192	PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease. 2011 , 3, 11	32
2191	Amyloid imaging in prodromal Alzheimer's disease. 2011 , 3, 26	18
2190	Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. 2011 , 3, 31	67
2189	Predicting Alzheimer's risk: why and how?. 2011 , 3, 33	12
2188	Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. 2011 , 3, 34	36
2187	Machine Learning classification of MRI features of Alzheimer's disease and mild cognitive impairment subjects to reduce the sample size in clinical trials. 2011 , 2011, 7957-60	13
2186	Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy. 2011 , 25, 213-26	29
2185	Use of biomarkers in clinical trials of Alzheimer disease: from concept to application. 2011 , 15, 313-25	15
2184	Brain microbleeds and Alzheimer's disease: innocent observation or key player?. 2011 , 134, 335-44	235
2183	Curcuminoid binds to amyloid- β -42 oligomer and fibril. 2011 , 24 Suppl 2, 33-42	72
2182	Meta-analysis of plasma amyloid- β levels in Alzheimer's disease. 2011 , 26, 365-75	95
2181	Neurodegenerative Disorders. 2011 ,	6
2180	Very new developments in mild Cognitive impairment and Alzheimer's disease: why should a psychiatrist care?. 2011 , 4, 72-4	
2179	Cognitively preserved subjects with transitional cerebrospinal fluid β amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas. 2011 , 70, 183-90	75
2178	Late-life depression and Alzheimer's disease: the glutamatergic system inside of this mirror relationship. 2011 , 67, 344-55	19
2177	Folate and homocysteine in the cerebrospinal fluid of patients with Alzheimer's disease or dementia: a case control study. 2011 , 65, 270-8	31
2176	Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease. 2011 , 5, 479-84	11

2175	Automated hippocampal shape analysis predicts the onset of dementia in mild cognitive impairment. 2011 , 56, 212-9	151
2174	Local MRI analysis approach in the diagnosis of early and prodromal Alzheimer's disease. 2011 , 58, 469-80	127
2173	Avances muy recientes en el deterioro cognitivo leve y la enfermedad de Alzheimer: ¿por qu'una asistencia psiquiátrica?. 2011 , 4, 72-74	
2172	Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. 2011 , 54 Suppl 1, S204-17	405
2171	βAmyloid affects frontal and posterior brain networks in normal aging. 2011 , 54, 1887-95	90
2170	The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. 2011 , 10, 698-712	1402
2169	Resolving controversies on the path to Alzheimer's therapeutics. 2011 , 17, 1060-5	383
2168	Amyloid imaging for Alzheimer's disease. 2011 , 5, 527-38	0
2167	Distinguishing Alzheimer's disease from other major forms of dementia. 2011 , 11, 1579-91	184
2166	Neuropsychological assessment of patients with dementing illness. 2011 , 7, 677-87	42
2165	Solanezumab for Alzheimer's disease. 2011 , 11, 787-98	35
2164	For debate: substituting placebo controls in long-term Alzheimer's prevention trials. 2011 , 3, 9	13
2163	Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study. 2011 , 3, 5	22
2162	Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. 2011 , 179, 1373-84	249
2161	Brain aging, Alzheimer's disease, and mitochondria. 2011 , 1812, 1630-9	206
2160	Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions. 2011 , 32, 247-57	78
2159	L'imagerie TEP-traceurs des plaques amyloïdes: le point de vue du clinicien. 2011 , 35, 608-612	1
2158	Lifespan brain activity, βamyloid, and Alzheimer's disease. 2011 , 15, 520-6	151

2157	Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. 2011 , 34, 430-42	235
2156	Biomarkers for Alzheimer's disease therapeutic trials. 2011 , 95, 579-93	100
2155	Biomarkers in frontotemporal lobar degenerations--progress and challenges. 2011 , 95, 636-48	30
2154	Functional magnetic resonance imaging as a dynamic candidate biomarker for Alzheimer's disease. 2011 , 95, 557-69	45
2153	Staging Alzheimer's disease progression with multimodality neuroimaging. 2011 , 95, 535-46	55
2152	Neurodegenerative disease biomarkers: guideposts for disease prevention through early diagnosis and intervention. 2011 , 95, 491-5	34
2151	The Parkinson Progression Marker Initiative (PPMI). 2011 , 95, 629-35	793
2150	Amyloid imaging as a biomarker for cerebral amyloidosis and risk prediction for Alzheimer dementia. 2011 , 32 Suppl 1, S20-36	103
2149	Clinical trial methodologies for disease-modifying therapeutic approaches. 2011 , 32 Suppl 1, S64-6	15
2148	Potential of functional MRI as a biomarker in early Alzheimer's disease. 2011 , 32 Suppl 1, S37-43	105
2147	Alliance for aging research AD biomarkers work group: structural MRI. 2011 , 32 Suppl 1, S48-57	43
2146	In vivo detection of amyloid deposition using ¹⁹ F magnetic resonance imaging with a ¹⁹ F-containing curcumin derivative in a mouse model of Alzheimer's disease. 2011 , 184, 120-7	68
2145	[Predementia Alzheimer's disease. Benefits of early diagnosis]. 2011 , 46 Suppl 1, 47-54	2
2144	[Therapeutic approaches targeting the presumed underlying pathogenic mechanisms in Alzheimer's disease]. 2011 , 32 Suppl 1, S22-5	
2143	Alzheimer's Disease. 2011 , 43-64	
2142	Dementia and Alzheimer's disease: a new direction.The 2010 Jay L. Foster Memorial Lecture. 2011 , 7, 540-50	21
2141	Multimodal classification of Alzheimer's disease and mild cognitive impairment. 2011 , 55, 856-67	837
2140	Longitudinal changes of CSF biomarkers in Alzheimer's disease. 2011 , 25, 583-94	64

2139	Tau transgenic mice as models for cerebrospinal fluid tau biomarkers. 2011 , 24 Suppl 2, 127-41	69
2138	Evidence for ordering of Alzheimer disease biomarkers. 2011 , 68, 1526-35	170
2137	Testing the right target and right drug at the right stage. 2011 , 3, 111cm33	366
2136	Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database. 2011 , 7, 151-60	81
2135	Biomarkers in Alzheimer's disease drug development. 2011 , 7, e13-44	87
2134	Transforming cerebrospinal fluid A β 2 measures into calculated Pittsburgh Compound B units of brain A β amyloid. 2011 , 7, 133-41	70
2133	Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment-Part 1. 2011 , 7, 15-34	44
2132	National estimates of the prevalence of Alzheimer's disease in the United States. 2011 , 7, 61-73	253
2131	Reducing case ascertainment costs in U.S. population studies of Alzheimer's disease, dementia, and cognitive impairment-Part 2. 2011 , 7, 110-23	25
2130	Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment-Part 2. 2011 , 7, 35-52	46
2129	Revision of the criteria for Alzheimer's disease: A symposium. 2011 , 7, e1-12	27
2128	Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. 2011 , 7, 280-92	4210
2127	Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. 2011 , 7, 257-62	1166
2126	The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. 2011 , 7, 263-9	8211
2125	Assessment of cognition in mild cognitive impairment: a comparative study. 2011 , 7, 338-55	59
2124	Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. 2011 , 7, 474-485.e4	139
2123	IC-02-05: MRI-based biomarkers from hippocampal subfields: Advances in automatic labeling, longitudinal atrophy estimation and postmortem anatomical atlas. 2011 , 7, S5-S6	
2122	Alzheimer's disease. 2011 , 377, 1019-31	1645

2121	Plasma beta-amyloid linked to cognitive decline. 2011 , 68, 799-801	
2120	Passive (amyloid- β) immunotherapy attenuates monoaminergic axonal degeneration in the APP ^{swe} /PS1 ^{dE9} mice. 2011 , 23, 271-9	12
2119	Biomarkers of Alzheimer's disease: from central nervous system to periphery?. 2010 , 2011, 342980	3
2118	Increasing the diagnostic accuracy of medial temporal lobe atrophy in Alzheimer's disease. 2011 , 25, 477-90	12
2117	Mild cognitive impairment and dementia: the importance of modifiable risk factors. 2011 , 108, 743-50	105
2116	Imaging the Alzheimer brain. 2011 , 26 Suppl 3, 1-27	30
2115	Diagnosis of Alzheimer's disease in Brazil: Supplementary exams. 2011 , 5, 167-177	14
2114	Bridging molecular genetics and biomarkers in lewy body and related disorders. 2011 , 2011, 842475	5
2113	Biomarkers for microglial activation in Alzheimer's disease. 2011 , 2011, 939426	18
2112	Minimally invasive biomarker confirms glial activation present in Alzheimer's disease: a preliminary study. 2011 , 7, 495-9	25
2111	Exercise-induced cognitive plasticity, implications for mild cognitive impairment and Alzheimer's disease. 2011 , 2, 28	119
2110	Biomarkers in Alzheimer's disease. 2011 , 2, 46	14
2109	Evaluation and tracking of Alzheimer's disease severity using resting-state magnetoencephalography. 2011 , 26 Suppl 3, 239-55	17
2108	Prediction of dementia in primary care patients. 2011 , 6, e16852	87
2107	Automated detection of amyloid- β -related cortical and subcortical signal changes in a transgenic model of Alzheimer's disease using high-field MRI. 2011 , 23, 221-37	24
2106	P300 energy loss in aging and Alzheimer's disease. 2011 , 26 Suppl 3, 229-38	29
2105	Why age (and timing) really matters in developing drugs for neurodegenerative disease. 2011 , 8, 459-461	
2104	Combining biomarkers: the future for Alzheimer's disease prevention studies?. 2011 , 1, 175-178	

2103	Focusing on atypical symptoms for improved diagnosis of early-onset Alzheimer's disease. 2011 , 6, 575-578	3
2102	In vivo human amyloid imaging. 2011 , 8, 366-72	30
2101	Developmental aspects of the intracerebral microvasculature and perivascular spaces: insights into brain response to late-life diseases. 2011 , 70, 1060-9	46
2100	Role of family history for Alzheimer biomarker abnormalities in the adult children study. 2011 , 68, 1313-9	46
2099	Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. 2011 , 70, 960-9	1068
2098	Revised NIA-AA criteria for the diagnosis of Alzheimer's disease: a step forward but not yet ready for widespread clinical use. 2011 , 23, 1191-6	26
2097	Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease. 2011 , 77, 1977-85	189
2096	Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients. 2011 , 23, 319-26	56
2095	Striving for an integrated drug-development process for neurodegeneration: the coalition against major diseases. 2011 , 1, 379-385	12
2094	Nutrition and brain aging: role of fatty acids with an epidemiological perspective. 2011 , 18, 228-235	
2093	Association of N-acetylaspartate and cerebrospinal fluid A β 2 in dementia. 2011 , 27, 393-9	8
2092	Amyloid- β 42 associated with cognitive impairment in healthy elderly and subjective cognitive impairment. 2011 , 26, 135-42	67
2091	Episodic memory decline predicts cortical amyloid status in community-dwelling older adults. 2011 , 27, 627-37	31
2090	Amyloid- β and glucose metabolism in Alzheimer's disease. 2011 , 26 Suppl 3, 105-16	19
2089	Experiences with cerebrospinal fluid analysis in Dutch memory clinics. 2011 , 18, 1014-6	5
2088	Apolipoprotein genotype for prediction of Alzheimer's disease in older Japanese: the Hisayama Study. 2011 , 59, 1074-9	20
2087	Neuroimaging as endpoints in clinical trials: are we there yet? Perspective from the first Provence workshop. 2011 , 16, 1064-6	9
2086	Obesity, leptin, and Alzheimer's disease. 2011 , 1243, 15-29	87

2085	Brain fuel metabolism, aging, and Alzheimer's disease. 2011 , 27, 3-20		374
2084	Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum. 2011 , 192, 140-6		15
2083	Apolipoprotein E in Alzheimer's disease and other neurological disorders. <i>Lancet Neurology, The</i> , 2011 , 10, 241-52	24.1	568
2082	Setting the stage for prevention of familial Alzheimer's disease. <i>Lancet Neurology, The</i> , 2011 , 10, 200-1	24.1	1
2081	Cerebral amyloid- β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. <i>Lancet Neurology, The</i> , 2011 , 10, 424-35	24.1	400
2080	Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. <i>Lancet Neurology, The</i> , 2011 , 10, 785-96	24.1	531
2079	Topology-based kernels with application to inference problems in Alzheimer's disease. 2011 , 30, 1760-70		55
2078	Plasma β amyloid peptides in canine aging and cognitive dysfunction as a model of Alzheimer's disease. 2011 , 46, 590-6		37
2077	De rol van de parieto-occipitale kwab in de vroege fase van de ziekte van Alzheimer. 2011 , 15, 113-120		
2076	Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease. 2012 , 10, 187-212		37
2075	Alzheimer's disease: the challenge of the second century. 2011 , 3, 77sr1		893
2074	Structural and functional imaging correlates of cognitive and brain reserve hypotheses in healthy and pathological aging. 2011 , 24, 340-57		105
2073	Atrophy in the parahippocampal gyrus as an early biomarker of Alzheimer's disease. 2011 , 215, 265-71		90
2072	The pathological process underlying Alzheimer's disease in individuals under thirty. 2011 , 121, 171-81		520
2071	Tau pathology in children and young adults: can you still be unconditionally baptist?. 2011 , 121, 145-7		58
2070	Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. 2011 , 121, 597-609		220
2069	Factors affecting A β plasma levels and their utility as biomarkers in ADNI. 2011 , 122, 401-13		123
2068	Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. 2011 , 118, 259-62		41

2067	[Diagnosis without therapy: early diagnosis of Alzheimer's disease in the stage of mild cognitive impairment]. 2011 , 82, 1151-9	6
2066	Individualized quantification of brain β amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. 2011 , 38, 1702-14	77
2065	Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond. 2011 , 13, 217-22	139
2064	Staging neurodegenerative disorders: structural, regional, biomarker, and functional progressions. 2011 , 19, 211-34	19
2063	Gene expression endophenotypes: a novel approach for gene discovery in Alzheimer's disease. 2011 , 6, 31	28
2062	Decreased brain stiffness in Alzheimer's disease determined by magnetic resonance elastography. 2011 , 34, 494-8	221
2061	Amyloid- β associated cortical thinning in clinically normal elderly. 2011 , 69, 1032-42	250
2060	Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. 2011 , 70, 274-85	113
2059	Microinfarcts, brain atrophy, and cognitive function: the Honolulu Asia Aging Study Autopsy Study. 2011 , 70, 774-80	119
2058	Oxysterols as biomarkers in neurodegenerative diseases. 2011 , 164, 515-24	149
2057	Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. 2011 , 68, 961-9	236
2056	Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. 2011 , 134, 1077-88	83
2055	Spectra to identify the spectre of Alzheimer disease?. 2011 , 77, 932-3	
2054	Predicting MCI outcome with clinically available MRI and CSF biomarkers. 2011 , 77, 1619-28	160
2053	Using biomarkers to improve detection of Alzheimer's disease. 2011 , 1, 127-139	22
2052	Terminal decline and practice effects in older adults without dementia: the MoVIES project. 2011 , 77, 722-30	52
2051	The dynamics of cortical and hippocampal atrophy in Alzheimer disease. 2011 , 68, 1040-8	207
2050	Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. 2011 , 134, 1479-92	96

2049 Diagnostik der Demenz. **2011**, 5, 9-17

2048 Neues zur Alzheimer Erkrankung. **2011**, 38, 234-241

1

2047 Longitudinal MR imaging in Alzheimer disease: a study anyone can join. **2011**, 258, 657-9

2046 Genetics of dementia. **2011**, 31, 449-60

37

2045 Early detection and characterization of Alzheimer's disease in clinical scenarios using Bioprofile concepts and K-means. **2011**, 2011, 6470-3

15

2044 The role of CREB signaling in Alzheimer's disease and other cognitive disorders. **2011**, 22, 153-69

181

2043 Neuropsychological correlates of apathy in mild cognitive impairment and Alzheimer's disease: the role of executive functioning. **2011**, 23, 1327-33

33

2042 Hippocampal sclerosis in the elderly: genetic and pathologic findings, some mimicking Alzheimer disease clinically. **2011**, 25, 364-8

68

2041 Mapping the road forward in Alzheimer's disease. **2011**, 3, 114ps48

53

2040 Relationship between cholesterol metabolism, ApoE and brain volumes in Alzheimer's disease. **2011**, 6, 613-626

1

2039 Bihemispheric cerebral FDG PET correlates of cognitive dysfunction as assessed by the CERAD in Alzheimer's disease. **2011**, 42, 71-6

18

2038 Relationships between Amyloid and functional connectivity in different components of the default mode network in aging. **2011**, 21, 2399-407

229

2037 Defaulting on the default network: increased risk for dementia. **2011**, 76, 498-500

5

2036 Beta-amyloid peptide variants in brains and cerebrospinal fluid from amyloid precursor protein (APP) transgenic mice: comparison with human Alzheimer amyloid. **2011**, 286, 33747-58

48

2035 Longitudinal change of biomarkers in cognitive decline. **2011**, 68, 1257-66

130

2034 Use of florbetapir-PET for imaging beta-amyloid pathology. **2011**, 305, 275-83

760

2033 Quantifying the pathophysiological timeline of Alzheimer's disease. **2011**, 26, 745-53

46

2032 Changing concepts of Alzheimer disease. **2011**, 305, 2458-9

64

2031	Mapping out biomarkers for Alzheimer disease. 2011 , 305, 304-5	18
2030	Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. 2011 , 52, 393-400	77
2029	Apolipoprotein E ϵ prevalence in Alzheimer's disease patients varies across global populations: a systematic literature review and meta-analysis. 2011 , 31, 20-30	79
2028	Minimal atrophy of the entorhinal cortex and hippocampus: progression of cognitive impairment. 2011 , 31, 276-83	24
2027	Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. 2011 , 68, 1398-403	127
2026	Treat Alzheimer disease before it is symptomatic. 2011 , 68, 1237-8	7
2025	Longitudinal patterns of β amyloid deposition in nondemented older adults. 2011 , 68, 644-9	77
2024	Cerebrospinal fluid biomarkers in Alzheimer's disease families with PSEN1 mutations. 2011 , 8, 202-7	23
2023	Dementia screening, biomarkers and protein misfolding: Implications for public health and diagnosis. 2011 , 5, 16-21	20
2022	Alzheimer's disease and intelligence. 2011 , 8, 345-53	14
2021	Brain amyloid imaging. 2011 , 52, 1733-40	184
2020	Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. 2011 , 1, a006437	81
2019	Gonadal hormones and cognitive aging: a midlife perspective. 2011 , 7, 81-93	28
2018	18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. 2011 , 134, 1089-100	255
2017	Challenges in the development of companion diagnostics for neuropsychiatric disorders. 2011 , 11, 829-37	8
2016	Structural and functional network connectivity breakdown in Alzheimer's disease studied with magnetic resonance imaging techniques. 2011 , 24, 455-74	62
2015	Amyloid imaging. 2011 , 23 Suppl 2, S41-9	23
2014	Plasma A β and PET PiB binding are inversely related in mild cognitive impairment. 2011 , 77, 125-31	42

2013	Evaluation of apparent diffusion coefficient mappings in amnesic mild cognitive impairment using an image analysis software brain search. 2011 , 52, 1147-54	10
2012	New tools for the study of Alzheimer's disease: what are biomarkers and morphometric markers teaching us?. 2011 , 17, 592-605	10
2011	Therapeutic antibodies for brain disorders. 2011 , 3, 84ps20	13
2010	Ethical issues in Alzheimer's disease: an overview. 2012 , 12, 557-67	16
2009	Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer's disease. 2012 , 9, 241-7	13
2008	Vascular burden and Alzheimer disease pathologic progression. 2012 , 79, 1349-55	121
2007	The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects. 2012 , 22, 2653-61	91
2006	Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. 2012 , 79, 1332-9	207
2005	Region-specific hierarchy between atrophy, hypometabolism, and β amyloid (A β) load in Alzheimer's disease dementia. 2012 , 32, 16265-73	245
2004	Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. 2012 , 25, 715-20	55
2003	Neuroimaging in dementias. 2012 , 25, 473-9	19
2002	The neurobiology of Alzheimer disease defined by neuroimaging. 2012 , 25, 410-20	28
2001	The neuropsychological profile of Alzheimer disease. 2012 , 2, a006171	309
2000	Injury markers predict time to dementia in subjects with MCI and amyloid pathology. 2012 , 79, 1809-16	110
1999	Amyloid- β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. 2012 , 79, 1636-44	174
1998	Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer's disease. 2012 , 33, 416-22	46
1997	Modeling Disease Progression via Fused Sparse Group Lasso. 2012 , 2012, 1095-1103	88
1996	Imaging approaches for dementia. 2012 , 33, 1836-44	18

1995	Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. 2012 , 135, 2115-25	91
1994	Family history of Alzheimer disease predicts hippocampal atrophy in healthy middle-aged adults. 2012 , 78, 1769-76	37
1993	APOE modifies the association between A β load and cognition in cognitively normal older adults. 2012 , 78, 232-40	128
1992	Transgenic expression of intraneuronal A β 2 but not A β 0 leads to cellular A β lesions, degeneration, and functional impairment without typical Alzheimer's disease pathology. 2012 , 32, 1273-83	31
1991	Activities of daily living: where do they fit in the diagnosis of Alzheimer's disease?. 2012 , 2, 483-491	95
1990	Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough. 2012 , 4, 343-357	10
1989	Clinical and biomarker changes in Alzheimer's disease. 2012 , 367, 2050; author reply 2051-2	5
1988	Effect of Alzheimer's disease risk genes on trajectories of cognitive function in the Cardiovascular Health Study. 2012 , 169, 954-62	56
1987	Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. 2012 , 53, 378-84	250
1986	Predicting positivity for a new era of Alzheimer disease prevention trials. 2012 , 79, 1530-1	10
1985	Alzheimer disease: biomarker trajectories across stages of Alzheimer disease. 2012 , 8, 299-300	19
1984	Gender modulates the APOE ϵ effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. 2012 , 32, 8254-62	176
1983	Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. 2012 , 83, 124-37	361
1982	Brain imaging in Alzheimer disease. 2012 , 2, a006213	336
1981	Indicators of amyloid burden in a population-based study of cognitively normal elderly. 2012 , 79, 1570-7	123
1980	Amyloid pathology in persons with "normal" cognition. 2012 , 78, 228-9	7
1979	Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. 2012 , 78, 379-86	117
1978	Applicability of the CANTAB-PAL computerized memory test in identifying amnesic mild cognitive impairment and Alzheimer's disease. 2012 , 34, 83-9	49

1977	Soluble β -synuclein is a novel modulator of Alzheimer's disease pathophysiology. 2012 , 32, 10253-66	85
1976	Cerebrospinal fluid levels of β -amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. 2012 , 69, 98-106	459
1975	APOE4 predicts amyloid- β in cortical brain biopsy but not idiopathic normal pressure hydrocephalus. 2012 , 83, 1119-24	20
1974	CSF biomarkers for secondary prevention trials: why markers of amyloid deposition and neurodegeneration are both important. 2012 , 69, 691-2	1
1973	Behavioral Neurobiology of Aging. 2012 ,	
1972	Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. 2012 , 69, 223-9	220
1971	Regional dynamics of amyloid- β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. 2012 , 135, 2126-39	179
1970	A β deposition in aging is associated with increases in brain activation during successful memory encoding. 2012 , 22, 1813-23	105
1969	Arterial spin labeling MRI: an emerging biomarker for Alzheimer's disease and other neurodegenerative conditions. 2012 , 25, 421-8	91
1968	Glymour et al. Respond to "Is Cognitive Aging Predicted by Educational Level?". 2012 , 175, 762-763	1
1967	Loss of semantic knowledge in mild cognitive impairment. 2012 , 169, 1226-9	6
1966	Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. 2012 , 69, 856-67	86
1965	Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. 2012 , 71, 266-73	563
1964	Added Diagnostic Value of (11)C-PiB-PET in Memory Clinic Patients with Uncertain Diagnosis. 2012 , 2, 610-21	38
1963	PSEN1 mutation carriers present lower cerebrospinal fluid amyloid- β 2 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers. 2012 , 30, 605-16	6
1962	Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease blood. 2012 , 30, 685-710	104
1961	Recent advances in imaging Alzheimer's disease. 2013 , 33 Suppl 1, S313-27	17
1960	Evolution of global and local grey matter atrophy on serial MRI scans during the progression from MCI to AD. 2012 , 9, 516-24	42

- 1959 Shifting our focus to blood-based biomarkers of Alzheimer's disease: the promise of ceramides and sphingomyelins. **2012**, 2, 91-94
- 1958 Early indications of magnetic resonance spectroscopy changes associated with Amyloid load in the cognitively normal. **2012**, 7, 117-118
- 1957 History and experience: the direction of Alzheimer's disease. **2012**, 19, 724-34 6
- 1956 Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. **2012**, 29, 319-27 54
- 1955 Lowered serum amyloid- β -42 autoantibodies in individuals with lifetime depression. **2012**, 32, 95-100 7
- 1954 Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. **2012**, 30, 767-78 62
- 1953 Patterns of gray and white matter changes in individuals at risk for Alzheimer's disease. **2012**, 9, 1097-105 3
- 1952 MRI- and PET-Based Imaging Markers for the Diagnosis of Alzheimer's Disease. **2012**, 80-114
- 1951 Evolutional aspects of Alzheimer's disease pathogenesis. **2013**, 33 Suppl 1, S155-61 24
- 1950 Alzheimer's disease and the quest for its biological measures. **2013**, 33 Suppl 1, S237-41 5
- 1949 Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents. **2012**, 91, 315-20 11
- 1948 Microvascular perfusion based on arterial spin labeled perfusion MRI as a measure of vascular risk in Alzheimer's disease. **2012**, 32, 677-87 18
- 1947 Neuropathological Basis of Alzheimer's Disease and Alzheimer's Disease Diagnosis. **2012**, 49-70 1
- 1946 Neurorestoration therapeutics for neurodegenerative and psychiatric disease. **2012**, 34, 129-42 9
- 1945 The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging. **2012**, 17, 176-206 24
- 1944 Amyloid and Alzheimer's disease: inside and out. **2012**, 39, 286-98 50
- 1943 Clinical data in early intervention. **2012**, 24 Suppl 1, S41-5 6
- 1942 Mapping the long slow progression of neurodegeneration leading to Alzheimer's disease. **2012**, 8, 567-571

1941	Possible involvement of ubiquitin ligase HRD1 insolubilization in amyloid β generation. 2012 , 35, 269-72	10
1940	Hippocampal Formation. 2012 , 896-942	47
1939	Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. 2012 , 135, 3749-56	179
1938	Considerations in the design of clinical trials for cognitive aging. 2012 , 67, 766-72	11
1937	Enriching amnesic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia. 2012 , 32, 373-85	25
1936	Alzheimer disease: from inherited to sporadic AD-crossing the biomarker bridge. 2012 , 8, 598-600	33
1935	Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. <i>Lancet Neurology, The</i> , 2012 , 11, 1048-56	24.1 347
1934	Resting-state brain functional connectivity is altered in type 2 diabetes. 2012 , 61, 2375-9	172
1933	Performance of $\alpha\text{II-40}$, $\alpha\text{II-42}$, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. 2012 , 29, 229-38	73
1932	Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. 2012 , 79, 897-905	175
1931	Alzheimer's disease: pathogenesis and prevention. 2012 , 8, 227-33	58
1930	Predicting the development of mild cognitive impairment: a new use of pattern recognition. 2012 , 60, 894-901	22
1929	Risk classification in mild cognitive impairment patients for developing Alzheimer's disease. 2012 , 30, 367-75	18
1928	Clinical and biomarker changes in dominantly inherited Alzheimer's disease. 2012 , 367, 795-804	2272
1927	A plaque-specific antibody clears existing β amyloid plaques in Alzheimer's disease mice. 2012 , 76, 908-20	186
1926	Alzheimer's disease. 2012 , 65, 329-52	176
1925	Presymptomatic studies in ALS: rationale, challenges, and approach. 2012 , 79, 1732-9	63
1924	Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. 2012 , 9, 179	307

1923	Stealth attack: plaque-specific antibody allows for efficient A β removal without side effects. 2012 , 76, 859-61	1
1922	Synapse-binding subpopulations of A β oligomers sensitive to peptide assembly blockers and scFv antibodies. 2012 , 3, 972-81	35
1921	Discovery of a novel pharmacological and structural class of gamma secretase modulators derived from the extract of <i>Actaea racemosa</i> . 2012 , 3, 941-51	54
1920	Comparison of cerebrospinal fluid levels of tau and A β 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. 2012 , 69, 1018-25	84
1919	Mild cognitive impairment associated with underlying Alzheimer's disease versus Lewy body disease. 2012 , 18 Suppl 1, S41-4	45
1918	Amyloid deposition, hypometabolism, and longitudinal cognitive decline. 2012 , 72, 578-86	400
1917	Relation of neuropathology to cognition in persons without cognitive impairment. 2012 , 72, 599-609	153
1916	Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. 2012 , 72, 730-8	118
1915	Use of proteomic methods in the analysis of human body fluids in Alzheimer research. 2012 , 33, 3617-30	30
1914	Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. 2012 , 124, 823-31	86
1913	[(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. 2012 , 124, 833-45	63
1912	Clinical diagnosis in preclinical stage of Alzheimer's disease. 2012 , 43, 667-70	4
1911	Early-onset Alzheimer's disease: nonamnestic subtypes and type 2 AD. 2012 , 43, 677-85	96
1910	The levels of water-soluble and triton-soluble A β are increased in Alzheimer's disease brain. 2012 , 1450, 138-47	43
1909	Is Alzheimer's disease amyloidosis the result of a repair mechanism gone astray?. 2012 , 8, 574-83	18
1908	A model for improving the treatment and care of Alzheimer's disease patients through interdisciplinary research. 2012 , 8, 564-73	14
1907	The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. 2012 , 8, S1-68	368
1906	Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults. 2012 , 8, 520-7	29

1905	National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. 2012 , 8, 1-13	1396
1904	Comparison of International Working Group criteria and National Institute on Aging-Alzheimer's Association criteria for Alzheimer's disease. 2012 , 8, 560-3	41
1903	Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. 2012 , 8, 312-36	92
1902	Biomarker development: a population-level perspective. 2012 , 8, 247-9	3
1901	Regional cerebral blood flow differences in patients with mild cognitive impairment between those who did and did not develop Alzheimer's disease. 2012 , 203, 201-6	32
1900	Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. 2012 , 56, 484-93	64
1899	What sleep characteristics predict cognitive decline in the elderly?. 2012 , 13, 886-92	158
1898	Cognitive dysfunction syndrome: a disease of canine and feline brain aging. 2012 , 42, 749-68, vii	115
1897	Mild cognitive impairment: a subset of minor neurocognitive disorder?. 2012 , 20, 821-6	13
1896	[The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinical stages, mild cognitive impairment, and dementia]. 2012 , 168, 471-82	19
1895	[Markers of prodromal Alzheimer's disease]. 2012 , 168, 815-24	
1894	Explaining the encoding/retrieval flip: memory-related deactivations and activations in the posteromedial cortex. 2012 , 50, 3764-74	82
1893	Recent Changes Leading to Subsequent Changes: Extensions of Multivariate Latent Difference Score Models. 2012 , 19, 268-292	120
1892	Potential sources of interference on Abeta immunoassays in biological samples. 2012 , 4, 39	10
1891	Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention. 2013 , 33 Suppl 1, S405-16	46
1890	New diagnostic criteria for Alzheimer's disease and mild cognitive impairment for the practical neurologist. 2012 , 12, 88-96	28
1889	Next frontiers in the genetic epidemiology of Alzheimer's disease. 2012 , 27, 831-6	3
1888	Plasma amyloid- β levels and prognosis in incident dementia cases of the 3-City Study. 2013 , 33, 381-91	16

1887	APOE genotype in the diagnosis of Alzheimer's disease in patients with cognitive impairment. 2012 , 27, 315-20	12
1886	"It Ain't Over 'til It's Over" (a) -The Search for Treatments and Cures for Alzheimer's Disease. 2012 , 3, 862-6	11
1885	Effects of ApoE4 and maternal history of dementia on hippocampal atrophy. 2012 , 33, 856-66	45
1884	Combination therapy prevents amyloid-dependent and -independent structural changes. 2012 , 33, 1273-83	9
1883	Preclinical AD Workgroup staging: pathological correlates and potential challenges. 2012 , 33, 622.e1-622.e16	54
1882	Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. 2012 , 33, 1591-8	44
1881	Structural MRI changes detectable up to ten years before clinical Alzheimer's disease. 2012 , 33, 825.e25-36	141
1880	Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. 2012 , 33, 2018-28	253
1879	Posterior cingulate atrophy and metabolic decline in early stage Alzheimer's disease. 2012 , 33, 2006-17	23
1878	Localized hippocampus measures are associated with Alzheimer pathology and cognition independent of total hippocampal volume. 2012 , 33, 1124.e31-41	37
1877	Deficits in the mitochondrial enzyme α -ketoglutarate dehydrogenase lead to Alzheimer's disease-like calcium dysregulation. 2012 , 33, 1121.e13-24	39
1876	Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. 2012 , 33, 2272-81	72
1875	Influence of functional connectivity and structural MRI measures on episodic memory. 2012 , 33, 2612-20	47
1874	Longitudinal imaging pattern analysis (SPARE-CD index) detects early structural and functional changes before cognitive decline in healthy older adults. 2012 , 33, 2733-45	26
1873	Preclinical studies of potential amyloid binding PET/SPECT ligands in Alzheimer's disease. 2012 , 39, 484-501	23
1872	Distributional impact of brain microbleeds on global cognitive function in adults without neurological disorder. 2012 , 43, 1800-5	50
1871	Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. 2012 , 135, 807-18	171
1870	New visual rating system for medial temporal lobe atrophy: a simple diagnostic tool for routine examinations. 2012 , 12, 88-92	5

1869	Molecular imaging of dementia. 2012 , 12, 106-14	16
1868	Tracking the insidious course of Alzheimer's disease. 2012 , 18, 1342-3	2
1867	The challenges of tau imaging. 2012 , 7, 409-421	74
1866	Characterizing dementia with Lewy bodies by means of diffusion tensor imaging. 2012 , 79, 906-14	74
1865	Preventing Alzheimer's disease. 2012 , 337, 1488-92	280
1864	CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. 2012 , 78, 709-19	81
1863	Power tools for Alzheimer's disease - an electrochemical preamp for A β . 2012 , 122, 231-2	2
1862	Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis. 2012 , 79, 1591-8	195
1861	Alzheimer's disease 2012: the great amyloid gamble. 2012 , 180, 1762-7	24
1860	PET amyloid-beta imaging in preclinical Alzheimer's disease. 2012 , 1822, 370-9	102
1859	The use of PIB-PET as a dual pathological and functional biomarker in AD. 2012 , 1822, 380-5	41
1858	Synthesis and biological evaluation of novel oxindole derivatives for imaging neurofibrillary tangles in Alzheimer's disease. 2012 , 22, 5700-3	21
1857	Alzheimer's disease markers from structural MRI and FDG-PET brain images. 2012 , 127, 1	13
1856	Neurodegenerative dementias: From MR Physics lab to assessment room. 2012 , 127, 1	3
1855	Diagnostic and economic evaluation of new biomarkers for Alzheimer's disease: the research protocol of a prospective cohort study. 2012 , 12, 72	20
1854	Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals. 2012 , 10, 127	37
1853	Association of the interleukin 1 beta gene and brain spontaneous activity in amnesic mild cognitive impairment. 2012 , 9, 263	18
1852	Prevention strategies for Alzheimer's disease. 2012 , 1, 13	17

1851	Apolipoprotein E, not fibrillar β amyloid, reduces cerebral glucose metabolism in normal aging. 2012 , 32, 18227-33		134
1850	Screening and treatment for Alzheimer's disease: predicting population-level outcomes. 2012 , 8, 31-8		2
1849	Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. 2012 , 69, 1621-7		170
1848	Road to Alzheimer's disease: the pathomechanism underlying. 2012 , 79, 55-71		13
1847	CSF biomarkers correlate with cerebral blood flow on SPECT in healthy elderly. 2012 , 33, 156-63		10
1846	Neuroprotective actions of glucagon-like peptide-1 in differentiated human neuroprogenitor cells. 2012 , 123, 919-31		23
1845	Gantenerumab for the treatment of Alzheimer's disease. 2012 , 12, 1077-86		28
1844	Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges. 2012 , 6, 391-400		45
1843	Diagnosis of Alzheimer's disease. 2012 , 12-46		
1842	Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease. 2012 , 64, 327-71		60
1841	Development of positron emission tomography β amyloid plaque imaging agents. 2012 , 42, 423-32		132
1840	Florbetapir PET analysis of amyloid- β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. <i>Lancet Neurology, The</i> , 2012 , 11, 1057-65	24.1	178
1839	Tracking brain amyloid- β in presymptomatic Alzheimer's disease. <i>Lancet Neurology, The</i> , 2012 , 11, 1018-20	24.1	3
1838	When, where, and how does Alzheimer's disease start?. <i>Lancet Neurology, The</i> , 2012 , 11, 1017-8	24.1	7
1837	Relative contributions of biomarkers in Alzheimer's disease. 2012 , 22, 868-75		6
1836	Automated detection of amnesic mild cognitive impairment in community-dwelling elderly adults: a combined spatial atrophy and white matter alteration approach. 2012 , 59, 1209-17		54
1835	High field magnetic resonance microscopy of the human hippocampus in Alzheimer's disease: quantitative imaging and correlation with iron. 2012 , 59, 1249-60		59
1834	Individual subject classification for Alzheimer's disease based on incremental learning using a spatial frequency representation of cortical thickness data. 2012 , 59, 2217-30		143

1833	Brain imaging in the study of Alzheimer's disease. 2012 , 61, 505-16	83
1832	An event-based model for disease progression and its application in familial Alzheimer's disease and Huntington's disease. 2012 , 60, 1880-9	125
1831	MRI hippocampal and entorhinal cortex mapping in predicting conversion to Alzheimer's disease. 2012 , 60, 1622-9	89
1830	Resting state FDG-PET functional connectivity as an early biomarker of Alzheimer's disease using conjoint univariate and independent component analyses. 2012 , 63, 936-46	68
1829	A computational neurodegenerative disease progression score: method and results with the Alzheimer's disease Neuroimaging Initiative cohort. 2012 , 63, 1478-86	148
1828	Emission Imaging in Dementia. 2012 , 223-247	
1827	Cognitive decline and amyloid accumulation in patients with mild cognitive impairment. 2012 , 34, 31-7	9
1826	The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. 2012 , 32, 3601-11	281
1825	The clinical value of large neuroimaging data sets in Alzheimer's disease. 2012 , 22, 107-18, ix	9
1824	CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade. 2012 , 6, 599-609	37
1823	A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. 2012 , 6, 517-27	265
1822	Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer's Disease. 2012 , 6, 610-20	46
1821	Cortical signatures of cognition and their relationship to Alzheimer's disease. 2012 , 6, 584-98	19
1820	Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). 2012 , 6, 502-16	303
1819	Confirmatory factor analysis of the ADNI Neuropsychological Battery. 2012 , 6, 528-39	40
1818	Dysexecutive and amnesic AD subtypes defined by single indicator and modern psychometric approaches: relationships with SNPs in ADNI. 2012 , 6, 649-60	10
1817	Advanced psychometric analysis and the Alzheimer's Disease Neuroimaging Initiative: reports from the 2011 Friday Harbor conference. 2012 , 6, 485-8	6
1816	Évaluation des procédures diagnostiques de la maladie d'Alzheimer : une revue systématique des méta-analyses. 2012 , 4, 330-344	1

1815	Alzheimer's disease pathologic cascades: who comes first, what drives what. 2012 , 22, 182-94	51
1814	Modifiable factors that alter the size of the hippocampus with ageing. 2012 , 8, 189-202	217
1813	Long night's journey into the day: amyloid- β imaging in Alzheimer's disease. 2013 , 33 Suppl 1, S349-59	19
1812	Neuroprevention: a new challenge?. 2012 , 168, 796-801	5
1811	Neuroimaging of Dementia. 2012 , 707-717	
1810	Transient pharmacologic lowering of A β production prior to deposition results in sustained reduction of amyloid plaque pathology. 2012 , 7, 39	28
1809	Sex and gonadal hormones in mouse models of Alzheimer's disease: what is relevant to the human condition?. 2012 , 3, 24	28
1808	Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. 2012 , 7, e29868	79
1807	Neuronal LR11 expression does not differentiate between clinically-defined Alzheimer's disease and control brains. 2012 , 7, e40527	9
1806	Rates of decline in Alzheimer disease decrease with age. 2012 , 7, e42325	72
1805	MRI-based volumetry correlates of autobiographical memory in Alzheimer's disease. 2012 , 7, e46200	18
1804	CSF and brain structural imaging markers of the Alzheimer's pathological cascade. 2012 , 7, e47406	32
1803	Enrichment and stratification for predementia Alzheimer disease clinical trials. 2012 , 7, e47739	56
1802	A possible role for CSF turnover and choroid plexus in the pathogenesis of late onset Alzheimer's disease. 2012 , 30, 17-26	76
1801	A novel subject synchronization clinical trial design for Alzheimer's disease. 2012 , 31, 507-16	2
1800	Executive Dysfunction in MCI: Subtype or Early Symptom. 2012 , 2012, 936272	32
1799	Promising Genetic Biomarkers of Preclinical Alzheimer's Disease: The Influence of APOE and TOMM40 on Brain Integrity. 2012 , 2012, 421452	18
1798	Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer's disease. 2013 , 33 Suppl 1, S329-47	16

1797	Selective impairment of optic flow perception in amnesic mild cognitive impairment: evidence from event-related potentials. 2012 , 28, 695-708	18
1796	MRI biomarkers in Huntington's disease. 2012 , E4, 1910-1925	8
1795	Grey matter and cognitive patterns in cognitive impaired subjects using CSF biomarker cut-offs. 2012 , 29, 741-9	1
1794	Imaging the onset and progression of Alzheimer's disease: implications for prevention trials. 2013 , 33 Suppl 1, S305-12	4
1793	Alzheimer's disease and the "Valley Of Death": not enough guidance from human brain tissue?. 2013 , 33 Suppl 1, S219-33	18
1792	Pathology of Neurodegenerative Diseases. 2012 ,	3
1791	Section summary and perspectives: Translational medicine in neurology. 253-260	
1790	Vascular Dementia and Alzheimer's Disease: Is There a Difference?. 2012 ,	0
1789	A two-study comparison of clinical and MRI markers of transition from mild cognitive impairment to Alzheimer's disease. 2012 , 2012, 483469	13
1788	Cholesterol Metabolism in Huntington's Disease. 2012 ,	
1787	Bioprofile analysis: a new approach for the analysis of biomedical data in Alzheimer's disease. 2012 , 32, 997-1010	5
1786	Alzheimer's Disease and Other Dementias. 2012 , 2274-2283	2
1785	Toward a dynamic biomarker model in Alzheimer's disease. 2012 , 30, 91-100	15
1784	Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. 2012 , 135, 170-80	122
1783	Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. 2012 , 263, 344-61	166
1782	CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. 2012 , 78, 1568-75	172
1781	Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. 2012 , 78, 1576-82	202
1780	Bioinorganic chemistry of Alzheimer's disease. 2012 , 112, 5193-239	473

1779	The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization. 2012 , 112, 5147-92	636
1778	Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI. 2012 , 33, 2586-602	73
1777	CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. 2012 , 124, 23-35	138
1776	An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. 2012 , 71, 765-75	435
1775	Ascorbic acid, cognitive function, and Alzheimer's disease: a current review and future direction. 2012 , 38, 114-22	43
1774	Midlife blood pressure, plasma β amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study. 2012 , 59, 780-6	147
1773	Appraisal of cognition in preclinical Alzheimer's disease: a conceptual review. 2012 , 2, 183-195	16
1772	Cerebrospinal fluid profiles of amyloid β -related biomarkers in Alzheimer's disease. 2012 , 14, 65-73	61
1771	Cognition et fragilité chez la personne âgée. 2012 , 4, 13-16	2
1770	Longitudinal imaging of Alzheimer pathology using $[^{11}\text{C}]\text{PIB}$, $[^{18}\text{F}]\text{FDDNP}$ and $[^{18}\text{F}]\text{FDG}$ PET. 2012 , 39, 990-1000	116
1769	The prognostic value of amyloid imaging. 2012 , 39, 1207-19	26
1768	'Clinical trials in Alzheimer's disease': immunotherapy approaches. 2012 , 120 Suppl 1, 186-193	105
1767	Measurement of $\text{A}\beta$ -42 in cerebrospinal fluid is influenced by matrix effects. 2012 , 120, 325-33	29
1766	Glial cells in (patho)physiology. 2012 , 121, 4-27	392
1765	Diagnostic accuracy of ^{18}F -FDG and ^{11}C -PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment. 2012 , 66, 185-98	85
1764	Dementia: new criteria but no new treatments. <i>Lancet Neurology, The</i> , 2012 , 11, 4-5	24.1 19
1763	Epilepsy: new epidemiological and therapeutic perspectives. <i>Lancet Neurology, The</i> , 2012 , 11, 5-7	24.1 5
1762	Novel antibody capture assay for paraffin-embedded tissue detects wide-ranging amyloid beta and paired helical filament-tau accumulation in cognitively normal older adults. 2012 , 22, 472-84	20

1761	Magnetic resonance elastography of the brain in a mouse model of Alzheimer's disease: initial results. 2012 , 30, 535-9	57
1760	Parietal cortex matters in Alzheimer's disease: an overview of structural, functional and metabolic findings. 2012 , 36, 297-309	149
1759	Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD. 2012 , 27, 127-34	33
1758	Neuroimaging results impose new views on Alzheimer's disease--the role of amyloid revised. 2012 , 45, 153-72	38
1757	AIImaging: feasible, pertinent, and vital to progress in Alzheimer's disease. 2012 , 39, 209-19	46
1756	Progress in Alzheimer's disease. 2012 , 259, 201-11	71
1755	Increased functional connectivity within medial temporal lobe in mild cognitive impairment. 2013 , 23, 1-6	63
1754	Fluid biomarkers in Alzheimer's disease - current concepts. 2013 , 8, 20	147
1753	Kinetics of neurodegeneration based on a risk-related biomarker in animal model of glaucoma. 2013 , 8, 4	8
1752	(18)F-florbetaben AIImaging in mild cognitive impairment. 2013 , 5, 4	40
1751	A diagnostic methodology for Alzheimer's disease. 2013 , 3, 9	3
1750	Straightforward synthesis of PET tracer precursors used for the early diagnosis of Alzheimers disease through SuzukiMIiyaura cross-coupling reactions. 2013 , 69, 7345-7353	7
1749	Recent advances in neuroimaging biomarkers in geriatric psychiatry. 2013 , 15, 360	3
1748	Memory decline shows stronger associations with estimated spatial patterns of amyloid deposition progression than total amyloid burden. 2013 , 34, 2835-42	22
1747	Physical activity and brain function in older adults at increased risk for Alzheimer's disease. 2013 , 3, 54-83	38
1746	Ushering in the study and treatment of preclinical Alzheimer disease. 2013 , 9, 371-81	103
1745	Other Genes Implicated in Alzheimer's Disease. 2013 , 209-230	
1744	Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. 2013 , 108, 21-43	368

1743	Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. 2013 , 17, 54-63	24
1742	Early detection of memory impairment in people over 65 years old consulting at Health Examination Centers for the French health insurance: the EVATEM protocol. 2013 , 13, 55	16
1741	APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease. 2013 , 37, 1322-35	82
1740	Genetic Variants in Alzheimer's Disease. 2013 ,	8
1739	Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. 2013 , 260, 640-50	42
1738	Augmentation of sensory-evoked hemodynamic response in an early Alzheimer's disease mouse model. 2013 , 37, 857-68	14
1737	Molecular imaging of dementia. 2013 , 1, 56-62	3
1736	ATR-FTIR: a "rejuvenated" tool to investigate amyloid proteins. 2013 , 1828, 2328-38	239
1735	Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. 2013 , 74, 655-68	129
1734	The therapeutics of Alzheimer's disease: where we stand and where we are heading. 2013 , 74, 328-36	91
1733	Glia-based biomarkers and their functional role in the CNS. 2013 , 10, 43-63	15
1732	Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia. 2013 , 40, 1394-405	38
1731	Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology. 2013 , 40, 125-32	91
1730	Alternative Approaches in Gene Discovery and Characterization in Alzheimer's Disease. 2013 , 1, 39-51	11
1729	Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimer's disease. 2013 , 120, 807-12	58
1728	FDG PET and the genetics of dementia. 2013 , 1, 235-246	2
1727	Magnetic resonance spectroscopy in common dementias. 2013 , 23, 393-406	36
1726	Dementia severity and weight loss: a comparison across eight cohorts. The 10/66 study. 2013 , 9, 649-56	45

1725	Les biomarqueurs du LCR et du plasma : utilisation diagnostique et pronostique dans la maladie d'Alzheimer et les syndromes apparentés. 2013 , 4, 65-72	
1724	Characterizing mild cognitive disorders in the young-old over 8 years: prevalence, estimated incidence, stability of diagnosis, and impact on IADLs. 2013 , 9, 640-8	34
1723	White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment. 2013 , 9, S124-31	53
1722	Amyloid positron emission tomography with (18)F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease. 2013 , 9, 295-301	43
1721	Regulatory innovation and drug development for early-stage Alzheimer's disease. 2013 , 368, 1169-71	158
1720	Cholinergic activity correlates with reserve proxies in Alzheimer's disease. 2013 , 34, 2694.e13-8	33
1719	Military risk factors for Alzheimer's disease. 2013 , 9, 445-51	54
1718	The diffeomorphometry of temporal lobe structures in preclinical Alzheimer's disease. 2013 , 3, 352-60	62
1717	Identification of β amyloid species in canine cerebrospinal fluid by mass spectrometry. 2013 , 34, 2125-32	9
1716	Potential diagnostic applications of side chain oxysterols analysis in plasma and cerebrospinal fluid. 2013 , 86, 26-36	30
1715	Improving Alzheimer's disease phase II clinical trials. 2013 , 9, 39-49	24
1714	Docosahexaenoic acid homeostasis, brain aging and Alzheimer's disease: Can we reconcile the evidence?. 2013 , 88, 61-70	59
1713	Emerging biomarkers in cognition. 2013 , 29, 809-28	11
1712	Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer's disease. 2014 , 38, 481-95	112
1711	How close are we to a readily available, clinically reliable blood test for Alzheimer's disease?. 2013 , 3, 397-400	
1710	Brain amyloid- β oligomers in ageing and Alzheimer's disease. 2013 , 136, 1383-98	325
1709	Contemplating Alzheimer's disease and the contribution of white matter hyperintensities. 2013 , 13, 415	75
1708	The common dementias: a pictorial review. 2013 , 23, 3405-17	26

1707	Cerebral amyloid PET imaging in Alzheimer's disease. 2013 , 126, 643-57		79
1706	Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. 2013 , 110, E4502-9		253
1705	Mild cognitive impairment. 2013 , 13, 1247-61		9
1704	Biomarker modeling of Alzheimer's disease. 2013 , 80, 1347-58		586
1703	βAmyloid (Aβ) oligomers impair brain-derived neurotrophic factor retrograde trafficking by down-regulating ubiquitin C-terminal hydrolase, UCH-L1. 2013 , 288, 16937-16948		77
1702	Meta-analysis of functional network alterations in Alzheimer's disease: toward a network biomarker. 2013 , 37, 753-65		81
1701	CSF biomarkers of Alzheimer disease: "noncognitive" outcomes. 2013 , 81, 2028-31		21
1700	The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. 2013 , 126, 479-97		287
1699	Mild Cognitive Impairment. 2013 , 77-95		1
1698	Diagnosis and Differential Diagnosis of Dementia. 2013 , 1-13		
1697	Spontaneous and induced nontransgenic animal models of AD: modeling AD using combinatorial approach. 2013 , 28, 318-26		12
1696	How early can we predict Alzheimer's disease using computational anatomy?. 2013 , 34, 2815-26		67
1695	Biomarkers for Alzheimer's: the sequel of an original model. <i>Lancet Neurology, The</i> , 2013 , 12, 126-8	24.1	9
1694	The impact of early dementia diagnosis and intervention on informal caregivers. 2013 , 110, 54-62		123
1693	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. <i>Lancet Neurology, The</i> , 2013 , 12, 207-16	24.1	2557
1692	Heightened emotional contagion in mild cognitive impairment and Alzheimer's disease is associated with temporal lobe degeneration. 2013 , 110, 9944-9		106
1691	Modeling Alzheimer's disease in transgenic rats. 2013 , 8, 37		103
1690	Computer-aided diagnostic reporting of FDG PET for the diagnosis of Alzheimer's disease. 2013 , 1, 279-288		2

1689	Multiagent imaging of the brain. 2013 , 1, 365-376	2
1688	Mild chronic cerebral hypoperfusion induces neurovascular dysfunction, triggering peripheral beta-amyloid brain entry and aggregation. 2013 , 1, 75	44
1687	Do preclinical Alzheimer's disease criteria work?. <i>Lancet Neurology, The</i> , 2013 , 12, 933-5	24.1 6
1686	Evidence and Rational Based Research on Chinese Drugs. 2013 ,	11
1685	Loss of fornix white matter volume as a predictor of cognitive impairment in cognitively normal elderly individuals. 2013 , 70, 1389-95	79
1684	Zuerst verändern sich die Biomarker. 2013 , 15, 32-33	
1683	A PET study of discrimination of cerebral glucose metabolism in Alzheimer's disease and mild cognitive impairment. 2013 ,	1
1682	Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems. 2013 , 5, 10	42
1681	Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia. 2013 , 5, S2	81
1680	Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians. 2013 , 5, S8	14
1679	Evidence for age-dependent in vivo conformational rearrangement within A β amyloid deposits. 2013 , 8, 1128-33	63
1678	Changes in amyloid- β and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. 2013 , 5, 194re2	125
1677	Meta-cognitive q-Gaussian RBF network for binary classification: Application to mild cognitive impairment (MCI). 2013 ,	6
1676	Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. 2013 , 34, 22-34	48
1675	Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers. 2013 , 34, 73-82	38
1674	Apolipoprotein E ϵ 4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. 2013 , 34, 1-12	167
1673	Aging-related cortical reorganization of verbal fluency processing: a functional near-infrared spectroscopy study. 2013 , 34, 439-50	63
1672	Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. 2013 , 34, 822-31	106

1671	Evolution of source EEG synchronization in early Alzheimer's disease. 2013 , 34, 694-705	48
1670	Can MRI screen for CSF biomarkers in neurodegenerative disease?. 2013 , 80, 132-8	19
1669	Resting state functional connectivity in preclinical Alzheimer's disease. 2013 , 74, 340-7	302
1668	Apolipoprotein E, neurodegeneration, and Alzheimer disease. 2013 , 70, 299-300	5
1667	Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs. 2013 , 34, 1-114	15
1666	Alzheimer disease: Aβ-independent processes-rethinking preclinical AD. 2013 , 9, 123-4	137
1665	Relationship between imaging biomarkers, age, progression and symptom severity in Alzheimer's disease. 2013 , 3, 84-94	49
1664	Amyloid imaging and cognitive decline in nondemented oldest-old: the 90+ Study. 2013 , 9, 199-203	37
1663	Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. 2013 , 2, 356-65	227
1662	Clinical trials with ß drugs? Based on 2 projects in Alzheimer's disease and malaria. 2013 , 213, 251-5	
1661	Cognitive aging in persons with minimal amyloid-β and white matter hyperintensities. 2013 , 51, 2202-9	26
1660	Using neuroimaging to inform clinical practice for the diagnosis and treatment of mild cognitive impairment. 2013 , 29, 829-45	5
1659	Abnormal thiamine-dependent processes in Alzheimer's Disease. Lessons from diabetes. 2013 , 55, 17-25	57
1658	The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. 2013 , 9, e111-94	296
1657	Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease. 2013 , 2, 497-511	74
1656	Arterial spin labeled MRI in prodromal Alzheimer's disease: A multi-site study. 2013 , 2, 630-6	65
1655	Biomarker evidence for uncoupling of amyloid build-up and toxicity in Alzheimer's disease. 2013 , 9, 459-62	8
1654	Aβ amyloid, cognition, and APOE genotype in healthy older adults. 2013 , 9, 538-45	45

1653	Different patterns of gray matter atrophy in early- and late-onset Alzheimer's disease. 2013 , 34, 2014-22	120
1652	Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects?. 2013 , 2, 249-57	35
1651	The ELISA-measured increase in cerebrospinal fluid tau that discriminates Alzheimer's disease from other neurodegenerative disorders is not attributable to differential recognition of tau assembly forms. 2013 , 33, 923-8	9
1650	Acides gras om̄a-3 'et d'clin cognitif': la controverse. 2013 , 48, 170-174	0
1649	Getting lost in Alzheimer's disease: a break in the mental frame syncing. 2013 , 80, 416-21	44
1648	Neural correlates of the DemTect in Alzheimer's disease and frontotemporal lobar degeneration - A combined MRI & FDG-PET study. 2013 , 2, 746-58	17
1647	Clinical trials with 'drugs? Based on 2 projects in Alzheimer's disease and malaria. 2013 , 213, 251-255	
1646	The retooling of old cognitive tests as an interim step on the path to validating a next generation of neuropsychological paradigms and assays. 2013 , 9, S1-3	5
1645	R-flurbiprofen improves tau, but not Aβ pathology in a triple transgenic model of Alzheimer's disease. 2013 , 1541, 115-27	27
1644	L'imagerie c'brale des plaques amyloides': le point de vue du clinicien. 2013 , 4, 59-63	
1643	Cerebrospinal fluid Aβ2 is the best predictor of clinical progression in patients with subjective complaints. 2013 , 9, 481-7	139
1642	Cognitive and functional resilience despite molecular evidence of Alzheimer's disease pathology. 2013 , 9, e89-95	35
1641	Risk and resilience: A new perspective on Alzheimer's disease. 2013 , 1, 47-55	2
1640	Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. 2013 , 9, 438-44	111
1639	Modeling disease progression via multi-task learning. 2013 , 78, 233-48	129
1638	The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly. 2013 , 9, 687-698.e1	55
1637	Muscle-directed anti-Aβ single-chain antibody delivery via AAV1 reduces cerebral Aβ load in an Alzheimer's disease mouse model. 2013 , 49, 277-88	16
1636	Alzheimer disease biomarkers and insights into mild cognitive impairment. 2013 , 80, 978-80	12

1635	A cross-sectional study on cerebrospinal fluid biomarker levels in cognitively normal elderly subjects with or without a family history of Alzheimer's disease. 2013 , 19, 38-42	12
1634	Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes. 2013 , 75, 146-61	37
1633	Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. <i>Lancet Neurology, The</i> , 2013 , 12, 357-67	24.1 1336
1632	[(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. 2013 , 9, 666-76	421
1631	White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease?. 2013 , 70, 455-61	137
1630	Neurosteroids as regenerative agents in the brain: therapeutic implications. 2013 , 9, 241-50	114
1629	Backwaters and rapids on the amyloid river. 2013 , 80, 878-9	5
1628	Brain β amyloid load approaches a plateau. 2013 , 80, 890-6	260
1627	Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET. 2013 , 70, 423-33	39
1626	Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid- β (1-42) and β proteins as Alzheimer disease biomarkers. 2013 , 59, 903-16	117
1625	Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease. 2013 , 9, 123-131.e1	82
1624	Different multivariate techniques for automated classification of MRI data in Alzheimer's disease and mild cognitive impairment. 2013 , 212, 89-98	80
1623	24S-hydroxycholesterol in plasma: a marker of cholesterol turnover in neurodegenerative diseases. 2013 , 95, 595-612	75
1622	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. 2013 , 9, 677-86	43
1621	Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. <i>Lancet Neurology, The</i> , 2013 , 12, 469-82	24.1 139
1620	Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls. 2013 , 34, 1996-2002	51
1619	Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β amyloid in cognitively normal older individuals. 2013 , 33, 5553-63	113
1618	Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease. 2013 , 33, 2147-55	131

1617	Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. 2013 , 70, 462-8	139
1616	Alzheimer's disease: connecting findings from graph theoretical studies of brain networks. 2013 , 34, 2023-36	279
1615	From soluble alpha to progressive alpha aggregation: could prion-like templated misfolding play a role?. 2013 , 23, 333-41	24
1614	Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond?. 2013 , 85, 289-305	159
1613	Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-beta changes occur before increases of tau in cerebrospinal fluid. 2013 , 126, 631-41	103
1612	Role of mitochondrial homeostasis and dynamics in Alzheimer's disease. 2013 , 51, 3-12	110
1611	International Work Group criteria for the diagnosis of Alzheimer disease. 2013 , 97, 363-8	55
1610	The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease. 2013 , 97, 369-76	47
1609	Amyloid imaging with PET in early Alzheimer disease diagnosis. 2013 , 97, 377-98	45
1608	Clinical trials in prodementia stages of Alzheimer disease. 2013 , 97, 439-57	37
1607	Lipid raft disarrangement as a result of neuropathological progresses: a novel strategy for early diagnosis?. 2013 , 245, 26-39	37
1606	Vitamin D: an intervention for cognitive impairment in hemodialysis patients that could make sense. 2013 , 8, 896-7	
1605	Brain changes in older adults at very low risk for Alzheimer's disease. 2013 , 33, 8237-42	152
1604	Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. 2013 , 9, 621-48	84
1603	Resting-state functional connectivity in normal brain aging. 2013 , 37, 384-400	345
1602	Videos in clinical medicine. Reduction of paraphimosis in boys. 2013 , 368, e16	6
1601	Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism. 2013 , 70, 1039-45	46
1600	Reductive stress in young healthy individuals at risk of Alzheimer disease. 2013 , 63, 274-9	33

1599	Mild cognitive impairment due to Alzheimer disease in the community. 2013 , 74, 199-208	175
1598	Brain regional correlation of amyloid- β with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid- β accumulation. 2013 , 125, 535-47	42
1597	Brain injury biomarkers are not dependent on β amyloid in normal elderly. 2013 , 73, 472-80	133
1596	Vulnerable neural systems and the borderland of brain aging and neurodegeneration. 2013 , 77, 219-34	222
1595	Binary classification of 18 F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI. 2013 , 64, 517-25	37
1594	Statistical analysis of longitudinal neuroimage data with Linear Mixed Effects models. 2013 , 66, 249-60	218
1593	A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease. 2013 , 110, 114-23	19
1592	Cerebrospinal fluid secretion by the choroid plexus. 2013 , 93, 1847-92	266
1591	From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers. 2013 , 25, 210-20	11
1590	Bivariate random change point models for longitudinal outcomes. 2013 , 32, 1038-53	9
1589	Prediction of Alzheimer's disease and mild cognitive impairment using cortical morphological patterns. 2013 , 34, 3411-25	161
1588	The role of amyloid- β , tau, and apolipoprotein E epsilon4 in Alzheimer disease: how is the team playing?. 2013 , 34, 511-2	3
1587	Effects of T2-Weighted MRI Based Cranial Volume Measurements on Studies of the Aging Brain. 2013 , 8669,	4
1586	Correlation of specific amyloid- β oligomers with tau in cerebrospinal fluid from cognitively normal older adults. 2013 , 70, 594-9	46
1585	Brain imaging and cognitive predictors of stroke and Alzheimer disease in the Framingham Heart Study. 2013 , 44, 2787-94	39
1584	Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: a marker for disease severity. 2013 , 267, 221-30	170
1583	Plasma Acetylcholinesterase Activity Correlates with Intracerebral β Amyloid Load. 2013 , 10, 48-56	2
1582	New diagnostic concepts in Alzheimer's disease. 2013 , 19, 242-249	3

1581	In vivo characterization of the early states of the amyloid-beta network. 2013 , 136, 2239-52	84
1580	Neuroimaging and the search for a cure for Alzheimer disease. 2013 , 269, 671-91	37
1579	Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. 2013 , 80, 359-65	80
1578	Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration. 2013 , 80, 648-54	106
1577	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. 2013 , 80, 1048-56	131
1576	Diagnosing Mild Cognitive Impairment (MCI) in clinical trials: a systematic review. 2013 , 3,	91
1575	Risk factors for β amyloid deposition in healthy aging: vascular and genetic effects. 2013 , 70, 600-6	173
1574	The aging brain and cognition: contribution of vascular injury and β to mild cognitive dysfunction. 2013 , 70, 488-95	98
1573	Amnesic mild cognitive impairment: topological reorganization of the default-mode network. 2013 , 268, 501-14	47
1572	Classification of Alzheimer Diagnosis from ADNI Plasma Biomarker Data. 2013 , 2013, 569	3
1571	The role of β amyloid in alzheimer's disease-related neurodegeneration. 2013 , 33, 12910-1	19
1570	Generative FDG-PET and MRI model of aging and disease progression in Alzheimer's disease. 2013 , 9, e1002987	56
1569	Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. 2013 , 70, 320-5	98
1568	Mild cognitive impairment: incidence and vascular risk factors in a population-based cohort. 2013 , 80, 2112-20	94
1567	Longitudinal trajectories of everyday function by diagnostic status. 2013 , 28, 1070-5	41
1566	Subgroup of ADNI normal controls characterized by atrophy and cognitive decline associated with vascular damage. 2013 , 28, 191-201	27
1565	The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE- ϵ 4 carriers. 2013 , 9, e1003685	49
1564	Preclinical AD predicts decline in memory and executive functions in subjective complaints. 2013 , 81, 1409-16	104

1563	Classification for Alzheimer’s Disease from Structural MRI by General N-Dimensional Principal Component Analysis. 2013 , 336-338, 2316-2319	
1562	The Women’s Healthy Ageing Project: fertile ground for investigation of healthy participants ‘at risk’ for dementia. 2013 , 25, 726-37	14
1561	Retinal vascular calibers associate differentially with cerebral gray matter and white matter atrophy. 2013 , 27, 351-5	13
1560	Effect of cognitive reserve markers on Alzheimer pathologic progression. 2013 , 27, 343-50	60
1559	Is Alzheimer’s a disease of the white matter?. 2013 , 26, 244-51	72
1558	Current World Literature. 2013 , 26, 295-303	
1557	Biomarkers of Alzheimer disease: current and future applications to diagnostic criteria. 2013 , 19, 325-38	22
1556	Impact of brain aging and neurodegeneration on cognition: evidence from MRI. 2013 , 26, 640-5	21
1555	A biased competition account of attention and memory in Alzheimer’s disease. 2013 , 368, 20130062	25
1554	The PredictAD project: development of novel biomarkers and analysis software for early diagnosis of the Alzheimer’s disease. 2013 , 3, 20120072	19
1553	Changes in plasticity across the lifespan: cause of disease and target for intervention. 2013 , 207, 91-120	73
1552	Amyloid imaging in dementia. 2013 , 23, 43-60	
1551	Neuroimaging biomarkers of neurodegenerative diseases and dementia. 2013 , 33, 386-416	87
1550	Contribution of cerebrovascular health to the diagnosis of Alzheimer disease. 2013 , 70, 438-9	9
1549	Studies on Alzheimer’s Disease. 2013 ,	
1548	Current guidelines for dementia screening: shortcomings and recommended changes. 2013 , 3, 565-573	10
1547	Amyloid- β load predicts medial temporal lobe dysfunction in Alzheimer dementia. 2013 , 54, 1909-14	18
1546	Single-domain amnesic mild cognitive impairment identified by cluster analysis predicts Alzheimer’s disease in the european prospective DESCRIPA study. 2013 , 36, 1-19	32

1545	Analysis of cognitive, functional, health service use, and cost trajectories prior to and following memory loss. 2013 , 68, 562-7	16
1544	Alzheimer's disease diagnosis by detecting exogenous fluorescent signal of ligand bound to Beta amyloid in the lens of human eye: an exploratory study. 2013 , 4, 62	29
1543	Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. 2013 , 81, 1732-40	142
1542	Decreased white matter integrity in neuropsychologically defined mild cognitive impairment is independent of cortical thinning. 2013 , 19, 925-37	23
1541	Proton MRS in mild cognitive impairment. 2013 , 37, 770-7	46
1540	Gender-Specific Effects of Health and Lifestyle Markers on Individual BrainAGE. 2013 ,	2
1539	Cerebrospinal fluid levels of phosphorylated tau and A β -38/A β -40/A β -42 in Alzheimer's disease with PS1 mutations. 2013 , 20, 107-12	17
1538	Dementia and mild cognitive impairment in adults with intellectual disability: issues of diagnosis. 2013 , 18, 31-42	62
1537	Translational research on disease-modifying therapies for neurodegenerative diseases. 2013 , 1, 3-10	4
1536	Disease-modifying therapy for Alzheimer's disease: Challenges and hopes. 2013 , 1, 49-54	9
1535	In vivo assessment of amyloid- β deposition in nondemented very elderly subjects. 2013 , 73, 751-61	80
1534	Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating Drug Development for Neurodegenerative Diseases. 2013 , 47, 632-638	7
1533	Cerebrovascular contributions to Alzheimer's disease pathophysiology and potential therapeutic interventions in mouse models. 2013 , 37, 1994-2004	8
1532	Prions and Diseases. 2013 ,	
1531	Several direct and calculated biomarkers from the amyloid- β pool in blood are associated with an increased likelihood of suffering from mild cognitive impairment. 2013 , 36, 211-9	12
1530	CSF protein biomarkers predicting longitudinal reduction of CSF β amyloid42 in cognitively healthy elders. 2013 , 3, e293	37
1529	Serum multivalent cationic pattern: speculation on the efficient approach for detection of Alzheimer's disease. 2013 , 3, 2782	14
1528	Is specific HIV eradication from the brain possible or needed?. 2013 , 13, 403-9	12

1527	Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. 2013 , 80, 1784-91	175
1526	Cerebrospinal fluid amyloid- β and phenotypic heterogeneity in de novo Parkinson's disease. 2013 , 84, 537-43	48
1525	A blood gene expression marker of early Alzheimer's disease. 2013 , 33, 737-53	60
1524	Sensitivity and specificity of diagnostic accuracy in Alzheimer's disease: a synthesis of existing evidence. 2013 , 28, 337-47	20
1523	From metabolic pathways to biomarkers: where are we now with metabolomics in Alzheimer's disease?. 2013 , 8, 491-494	
1522	Longitudinal monitoring of sex-related in vivo metabolic changes in the brain of Alzheimer's disease transgenic mouse using magnetic resonance spectroscopy. 2013 , 34, 1051-9	15
1521	Neuropsychological signs of Alzheimer's disease 8 years prior to diagnosis. 2013 , 34, 537-46	37
1520	Alzheimer's disease: the downside of a highly evolved parietal lobe?. 2013 , 35, 227-40	59
1519	Amyloid- β interacts with blood-brain barrier function in dementia: a systematic review. 2013 , 35, 859-73	33
1518	Cerebrospinal fluid biomarkers mirror rate of cognitive decline. 2013 , 34, 949-56	30
1517	Calmodulin levels in blood cells as a potential biomarker of Alzheimer's disease. 2013 , 5, 55	19
1516	Factors affecting subjective memory complaints in the AIBL aging study: biomarkers, memory, affect, and age. 2013 , 25, 1307-15	117
1515	Potential benefits of adherence to the Mediterranean diet on cognitive health. 2013 , 72, 140-52	112
1514	Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β amyloidosis. 2013 , 70, 1030-8	58
1513	The effect of neuronal activity and connectivity on Alzheimer's disease: a new direction and its implications for future treatment strategies. 2013 , 3, 93-95	
1512	Research Highlights: Highlights from the latest articles in biomarkers in medicine. 2013 , 7, 923-928	1
1511	Interview: Understanding the complex pathways from normal cognition to dementia: the role of neuroimaging. 2013 , 3, 413-416	
1510	The AD-CSF-index discriminates Alzheimer's disease patients from healthy controls: a validation study. 2013 , 36, 67-77	43

1509	Comparing brain amyloid deposition, glucose metabolism, and atrophy in mild cognitive impairment with and without a family history of dementia. 2013 , 35, 509-24	31
1508	A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia. 2013 , 36, 421-31	51
1507	Altered default mode network connectivity in older adults with cognitive complaints and amnesic mild cognitive impairment. 2013 , 35, 751-60	117
1506	Mild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's disease. 2013 , 35, 284-94	14
1505	Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly. 2013 , 18, 1150-73	15
1504	Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment. 2013 , 33, 723-36	80
1503	Acides gras oméga-3 et déclin cognitif : la controverse. 2013 , 20, 88-92	2
1502	Variation in Variables that Predict Progression from MCI to AD Dementia over Duration of Follow-up. 2013 , 2, 12-28	20
1501	Disturbed sleep in preclinical cognitive impairment: cause and effect?. 2013 , 36, 1275-6	7
1500	The role of the innate immune system in Alzheimer's disease and frontotemporal lobar degeneration: an eye on microglia. 2013 , 2013, 939786	22
1499	Clinical observational research on Alzheimer's disease: what clinical trial registries can tell. 2013 , 34, 183-90	1
1498	Targeted recruitment using cerebrospinal fluid biomarkers: implications for Alzheimer's disease therapeutic trials. 2013 , 34, 431-7	7
1497	MR microscopy of human amyloid- β deposits: characterization of parenchymal amyloid, diffuse plaques, and vascular amyloid. 2013 , 34, 1037-49	15
1496	Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints. 2013 , 36, 475-86	5
1495	Retrogenesis: a model of dementia progression in Alzheimer's disease related to neuroplasticity. 2013 , 33, 1191-3	6
1494	Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI. 2013 , 8, e55531	32
1493	Regional amyloid deposition in amnesic mild cognitive impairment and Alzheimer's disease evaluated by [18F]AV-45 positron emission tomography in Chinese population. 2013 , 8, e58974	37
1492	Cerebrospinal fluid melanin-concentrating hormone (MCH) and hypocretin-1 (HCRT-1, orexin-A) in Alzheimer's disease. 2013 , 8, e63136	45

1491	BrainAGE in Mild Cognitive Impaired Patients: Predicting the Conversion to Alzheimer's Disease. 2013 , 8, e67346	242
1490	Cognitive declines precede and predict functional declines in aging and Alzheimer's disease. 2013 , 8, e73645	47
1489	Early indications of future cognitive decline: stable versus declining controls. 2013 , 8, e74062	23
1488	White matter abnormalities and structural hippocampal disconnections in amnesic mild cognitive impairment and Alzheimer's disease. 2013 , 8, e74776	23
1487	Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature. 2013 , 36, 401-8	15
1486	Evaluation of annexin A5 as a biomarker for Alzheimer's disease and dementia with lewy bodies. 2013 , 5, 15	19
1485	Faster cognitive decline in the years prior to MR imaging is associated with smaller hippocampal volumes in cognitively healthy older persons. 2013 , 5, 21	6
1484	Blood-brain transfer of Pittsburgh compound B in humans. 2013 , 5, 70	16
1483	PiB Fails to Map Amyloid Deposits in Cerebral Cortex of Aged Dogs with Canine Cognitive Dysfunction. 2013 , 5, 99	15
1482	The attenuation of retinal nerve fiber layer thickness and cognitive deterioration. 2013 , 7, 142	32
1481	Animal models of neurodegenerative diseases. 2013 , 35 Suppl 2, S82-91	34
1480	Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. 2013 , 5, 6	69
1479	Metal dyshomeostasis and inflammation in Alzheimer's and Parkinson's diseases: possible impact of environmental exposures. 2013 , 2013, 726954	79
1478	The Beta-amyloid protein of Alzheimer's disease: communication breakdown by modifying the neuronal cytoskeleton. 2013 , 2013, 910502	33
1477	Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease. 2013 , 2013, 589308	7
1476	Role of copper and cholesterol association in the neurodegenerative process. 2013 , 2013, 414817	12
1475	Magnetic resonance spectroscopy in Alzheimer's disease. 2013 , 9, 687-96	46
1474	Predicting Cognitive Decline in Alzheimer's Disease (AD): The Role of Clinical, Cognitive Characteristics and Biomarkers. 2013 ,	

1473	. 2013,	1
1472	The LIFE Cognition Study: design and baseline characteristics. 2014 , 9, 1425-36	14
1471	General anesthetic and the risk of dementia in elderly patients: current insights. 2014 , 9, 1619-28	47
1470	Multi-task linear programming discriminant analysis for the identification of progressive MCI individuals. 2014 , 9, e96458	17
1469	Widespread disruption of functional brain organization in early-onset Alzheimer's disease. 2014 , 9, e102995	40
1468	Gray and white matter changes in subjective cognitive impairment, amnesic mild cognitive impairment and Alzheimer's disease: a voxel-based analysis study. 2014 , 9, e104007	22
1467	Predicting progression of Alzheimer's disease using ordinal regression. 2014 , 9, e105542	40
1466	Changes in white matter integrity before conversion from mild cognitive impairment to Alzheimer's disease. 2014 , 9, e106062	19
1465	A clinical index to predict progression from mild cognitive impairment to dementia due to Alzheimer's disease. 2014 , 9, e113535	26
1464	Currently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer's Disease and Mild Cognitive Impairment. 2014 , 2014, 1-15	2
1463	CSF Biomarkers of Alzheimer's Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design. 2014 , 2014, 1-14	11
1462	Structure-Function Relationships behind the Phenomenon of Cognitive Resilience in Neurology: Insights for Neuroscience and Medicine. 2014 , 2014, 1-28	52
1461	Neuronal Networks and Therapeutics in Neurodegenerative Disorders. 2014 , 335-348	1
1460	Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria. 2014 , 6, 47	74
1459	Possible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factors. 2014 , 6, 71	34
1458	Vitamin d in older adults: the need to specify standard values with respect to cognition. 2014 , 6, 72	16
1457	Gender-specific impact of personal health parameters on individual brain aging in cognitively unimpaired elderly subjects. 2014 , 6, 94	56
1456	Early Brain Loss in Circuits Affected by Alzheimer's Disease is Predicted by Fornix Microstructure but may be Independent of Gray Matter. 2014 , 6, 106	27

1455	Genetic variation modifies risk for neurodegeneration based on biomarker status. 2014 , 6, 183	14
1454	Aging reduces glial uptake and promotes extracellular accumulation of A β from a lentiviral vector. 2014 , 6, 210	19
1453	Alzheimer's disease and the fornix. 2014 , 6, 241	42
1452	Integrative analysis of multi-dimensional imaging genomics data for Alzheimer's disease prediction. 2014 , 6, 260	24
1451	Amyloid Beta1-42 and the Phosphorylated Tau Threonine 231 in Brains of Aged Cynomolgus Monkeys (<i>Macaca fascicularis</i>). 2014 , 6, 313	17
1450	The Insight ToolKit image registration framework. 2014 , 8, 44	272
1449	Imaging Brain Metabolism and Pathology in Alzheimer's Disease with Positron Emission Tomography. 2014 , 4,	11
1448	Online Learning for Classification of Alzheimer Disease based on Cortical Thickness and Hippocampal Shape Analysis. 2014 , 20, 61-8	5
1447	Role of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's disease modifying therapies. 2014 , 18, 447-56	11
1446	Biological markers of Alzheimer's disease. 2014 , 72, 227-31	14
1445	Optimizing regions-of-interest composites for capturing treatment effects on brain amyloid in clinical trials. 2015 , 43, 809-21	15
1444	Plasma concentrations of the amyloid- β peptides in young volunteers: the influence of the APOE genotype. 2014 , 40, 1055-60	7
1443	Biomarkers for predicting cognitive decline in those with normal cognition. 2014 , 40, 587-94	27
1442	The link between cardiovascular risk, Alzheimer's disease, and mild cognitive impairment: support from recent functional neuroimaging studies. 2014 , 36, 344-57	7
1441	Biomarker Research of Preclinical Alzheimer's Disease and MCI Based on Neuroimage Techniques. 2014 , 1, 92-101	
1440	Vascular pathophysiology of Alzheimer's disease. 2014 , 11, 1-3	3
1439	What have novel imaging techniques revealed about metabolism in the aging brain?. 2014 , 9, 341-354	26
1438	Amyloid imaging in Alzheimer's disease: a literature review. 2014 , 18, 723-40	8

1437	Welche bildgebenden Verfahren sind in der Demenzdiagnostik sinnvoll?. 2014 , 15, 38-49	1
1436	β-Secretase processing and effects of β-Secretase inhibitors and modulators on long Aβ-peptides in cells. 2014 , 289, 3276-87	21
1435	Models of β-amyloid induced Tau-pathology: the long and "folded" road to understand the mechanism. 2014 , 9, 51	172
1434	The Dutch Parelnoer Institute--Neurodegenerative diseases; methods, design and baseline results. 2014 , 14, 254	42
1433	[Clinically validated molecular biomarkers of neurodegenerative dementia]. 2014 , 85, 1372-81	4
1432	Advances in MRI biomarkers for the diagnosis of Alzheimer's disease. 2014 , 8, 1151-69	33
1431	Alzheimer's disease progression model based on integrated biomarkers and clinical measures. 2014 , 35, 1111-20	15
1430	Gadolinium-based contrast agents targeted to amyloid aggregates for the early diagnosis of Alzheimer's disease by MRI. 2014 , 87, 843-61	40
1429	Interleukin-6 and C-reactive protein as predictors of cognitive decline in late midlife. 2014 , 83, 486-93	125
1428	Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. 2014 , 55, 347-65	28
1427	Neuroscience research on aging and implications for counseling psychology. 2014 , 61, 534-40	6
1426	Promise and challenge: the lens model as a biomarker for early diagnosis of Alzheimer's disease. 2014 , 2014, 826503	15
1425	2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. 2014 , 10, S430-52	57
1424	Metabolomics in the Study of Alzheimer's Disease. 2014 , 64, 249-278	1
1423	Is verbal episodic memory in elderly with amyloid deposits preserved through altered neuronal function?. 2014 , 24, 2210-8	30
1422	Apathy correlates with prefrontal amyloid β-deposition in Alzheimer's disease. 2014 , 85, 449-55	66
1421	Preclinical biomarkers in Alzheimer disease: a sum greater than the parts. 2014 , 71, 1357-8	3
1420	A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. 2014 , 2014, 785039	37

1419	Epidemic spreading model to characterize misfolded proteins propagation in aging and associated neurodegenerative disorders. 2014 , 10, e1003956	105
1418	Association of hypometabolism and amyloid levels in aging, normal subjects. 2014 , 82, 1959-67	60
1417	Genome-wide association meta-analysis of neuropathologic features of Alzheimer's disease and related dementias. 2014 , 10, e1004606	219
1416	Brain imaging of cognitively normal individuals with 2 parents affected by late-onset AD. 2014 , 82, 752-60	37
1415	TEMPORARY REMOVAL: Blood methylomic signatures of presymptomatic dementia in elderly subjects with type 2 diabetes mellitus. 2014 ,	0
1414	Molecular imaging of Alzheimer disease pathology. 2014 , 35, S12-7	13
1413	Demenz –eine Übersicht. 2014 , 06, 155-164	
1412	Unresolved questions in Alzheimer's research: will biomarkers help?. 2014 , 8, 61-3	2
1411	A data-driven model of biomarker changes in sporadic Alzheimer's disease. 2014 , 137, 2564-77	149
1410	Tracking the earliest pathologic changes in Alzheimer disease. 2014 , 82, 1576-7	16
1409	PET approaches for diagnosis of dementia. 2014 , 35, 2030-8	76
1408	Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. 2014 , 6, 445-54	133
1407	Nonamyloid PET biomarkers and Alzheimer's disease: current and future perspectives. 2014 , 9, 597-613	2
1406	Amyloid beta peptide immunotherapy in Alzheimer disease. 2014 , 170, 739-48	21
1405	Amyloid and its association with default network integrity in Alzheimer's disease. 2014 , 35, 779-91	28
1404	Diagnostic methods and biomarkers for Alzheimer's disease. 2014 , 6, 133-147	8
1403	Cognitive decline and brain pathology in aging--need for a dimensional, lifespan and systems vulnerability view. 2014 , 55, 244-54	33
1402	Dementia in older people: an update. 2014 , 44, 1066-73	34

1401	The emerging role of glutathione in Alzheimer's disease. 2014 , 40, 519-29	109
1400	Structural and functional brain changes in the default mode network in subtypes of amnesic mild cognitive impairment. 2014 , 27, 188-98	23
1399	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. 2014 , 1, 534-43	78
1398	Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's disease. 2014 , 35, 2665-2670	23
1397	Alzheimer's disease research and development: a call for a new research roadmap. 2014 , 1313, 1-16	24
1396	Amyloid-directed immunotherapy for Alzheimer's disease. 2014 , 275, 284-95	106
1395	Mitochondrial dysfunction: cause and consequence of Alzheimer's disease. 2014 , 127, 183-210	61
1394	Nutrient intake and brain biomarkers of Alzheimer's disease in at-risk cognitively normal individuals: a cross-sectional neuroimaging pilot study. 2014 , 4, e004850	59
1393	Possible role of orexin in the pathogenesis of Alzheimer disease. 2014 , 71, 1478-80	7
1392	White matter integrity determined with diffusion tensor imaging in older adults without dementia: influence of amyloid load and neurodegeneration. 2014 , 71, 1547-54	45
1391	Accelerating cortical thinning: unique to dementia or universal in aging?. 2014 , 24, 919-34	187
1390	Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. 2014 , 6, 226ra30	244
1389	The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. 2014 , 6, 46	135
1388	Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer's disease mouse model. 2014 , 7, 65	80
1387	Pro: Are we ready to translate Alzheimer's disease modifying therapies to people with Down syndrome?. 2014 , 6, 60	4
1386	Applying a cumulative deficit model of frailty to dementia: progress and future challenges. 2014 , 6, 84	12
1385	Optimizing cognitive development over the life course and preventing cognitive decline: Introducing the Cognitive Health Environment Life Course Model (CHELM). 2014 , 38, 1-10	30
1384	Preclinical Alzheimer's disease. 2014 , 24, 117-121	

1383	Chronic kidney disease is associated with dementia independent of cerebral small-vessel disease. 2014 , 82, 1051-7	71
1382	Neuropsychiatric symptoms in the prodromal stages of dementia. 2014 , 27, 230-5	36
1381	FDG-PET and amyloid-PET imaging: the diverging paths. 2014 , 27, 405-13	48
1380	Association between neuropathology and brain volume in the Framingham Heart Study. 2014 , 28, 219-25	24
1379	Theoretical impact of Florbetapir (18F) amyloid imaging on diagnosis of alzheimer dementia and detection of preclinical cortical amyloid. 2014 , 73, 948-53	25
1378	Alzheimer disease cerebrospinal fluid biomarkers predict cognitive decline in healthy elderly over 2 years. 2014 , 28, 234-8	5
1377	Impact of sleep on the risk of cognitive decline and dementia. 2014 , 27, 478-83	136
1376	Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β amyloid 42: a cross-validation study against amyloid positron emission tomography. 2014 , 71, 1282-9	254
1375	Lobar microbleeds are associated with a decline in executive functioning in older adults. 2014 , 38, 377-83	37
1374	Neuroinflammation and β amyloid deposition in Alzheimer's disease: in vivo quantification with molecular imaging. 2014 , 37, 1-18	19
1373	Amyloid burden, neuronal function, and cognitive decline in middle-aged adults at risk for Alzheimer's disease. 2014 , 20, 422-33	21
1372	Interactions between gold nanoparticles and amyloid β 5-35 peptide. 2014 , 8, 295-303	6
1371	Unregulated Lipid Peroxidation in Neurological Dysfunction. 2014 , 31-55	1
1370	Why the Negative Studies in Alzheimer's Disease?. 2014 , 99-116	
1369	Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. 2014 , 71, 855-62	113
1368	Emerging β amyloid pathology and accelerated cortical atrophy. 2014 , 71, 725-34	43
1367	Learning Imaging Biomarker Trajectories from Noisy Alzheimer's Disease Data Using a Bayesian Multilevel Model. 2014 , 85-94	8
1366	Tauopathy contributes to synaptic and cognitive deficits in a murine model for Alzheimer's disease. 2014 , 28, 2620-31	31

1365	Predicting aggressive decline in mild cognitive impairment: the importance of white matter hyperintensities. 2014 , 71, 872-7	63
1364	Biomarker in der Neurologie âStandardisierung dringend erforderlich1). 2014 , 38,	
1363	Molecular neuropsychology: creation of test-specific blood biomarker algorithms. 2014 , 37, 45-57	12
1362	Fractal Structure and Entropy Production within the Central Nervous System. 2014 , 16, 4497-4520	16
1361	Biomarkers for neurological disorders âall for standardization. 2014 , 38,	
1360	Preclinical and Translational PET/MR Imaging. 2014 , 55, 11S-18S	51
1359	A sensitive aligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid. 2014 , 34, 2884-97	103
1358	Cerebral blood flow measured by arterial spin labeling MRI as a preclinical marker of Alzheimer's disease. 2014 , 42 Suppl 4, S411-9	123
1357	A distinct subfraction of As responsible for the high-affinity Pittsburgh compound B-binding site in Alzheimer's disease brain. 2014 , 131, 356-68	22
1356	Covarying alterations in Adeposition, glucose metabolism, and gray matter volume in cognitively normal elderly. 2014 , 35, 297-308	66
1355	The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. 2014 , 1842, 1219-31	411
1354	Biomarkers in pharmacology and drug discovery. 2014 , 87, 172-88	45
1353	Comparison between clinical diagnosis and CSF biomarkers of Alzheimer disease in elderly patients with late onset psychosis: Helsinki Old Age Psychosis Study (HOPS). 2014 , 22, 908-16	9
1352	A point-based tool to predict conversion from mild cognitive impairment to probable Alzheimer's disease. 2014 , 10, 646-55	34
1351	Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. 2014 , 2, 246-55	331
1350	APOE-epsilon4 and aging of medial temporal lobe gray matter in healthy adults older than 50 years. 2014 , 35, 2479-2485	29
1349	Distinct pattern of hypometabolism and atrophy in preclinical and prodementia Alzheimer's disease. 2014 , 35, 1973-81	38
1348	A novel approach for integrative studies on neurodegenerative diseases in human brains. 2014 , 226, 171-183	15

1347	Association of homocysteine with hippocampal volume independent of cerebral amyloid and vascular burden. 2014 , 35, 1519-25	52
1346	Amyloid- β diurnal pattern: possible role of sleep in Alzheimer's disease pathogenesis. 2014 , 35 Suppl 2, S29-34	96
1345	Inferring changepoint times of medial temporal lobe morphometric change in preclinical Alzheimer's disease. 2014 , 5, 178-87	68
1344	Genetic modification of the relationship between phosphorylated tau and neurodegeneration. 2014 , 10, 637-645.e1	18
1343	Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age: a post-hoc analysis of the Whitehall II cohort study. 2014 , 2, 228-35	122
1342	A phase 1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. 2014 , 10, 571-81	136
1341	Biological heterogeneity in ADNI amnesic mild cognitive impairment. 2014 , 10, 511-521.e1	74
1340	Diagnosticare la malattia di Alzheimer. 2014 , 14, 1-14	
1339	The future of blood-based biomarkers for Alzheimer's disease. 2014 , 10, 115-31	196
1338	Recent advances in the application of metabolomics to Alzheimer's Disease. 2014 , 1842, 1232-9	112
1337	Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia. 2014 , 35, 143-51	85
1336	Five-year follow-up of ¹¹ C-PIB uptake in Alzheimer's disease and MCI. 2014 , 41, 283-9	24
1335	Biomarker modelling of early molecular changes in Alzheimer's disease. 2014 , 18, 213-27	4
1334	Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease. 2014 , 88, 617-30	32
1333	Neuroimaging and genetic risk for Alzheimer's disease and addiction-related degenerative brain disorders. 2014 , 8, 217-233	10
1332	Machine Learning in Healthcare Informatics. 2014 ,	26
1331	On-chip magneto-immunoassay for Alzheimer's biomarker electrochemical detection by using quantum dots as labels. 2014 , 54, 279-84	79
1330	The biological functions and signaling mechanisms of the p75 neurotrophin receptor. 2014 , 220, 121-64	77

1329	Neuroimaging in dementia. 2014 , 79, 202-8		16
1328	Neurodegenerative Diseases. 2014 ,		2
1327	Early adult to midlife cardiovascular risk factors and cognitive function. 2014 , 129, 1560-7		173
1326	Conceptualizing neuropsychiatric diseases with multimodal data-driven meta-analyses - the case of behavioral variant frontotemporal dementia. 2014 , 57, 22-37		63
1325	A 2-process model for neuropathology of Alzheimer's disease. 2014 , 35, 301-8		44
1324	What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. 2014 , 117, 20-40		412
1323	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology, The</i> , 2014 , 13, 614-29	24.1	1985
1322	Understanding the cause of sporadic Alzheimer's disease. 2014 , 14, 621-30		31
1321	Apolipoproteins E and J interfere with amyloid-beta uptake by primary human astrocytes and microglia in vitro. 2014 , 62, 493-503		58
1320	Differential effects of the ApoE4 genotype on brain structure and function. 2014 , 89, 81-91		44
1319	Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults. 2014 , 62, 16-24		485
1318	Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. 2014 , 137, 221-31		145
1317	Magnetization transfer contrast imaging reveals amyloid pathology in Alzheimer's disease transgenic mice. 2014 , 87, 111-9		18
1316	Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. 2014 , 370, 322-33		1274
1315	Synthesis of superparamagnetic iron oxide nanoparticles coated with a DDNP-carboxyl derivative for in vitro magnetic resonance imaging of Alzheimer's disease. 2014 , 37, 348-55		34
1314	Mild Cognitive Impairment: A Brief Review and Suggested Clinical Algorithm. 2014 , 29, 293-302		10
1313	Early identification and heritability of mild cognitive impairment. 2014 , 43, 600-10		43
1312	A focus on structural brain imaging in the Alzheimer's disease neuroimaging initiative. 2014 , 75, 527-33		26

1311	Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. 2014 , 71, 11-22	166
1310	Human APOE genotype affects intraneuronal A β -42 accumulation in a lentiviral gene transfer model. 2014 , 23, 1365-75	26
1309	Emerging therapeutics for Alzheimer's disease. 2014 , 54, 381-405	63
1308	Diagnostic classification of arterial spin labeling and structural MRI in presenile early stage dementia. 2014 , 35, 4916-31	65
1307	Task-induced brain activity patterns in type 2 diabetes: a potential biomarker for cognitive decline. 2014 , 63, 3112-9	34
1306	The evolution of preclinical Alzheimer's disease: implications for prevention trials. 2014 , 84, 608-22	429
1305	Biomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer disease. 2014 , 10, 690-703	24
1304	APOE ϵ and risk for Alzheimer's disease: do regionally distributed white matter hyperintensities play a role?. 2014 , 10, 619-29	41
1303	Longitudinal PET-MRI reveals β amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion. 2014 , 20, 1485-92	87
1302	MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research. 2014 , 37, 629-41	32
1301	Novel radioiodinated 1,3,4-oxadiazole derivatives with improved in vivo properties for SPECT imaging of β amyloid plaques. 2014 , 5, 82-85	5
1300	Neuroimaging and neurocognitive abnormalities associated with bipolar disorder in old age. 2014 , 29, 421-7	24
1299	CSF A β 2 predicts early-onset dementia in Parkinson disease. 2014 , 82, 1784-90	108
1298	A comparison of early diagnostic utility of Alzheimer disease biomarkers in magnetic resonance and cerebrospinal fluid. 2014 , 29, 397-401	
1297	What is the role of neuroimaging in dementia? A review. 2014 , 23, 20120015	
1296	Designing BODIPY-based probes for fluorescence imaging of β amyloid plaques. 2014 , 4, 51032-51037	21
1295	Vascular risk and A β interact to reduce cortical thickness in AD vulnerable brain regions. 2014 , 83, 40-7	67
1294	Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease. 2014 , 42, 901-8	79

1293	Within-patient correspondence of amyloid- β and intrinsic network connectivity in Alzheimer's disease. 2014 , 137, 2052-64		97
1292	Gene-environment interactions: lifetime cognitive activity, APOE genotype, and β amyloid burden. 2014 , 34, 8612-7		93
1291	Prognostic classification of mild cognitive impairment and Alzheimer's disease: MRI independent component analysis. 2014 , 224, 81-8		36
1290	Mild cognitive impairment: diagnosis, longitudinal course, and emerging treatments. 2014 , 16, 490		82
1289	Standardization of MRI and Amyloid Imaging. 2014 , 131-156		0
1288	The role of olfactory challenge tests in incipient dementia and clinical trial design. 2014 , 14, 479		17
1287	Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in prodementia stages of Alzheimer's disease. 2014 , 10, 421-429.e3		66
1286	Functional and Structural MRI in Alzheimer's Disease: A Multimodal Approach. 2014 , 371-422		
1285	APOE2 enhances neuroprotection against Alzheimer's disease through multiple molecular mechanisms. 2014 , 19, 1243-50		115
1284	Vitamin D in relation to cognitive impairment, cerebrospinal fluid biomarkers, and brain volumes. 2014 , 69, 1132-8		54
1283	Preventing Alzheimer's Disease. 2014 , 33-46		1
1282	Involvement of oxysterols in age-related diseases and ageing processes. 2014 , 18, 148-62		111
1281	Age-specific population frequencies of cerebral β amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. <i>Lancet Neurology, The</i> , 2014 , 13, 997-1005	24.1	246
1280	Recollection and familiarity in aging individuals with mild cognitive impairment and Alzheimer's disease: a literature review. 2014 , 24, 313-31		43
1279	How does it STAC up? Revisiting the scaffolding theory of aging and cognition. 2014 , 24, 355-70		409
1278	Alzheimer-Demenz: Praxis und neue Entwicklungen. 2014 , 16, 40-51		
1277	Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging. 2014 , 11, 120		66
1276	Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid- β 2014 , 6, 14		23

1275	Perspectives on future Alzheimer therapies: amyloid- β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. 2014 , 6, 16	96
1274	Roadblocks for integration of novel biomarker concepts into clinical routine: the peptoid approach. 2014 , 6, 23	3
1273	Considerations for animal models of blast-related traumatic brain injury and chronic traumatic encephalopathy. 2014 , 6, 64	43
1272	Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects. 2014 , 137, 3327-38	89
1271	The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease. 2014 , 275, 418-27	35
1270	Biomarkers in dementia: clinical utility and new directions. 2014 , 85, 1426-34	98
1269	Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. 2014 , 63, 2253-61	163
1268	Brain network alterations in Alzheimer's disease measured by eigenvector centrality in fMRI are related to cognition and CSF biomarkers. 2014 , 35, 2383-93	84
1267	Gray-matter macrostructure in cognitively healthy older persons: associations with age and cognition. 2014 , 219, 2029-49	26
1266	Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies. 2014 , 6, 11	62
1265	Movement Disorders in Dementias. 2014 ,	2
1264	Depressive, functional status, and neuropsychiatric symptom trajectories before an Alzheimer's disease diagnosis. 2014 , 18, 110-6	8
1263	Manifold population modeling as a neuro-imaging biomarker: application to ADNI and ADNI-GO. 2014 , 94, 275-286	37
1262	Potential Clinical Applications of PET/MR Imaging in Neurodegenerative Diseases. 2014 , 55, 475-555	46
1261	Pharma-Nutrition. 2014 ,	
1260	Quantitative evaluation of disease progression in a longitudinal mild cognitive impairment cohort. 2014 , 39, 49-61	18
1259	A Bayesian Nonparametric Regression Model With Normalized Weights: A Study of Hippocampal Atrophy in Alzheimer's Disease. 2014 , 109, 477-490	6
1258	Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease. 2014 , 30, 317-30	61

1257	Total management of diabetes mellitus in the elderly. 2014 , 5, 155-157	1
1256	MRI in Psychiatry. 2014 ,	2
1255	Network dysfunction in Alzheimer's disease: refining the disconnection hypothesis. 2014 , 4, 299-311	100
1254	Distinct perfusion patterns in Alzheimer's disease, frontotemporal dementia and dementia with Lewy bodies. 2014 , 24, 2326-33	46
1253	Regional cerebral blood flow-SPECT DIFFUSION case report of catatonia. 2014 , 33, 299-301	3
1252	Myeloid microvesicles in cerebrospinal fluid are associated with myelin damage and neuronal loss in mild cognitive impairment and Alzheimer disease. 2014 , 76, 813-25	62
1251	Neuroprotective pathways: lifestyle activity, brain pathology, and cognition in cognitively normal older adults. 2014 , 35, 1873-82	82
1250	Automatic temporal lobe atrophy assessment in prodromal AD: Data from the DESCRIPA study. 2014 , 10, 456-467	12
1249	Operationalizing hippocampal volume as an enrichment biomarker for amnesic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size. 2014 , 35, 808-18	31
1248	Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers. 2014 , 20, 8-15	30
1247	White matter integrity is associated with cerebrospinal fluid markers of Alzheimer's disease in normal adults. 2014 , 35, 2263-71	45
1246	Utilidad de la neuroimagen amiloidea en Neurología asistencial. 2014 , 6, 68-76	6
1245	Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects. 2014 , 10, S344-53	58
1244	No evidence of a longitudinal association between diurnal cortisol patterns and cognition. 2014 , 35, 2239-45	31
1243	Al and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease. 2014 , 10, 743-751.e1	62
1242	Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. 2014 , 35, 614-22	36
1241	Polyfluorinated bis-styrylbenzenes as amyloid- β plaque binding ligands. 2014 , 22, 2469-81	12
1240	Cognitive decline is mediated by gray matter changes during middle age. 2014 , 35, 1086-94	38

1239	Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. 2014 , 4, 164-73	88
1238	Age-associated changes of cerebrospinal fluid amyloid- β and tau in cynomolgus monkeys. 2014 , 35, 1656-9	15
1237	Gray matter atrophy pattern in elderly with subjective memory impairment. 2014 , 10, 99-108	100
1236	Midlife risk score for the prediction of dementia four decades later. 2014 , 10, 562-70	143
1235	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. 2014 , 88, 426-49	84
1234	Memory deficits in aging and neurological diseases. 2014 , 122, 1-29	21
1233	The Italian Alzheimer's Disease Neuroimaging Initiative (I-ADNI): validation of structural MR imaging. 2014 , 40, 941-52	14
1232	A cell model for the initial phase of sporadic Alzheimer's disease. 2014 , 42, 395-411	24
1231	In vivo tau imaging: obstacles and progress. 2014 , 10, S254-64	75
1230	White matter changes in preclinical Alzheimer's disease: a magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid β protein 42 levels. 2014 , 35, 2671-2680	56
1229	The role of egocentric and allocentric abilities in Alzheimer's disease: a systematic review. 2014 , 16, 32-44	71
1228	Cerebrospinal fluid sphingolipids, β amyloid, and tau in adults at risk for Alzheimer's disease. 2014 , 35, 2486-2494	45
1227	Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease. 2014 , 10, 684-9	49
1226	Progress update: fluid and imaging biomarkers in Alzheimer's disease. 2014 , 75, 520-6	18
1225	The clearance of misfolded proteins in neurodegenerative diseases by zinc metalloproteases: An inorganic perspective. 2014 , 260, 139-155	24
1224	Evaluation of memory endophenotypes for association with CLU, CR1, and PICALM variants in black and white subjects. 2014 , 10, 205-13	35
1223	Synergistic effects of amyloid-beta and wild-type human tau on dendritic spine loss in a floxed double transgenic model of Alzheimer's disease. 2014 , 64, 107-17	68
1222	Estimating long-term multivariate progression from short-term data. 2014 , 10, S400-10	101

1221	A comparison of early diagnostic utility of Alzheimer disease biomarkers in brain magnetic resonance and cerebrospinal fluid. 2014 , 29, 397-401	5
1220	The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it's time for reconciliation. 2014 , 62, 144-59	83
1219	A blood-based predictor for neocortical A β burden in Alzheimer's disease: results from the AIBL study. 2014 , 19, 519-26	85
1218	Amyloid- β 2/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays. 2015 , 43, 183-91	114
1217	[Drug development for overcoming dementia in Japan]. 2014 , 54, 1181-3	1
1216	Multivariate data analysis and machine learning in Alzheimer's disease with a focus on structural magnetic resonance imaging. 2014 , 41, 685-708	121
1215	Further validation of the Internet-based Dementia Risk Assessment. 2014 , 41, 937-45	1
1214	Human brain networks in cognitive decline: a graph theoretical analysis of cortical connectivity from EEG data. 2014 , 41, 113-27	105
1213	Plasma amyloid- β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden. 2014 , 40, 95-104	34
1212	A review of β amyloid neuroimaging in Alzheimer's disease. 2014 , 8, 327	61
1211	Functional Changes Associated with the Aging Nervous System. 2014 , 38-68	0
1210	Classification of non-demented patients attending a memory clinic using the new diagnostic criteria for Alzheimer's disease with disease-related biomarkers. 2015 , 43, 835-47	23
1209	Cerebrospinal fluid levels of a 20-22 kDa NH2 fragment of human tau provide a novel neuronal injury biomarker in Alzheimer's disease and other dementias. 2014 , 42, 211-26	32
1208	Severe diabetic retinal disease and dementia risk in type 2 diabetes. 2014 , 42 Suppl 3, S109-17	49
1207	Intellectual dysfunction. 34-64	
1206	Novel plasma biomarker surrogating cerebral amyloid deposition. 2014 , 90, 353-64	81
1205	Advancing brain imaging for Alzheimer's disease: integrating anatomic and physiologic measures. 2014 , 41, 759-63	2
1204	Interplay between age, cerebral small vessel disease, parenchymal amyloid- β and tau pathology: longitudinal studies in hypertensive stroke-prone rats. 2014 , 42 Suppl 3, S205-15	29

1203	The Pattern of Brain Amyloid Load in Posterior Cortical Atrophy Using (18)F-AV45: Is Amyloid the Principal Actor in the Disease?. 2014 , 4, 431-41	7
1202	Preferred features of a fluorine-19 MRI probe for amyloid detection in the brain. 2014 , 39, 617-31	24
1201	Ageing and apoE change DHA homeostasis: relevance to age-related cognitive decline. 2014 , 73, 80-6	32
1200	Rates of Amyloid accumulation are independent of hippocampal neurodegeneration. 2014 , 82, 1605-12	100
1199	Longitudinal MR cortical thinning of individuals and its correlation with PET metabolic reduction: a measurement consistency and correctness studies. 2014 ,	
1198	Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition. 2015 , 21, 841-50	37
1197	Is late-onset Alzheimer's disease really a disease of midlife?. 2015 , 1, 122-130	59
1196	The role of nutrition on cognition and brain health in ageing: a targeted approach. 2015 , 28, 167-180	17
1195	Early Cognitively Based Functional Limitations Predict Loss of Independence in Instrumental Activities of Daily Living in Older Adults. 2015 , 21, 688-98	49
1194	A systematic review and meta-analysis of (18)F-labeled amyloid imaging in Alzheimer's disease. 2015 , 1, 5-13	43
1193	A clinical trial to validate event-related potential markers of Alzheimer's disease in outpatient settings. 2015 , 1, 387-94	28
1192	[Differences in Attitudes of Patients with Mild Cognitive Impairment Towards Early Diagnosis at a University Clinic and a Specialist Physician's Office]. 2015 , 83, 563-7	0
1191	Novel curcumin derivatives as potent inhibitors of amyloid aggregation. 2015 , 4, 357-368	25
1190	Cognitive Function, Progression of Age-related Behavioral Changes, Biomarkers, and Survival in Dogs More Than 8 Years Old. 2015 , 29, 1569-77	34
1189	Cognitive Enhancers and Treatments for Alzheimer's Disease. 2015 , 2236-2260	
1188	[The Cutting-edge of Medicine; Pre-clinical diagnosis of neurodegenerative diseases]. 2015 , 104, 323-9	1
1187	Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography. 2015 , 5, 16404	79
1186	BFLCRM: A BAYESIAN FUNCTIONAL LINEAR COX REGRESSION MODEL FOR PREDICTING TIME TO CONVERSION TO ALZHEIMER'S DISEASE. 2015 , 9, 2153-2178	19

1185	Alzheimer's disease. 2015 , 1, 15056	755
1184	Hyperconnectivity is a fundamental response to neurological disruption. 2015 , 29, 59-75	140
1183	Absence of practice effects in preclinical Alzheimer's disease. 2015 , 29, 940-8	73
1182	Correlations of amyloid- β concentrations between CSF and plasma in acute Alzheimer mouse model. 2014 , 4, 6777	30
1181	Can oral infection be a risk factor for Alzheimer's disease?. 2015 , 7, 29143	97
1180	Anemia and Mild Cognitive Impairment in the German General Population. 2016 , 49, 1031-42	18
1179	T-Tau is Associated with Objective Memory Decline Over Two Years in Persons Seeking Help for Subjective Cognitive Decline: A Report from the Gothenburg-Oslo MCI Study. 2015 , 47, 619-28	17
1178	Differential Impact of Neurofilament Light Subunit on Cognition and Functional Outcome in Memory Clinic Patients with and without Vascular Burden. 2015 , 45, 873-81	8
1177	Circulating microRNAs as Biomarkers of Alzheimer's Disease: A Systematic Review. 2016 , 49, 755-66	70
1176	Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects. 2015 , 48, 433-41	28
1175	Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease. 2016 , 49, 1123-34	24
1174	Amnesic mild cognitive impairment and conversion to Alzheimer's disease: insulin resistance and glycoxidation as early biomarker clusters. 2015 , 45, 89-95	12
1173	The Utilization of Retinal Nerve Fiber Layer Thickness to Predict Cognitive Deterioration. 2016 , 49, 399-405	12
1172	Tau and Amyloid- β Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment. 2015 , 47, 965-75	16
1171	Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years. 2016 , 49, 733-41	15
1170	Prevention of Age-Related Cognitive Decline: Which Strategies, When, and for Whom?. 2015 , 48, 35-53	31
1169	A correlativity study of plasma APL128 and clusterin levels with MMSE/MoCA/CASI in aMCI patients. 2015 , 5, 15546	7
1168	Biomarkers in Sporadic and Familial Alzheimer's Disease. 2015 , 47, 291-317	61

1167	Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease. 2015 , 47, 231-42	101
1166	Epistasis analysis links immune cascades and cerebral amyloidosis. 2015 , 12, 227	8
1165	Integrative biomarker discovery in neurodegenerative diseases. 2015 , 7, 357-79	4
1164	Neuropsychological and neuroimaging characteristics of amnesic mild cognitive impairment subtypes: a selective overview. 2015 , 21, 776-83	19
1163	Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with A β 2 and influence of disease on the total-A β 2/A β 0 ratio. 2015 , 135, 1049-58	14
1162	Assessing treatment effects with surrogate survival outcomes using an internal validation subsample. 2015 , 12, 333-41	3
1161	Diffusion imaging changes in grey matter in Alzheimer's disease: a potential marker of early neurodegeneration. 2015 , 7, 47	83
1160	An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid- β concentrations collected by lumbar puncture and indwelling lumbar catheter. 2015 , 7, 53	20
1159	Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease. 2015 , 7, 74	86
1158	The impact of companion diagnostic device measurement performance on clinical validation of personalized medicine. 2015 , 34, 2222-34	11
1157	Direct and Indirect Interventions for Cognitive-Communication Disorders of Dementia. 2015 , 25, 142-157	0
1156	Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting. 2015 , 48, 425-32	14
1155	Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. 2015 , 47, 205-14	39
1154	Seven-Tesla MRI and neuroimaging biomarkers for Alzheimer's disease. 2015 , 39, E4	12
1153	Relationship of medial temporal lobe atrophy, APOE genotype, and cognitive reserve in preclinical Alzheimer's disease. 2015 , 36, 2826-41	68
1152	Nonparametric discrete survival function estimation with uncertain endpoints using an internal validation subsample. 2015 , 71, 772-81	3
1151	Mild Neurocognitive Disorder: An Old Wine in a New Bottle. 2015 , 23, 368-76	40
1150	Obesity and Aging: Consequences for Cognition, Brain Structure, and Brain Function. 2015 , 77, 697-709	84

1149	Long-term dantrolene treatment reduced intraneuronal amyloid in aged Alzheimer triple transgenic mice. 2015 , 29, 184-191	28
1148	. 2015 ,	3
1147	Alzheimer's Disease, Neural Basis of. 2015 , 591-596	0
1146	The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer's Disease. 2016 , 13, 53-67	43
1145	Comparison of regional gray matter atrophy, white matter alteration, and glucose metabolism as a predictor of the conversion to Alzheimer's disease in mild cognitive impairment. 2015 , 30, 779-87	10
1144	New perspectives in the search for reliable biomarkers in Alzheimer disease. 2015 , 29, 51-65	3
1143	Functional Connectivity Hubs Could Serve as a Potential Biomarker in Alzheimer's Disease: A Reproducible Study. 2015 , 12, 974-83	15
1142	Amyloid burden in cognitively normal elderly is associated with preferential hippocampal subfield volume loss. 2015 , 45, 27-33	33
1141	Verbal fluency and intrinsic brain activity in Alzheimer's disease. 2015 , 56, 573-7	5
1140	Palmomental Reflex a Relevant Sign in Early Alzheimer's Disease Diagnosis?. 2016 , 49, 1135-41	4
1139	The fornix in mild cognitive impairment and Alzheimer's disease. 2015 , 7, 1	147
1138	Clinical trial design of serious gaming in mild cognitive impairment. 2015 , 7, 26	6
1137	Role of physical and mental training in brain network configuration. 2015 , 7, 117	18
1136	Transmembrane Amyloid-Related Proteins in CSF as Potential Biomarkers for Alzheimer's Disease. 2015 , 6, 125	13
1135	Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD. 2015 , 6, 142	18
1134	Barriers to developing a valid rodent model of Alzheimer's disease: from behavioral analysis to etiological mechanisms. 2015 , 9, 245	16
1133	Voxel Level Survival Analysis of Grey Matter Volume and Incident Mild Cognitive Impairment or Alzheimer's Disease. 2015 , 46, 167-78	15
1132	Neurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. 2015 , 12, 712-22	104

1131	Analysis of causal relationships by structural equation modeling to determine the factors influencing cognitive function in elderly people in Japan. 2015 , 10, e0117554	4
1130	Quantitative amyloid imaging using image-derived arterial input function. 2015 , 10, e0122920	20
1129	Brain Amyloid Deposition and Longitudinal Cognitive Decline in Nondemented Older Subjects: Results from a Multi-Ethnic Population. 2015 , 10, e0123743	23
1128	A spectral graph regression model for learning brain connectivity of Alzheimer's disease. 2015 , 10, e0128136	20
1127	Microstructural White Matter Properties Mediate the Association between APOE and Perceptual Speed in Very Old Persons without Dementia. 2015 , 10, e0134766	9
1126	Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE ϵ and Is Detectable over 18-Months. 2015 , 10, e0139082	20
1125	Postoperative Structural Brain Changes and Cognitive Dysfunction in Patients with Breast Cancer. 2015 , 10, e0140655	21
1124	Heterogeneity of Regional Brain Atrophy Patterns Associated with Distinct Progression Rates in Alzheimer's Disease. 2015 , 10, e0142756	54
1123	Regional cingulum disruption, not gray matter atrophy, detects cognitive changes in amnesic mild cognitive impairment subtypes. 2015 , 44, 125-38	15
1122	Improved Diagnostic Multimodal Biomarkers for Alzheimer's Disease and Mild Cognitive Impairment. 2015 , 2015, 961314	12
1121	Multimodal prediction of dementia with up to 10 years follow up: the Gothenburg MCI study. 2015 , 44, 205-14	37
1120	Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's Disease. 2015 , 5, 581-94	22
1119	What does it mean to be 'amyloid-positive'?. 2015 , 138, 514-6	8
1118	Multi-resolution statistical analysis of brain connectivity graphs in preclinical Alzheimer's disease. 2015 , 118, 103-17	38
1117	Subjective memory impairment in older adults predicts future dementia independent of baseline memory performance: Evidence from the Betula prospective cohort study. 2015 , 11, 1385-92	92
1116	The effects of white matter hyperintensities and amyloid deposition on Alzheimer dementia. 2015 , 8, 246-52	32
1115	Amyloid disrupts human NREM slow waves and related hippocampus-dependent memory consolidation. 2015 , 18, 1051-7	276
1114	Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. 2015 , 11, 1191-201	59

1113	Repeated head trauma is associated with smaller thalamic volumes and slower processing speed: the Professional Fighters' Brain Health Study. 2015 , 49, 1007-11	65
1112	Worsening cognitive impairment and neurodegenerative pathology progressively increase risk for delirium. 2015 , 23, 403-415	84
1111	Clinical effect of white matter network disruption related to amyloid and small vessel disease. 2015 , 85, 63-70	58
1110	Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. 2015 , 138, 2020-33	227
1109	EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid- β oligomers and plaques. 2015 , 6, 8997	79
1108	Voices from the field: Expert reflections on mild cognitive impairment. 2015 , 14, 285-97	8
1107	Amyloid- β sequester proteins as blood-based biomarkers of cognitive decline. 2015 , 1, 270-80	27
1106	Revolutionizing Alzheimer's disease and clinical trials through biomarkers. 2015 , 1, 412-9	66
1105	Posterior compensatory network in cognitively intact elders with hippocampal atrophy. 2015 , 25, 581-93	6
1104	Amyloid-beta and depression in healthy older adults: a systematic review. 2015 , 49, 36-46	45
1103	Current status and future role of brain PET/MRI in clinical and research settings. 2015 , 42, 512-26	62
1102	Greater cortical thinning in normal older adults predicts later cognitive impairment. 2015 , 36, 903-8	53
1101	Thickness network features for prognostic applications in dementia. 2015 , 36 Suppl 1, S91-S102	32
1100	Accumulation of amyloid in cognitive impairment after mild traumatic brain injury. 2015 , 349, 99-104	36
1099	Nutritional status according to the stages of Alzheimer's disease. 2015 , 27, 507-13	10
1098	Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease. 2015 , 11, 511-22	45
1097	Cerebrospinal Fluid in Clinical Neurology. 2015 ,	13
1096	A computational method for computing an Alzheimer's disease progression score; experiments and validation with the ADNI data set. 2015 , 36 Suppl 1, S178-84	12

1095	Network Diffusion Model of Progression Predicts Longitudinal Patterns of Atrophy and Metabolism in Alzheimer's Disease. 2015 , 10, 359-369	116
1094	Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease. 2015 , 203, 40-50	85
1093	CSF and plasma amyloid- β temporal profiles and relationships with neurological status and mortality after severe traumatic brain injury. 2014 , 4, 6446	60
1092	Disentangling normal aging from Alzheimer's disease in structural magnetic resonance images. 2015 , 36 Suppl 1, S42-52	43
1091	Age dependent levels of plasma homocysteine and cognitive performance. 2015 , 283, 139-44	25
1090	Let Food Be Thy Medicine: Diet, Nutrition, and Biomarkers' Risk of Alzheimer's Disease. 2015 , 4, 126-135	13
1089	Brain amyloid-beta fragment signatures in pathological ageing and Alzheimer's disease by hybrid immunoprecipitation mass spectrometry. 2015 , 15, 50-7	33
1088	Identifying and Mapping Connectivity Patterns of Brain Network Hubs in Alzheimer's Disease. 2015 , 25, 3723-42	184
1087	Explorative and targeted neuroproteomics in Alzheimer's disease. 2015 , 1854, 769-78	36
1086	Degree of abnormality is associated with rate of change in measures of beta-amyloid, glucose metabolism and cognition in an autopsy-verified Alzheimer's disease case. 2015 , 21, 738-47	
1085	Is there an MCI reversion to cognitively normal? Analysis of Alzheimer's disease biomarkers profiles. 2015 , 27, 429-37	15
1084	Biomarkers of Alzheimer's disease and mild cognitive impairment: a current perspective. 2015 , 60, 76-82	47
1083	Biomarkers, ketone bodies, and the prevention of Alzheimer's disease. 2015 , 64, S51-7	15
1082	Association of Alzheimer's disease GWAS loci with MRI markers of brain aging. 2015 , 36, 1765.e7-1765.e16	63
1081	Building a roadmap for developing combination therapies for Alzheimer's disease. 2015 , 15, 327-33	39
1080	Clinical and imaging features of mixed Alzheimer and vascular pathologies. 2015 , 7, 21	69
1079	Mild cognitive impairment definitions: more evolution than revolution. 2015 , 5, 11-7	6
1078	Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. 2015 , 77, 953-71	203

1077	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. 2015 , 11, e1-120	206
1076	APOE and mild cognitive impairment: the Framingham Heart Study. 2015 , 44, 307-11	15
1075	The relationship between atrophy and hypometabolism: is it regionally dependent in dementias?. 2015 , 15, 44	6
1074	VSNL1 Co-Expression Networks in Aging Include Calcium Signaling, Synaptic Plasticity, and Alzheimer's Disease Pathways. 2015 , 6, 30	11
1073	RBC acetyl cholinesterase: A poor man's early diagnostic biomarker for familial alzheimer's and Parkinson's disease dementia. 2015 , 6, 33-8	9
1072	Metabolomics of neurodegenerative diseases. 2015 , 122, 53-80	28
1071	Different post label delay cerebral blood flow measurements in patients with Alzheimer's disease using 3D arterial spin labeling. 2015 , 33, 1019-1025	12
1070	What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?. 2015 , 2, 756-764	11
1069	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. 2015 , 11, 865-84	132
1068	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. 2015 , 11, 772-91	53
1067	Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative. 2015 , 11, 730-3	38
1066	The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment. 2015 , 11, 1510-1519	62
1065	Educational inequalities in aging-related declines in fluid cognition and the onset of cognitive pathology. 2015 , 1, 303-310	22
1064	Impact of amyloid precursor protein hydrophilic transmembrane residues on amyloid-beta generation. 2015 , 54, 2777-84	13
1063	Alzheimer's Disease Neuroimaging Initiative: A decade of progress in Alzheimer's disease. 2015 , 11, 727-9	7
1062	Regional cerebral blood flow estimated by early PiB uptake is reduced in mild cognitive impairment and associated with age in an amyloid-dependent manner. 2015 , 36, 1619-1628	27
1061	Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study. <i>Lancet Neurology, The</i> , 2015 , 14, 804-813	24.1 74
1060	The trajectory of cognitive decline in the pre-dementia phase in memory clinic visitors: findings from the 4C-MCI study. 2015 , 45, 1509-19	30

1059	Altered whole-brain white matter networks in preclinical Alzheimer's disease. 2015 , 8, 660-6	61
1058	DHA-PC and PSD-95 decrease after loss of synaptophysin and before neuronal loss in patients with Alzheimer's disease. 2014 , 4, 7130	89
1057	Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia. 2015 , 85, 898-904	128
1056	Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy. 2015 , 30, 505-13	16
1055	Where is hippocampal activity in the cascade of Alzheimer's disease biomarkers?. 2015 , 138, 831-3	7
1054	Stroke risk interacts with Alzheimer's disease biomarkers on brain aging outcomes. 2015 , 36, 2501-8	21
1053	Nonlinear cerebral atrophy patterns across the Alzheimer's disease continuum: impact of APOE4 genotype. 2015 , 36, 2687-701	35
1052	Alzheimer's Disease: Lessons Learned from Amyloidcentric Clinical Trials. 2015 , 29, 487-502	22
1051	The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. 2015 , 11, 757-71	132
1050	The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding. 2015 , 11, 823-31	41
1049	The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update. 2015 , 11, 850-9	33
1048	Alzheimer's disease research in the context of the national plan to address Alzheimer's disease. 2015 , 43-44, 16-24	11
1047	PET Quantification of Tau Pathology in Human Brain with 11C-PBB3. 2015 , 56, 1359-65	77
1046	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. 2015 , 11, 740-56	101
1045	Cytokine-producing microglia have an altered beta-amyloid load in aged APP/PS1 Tg mice. 2015 , 48, 86-101	63
1044	Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study. 2015 , 44, 471-80	40
1043	Predicting conversion from MCI to AD with FDG-PET brain images at different prodromal stages. 2015 , 58, 101-9	61
1042	Differential Patterns of Dysfunction in Neurodegenerative Dementias. 2015 , 625-631	1

1041	Neuronal hyperactivity--A key defect in Alzheimer's disease?. 2015 , 37, 624-32	109
1040	Development of Novel Pharmaceutical Agents for Alzheimer's Disease: The Impact of Regulatory Initiatives in Japan and the United States. 2015 , 37, 1652-60	4
1039	Vascular risk factors, cerebrovascular reactivity, and the default-mode brain network. 2015 , 115, 7-16	43
1038	The role of positron emission tomography imaging in understanding Alzheimer's disease. 2015 , 15, 395-406	19
1037	[Novel methods for dementia diagnostics]. 2015 , 86, 452-60	4
1036	Neuropsychological Testing Predicts Cerebrospinal Fluid Amyloid- β In Mild Cognitive Impairment. 2015 , 46, 901-12	17
1035	The relation of SMI and the VSEP in a risk sample for neurodegenerative disorders. 2015 , 122, 1167-74	7
1034	Brain aerobic glycolysis functions and Alzheimer's disease. 2015 , 3, 27-37	49
1033	Beta-amyloid imaging with florbetaben. 2015 , 3, 13-26	93
1032	Insights into cognitive aging and Alzheimer's disease using amyloid PET and structural MRI scans. 2015 , 3, 65-74	6
1031	Blood methylomic signatures of presymptomatic dementia in elderly subjects with type 2 diabetes mellitus. 2015 , 36, 1600.e1-4	12
1030	Fitting the epidemiology and neuropathology of the early stages of Alzheimer's disease to prevent dementia. 2015 , 7, 2	17
1029	Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. 2015 , 72, 656-65	66
1028	Biochemical and neuroimaging studies in subjective cognitive decline: progress and perspectives. 2015 , 21, 768-75	36
1027	Age, Sex, and APOE ϵ Effects on Memory, Brain Structure, and β Amyloid Across the Adult Life Span. 2015 , 72, 511-9	229
1026	The diagnostic utility of 99mTc-HMPAO SPECT imaging: a retrospective case series from a tertiary referral early-onset cognitive disorders clinic. 2015 , 39, 186-93	8
1025	Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. 2015 , 7, 26	80
1024	Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression. 2015 , 84, 508-15	96

1023	Verbal memory and brain aging: an exploratory analysis of the role of error responses in the Framingham Study. 2015 , 30, 622-8	4
1022	Association between body mass index and cortical thickness: among elderly cognitively normal men and women. 2015 , 27, 121-30	14
1021	Alzheimer amyloid peptide $\text{A}\beta$ 2 regulates gene expression of transcription and growth factors. 2015 , 44, 613-24	35
1020	Statins, cognition, and dementia—Systematic review and methodological commentary. 2015 , 11, 220-9	73
1019	Is interaction of amyloid β peptides with metals involved in cognitive activity?. 2015 , 7, 1205-12	15
1018	Infection, systemic inflammation, and Alzheimer's disease. 2015 , 17, 549-56	68
1017	Neurodegenerative diseases: expanding the prion concept. 2015 , 38, 87-103	221
1016	Mild cognitive impairment due to Alzheimer disease is less likely under the age of 65. 2015 , 29, 26-31	6
1015	Pulse pressure in relation to tau-mediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults. 2015 , 72, 546-53	75
1014	Evaluation of the cholinergic hypothesis in Alzheimer's disease with neuropsychological methods. 2015 , 27, 727-33	22
1013	The transitional association between β amyloid pathology and regional brain atrophy. 2015 , 11, 1171-9	29
1012	Nutrient patterns and brain biomarkers of Alzheimer's disease in cognitively normal individuals. 2015 , 19, 413-23	100
1011	Toward systems neuroscience in mild cognitive impairment and Alzheimer's disease: a meta-analysis of 75 fMRI studies. 2015 , 36, 1217-32	103
1010	Concordance between ^{11}C -PIB-PET and clinical diagnosis in a memory clinic. 2015 , 30, 599-606	11
1009	Amyloid biomarkers in Alzheimer's disease. 2015 , 36, 297-309	320
1008	Association of plasma β amyloid with MRI markers of structural brain aging the 3-City Dijon study. 2015 , 36, 2663-70	14
1007	Electrochemical quantification of the Alzheimer's disease amyloid- β (1-40) using amyloid- β fibrillization promoting peptide. 2015 , 6, 7-12	6
1006	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. 2015 , 7, 59	80

1005	Empirically Derived Trajectories to Dementia Over 15 Years of Follow-up Identified by Using Mixed Membership Models. 2015 , 182, 366-74	7
1004	Dissociation of amyloid biomarkers in PET and CSF in Alzheimer's disease: a case report. 2015 , 15, 152	2
1003	[Influence of lifestyle on neurodegenerative diseases]. 2015 , 86, 954-9	10
1002	Declining functional connectivity and changing hub locations in Alzheimer's disease: an EEG study. 2015 , 15, 145	85
1001	Plasma BDNF levels associate with Pittsburgh compound B binding in the brain. 2015 , 1, 187-193	17
1000	Mediterranean diet and brain structure in a multiethnic elderly cohort. 2015 , 85, 1744-51	120
999	Hypothesis: glutaminy cyclase inhibitors decrease risks of Alzheimer's disease and related dementias. 2015 , 15, 1245-8	7
998	Lewy body dementias. 2015 , 386, 1683-97	303
997	C-Terminally Truncated Forms of Tau, But Not Full-Length Tau or Its C-Terminal Fragments, Are Released from Neurons Independently of Cell Death. 2015 , 35, 10851-65	106
996	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. 2015 , 85, 790-8	23
995	A simulation system for biomarker evolution in neurodegenerative disease. 2015 , 26, 47-56	8
994	Amyloid burden, cortical thickness, and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. 2015 , 1, 160-169	26
993	Machine Learning in Medical Imaging. 2015 ,	4
992	Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia. 2015 , 1, 455-63	61
991	Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer's disease. 2015 , 11, 1080-9	58
990	Amyloid- β Oligomers May Impair SNARE-Mediated Exocytosis by Direct Binding to Syntaxin 1a. 2015 , 12, 1244-51	34
989	Structure-Activity Relationship Study of Heterocyclic Phenylethenyl and Pyridinylethenyl Derivatives as Tau-Imaging Agents That Selectively Detect Neurofibrillary Tangles in Alzheimer's Disease Brains. 2015 , 58, 7241-57	36
988	Asymmetries of amyloid- β burden and neuronal dysfunction are positively correlated in Alzheimer's disease. 2015 , 138, 3089-99	39

987	Neurogranin Levels in Cerebrospinal Fluid: A New Addition to the Alzheimer Disease Diagnostic Toolbox. 2015 , 72, 1237-8	17
986	Autophagy is involved in oral rAAV/A β vaccine-induced A β clearance in APP/PS1 transgenic mice. 2015 , 31, 491-504	22
985	Plasma β amyloid 40 levels are positively associated with mortality risks in the elderly. 2015 , 11, 672-80	16
984	Quantification of β Amyloidosis and rCBF with Dedicated PET, 7 T MR Imaging, and High-Resolution Microscopic MR Imaging at 16.4 T in APP23 Mice. 2015 , 56, 1593-9	9
983	Targeting protein aggregation for the treatment of degenerative diseases. 2015 , 14, 759-80	255
982	Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease. 2015 , 256, 168-83	42
981	The relationship between iron dyshomeostasis and amyloidogenesis in Alzheimer's disease: Two sides of the same coin. 2015 , 81, 49-65	82
980	Locus Coeruleus, norepinephrine and A β peptides in Alzheimer's disease. 2015 , 2, 73-84	41
979	Charting a path toward combination therapy for Alzheimer's disease. 2015 , 15, 107-13	28
978	Blood-brain barrier impairment in dementia: current and future in vivo assessments. 2015 , 49, 71-81	46
977	Alzheimer Disease. 2015 , 321-338	3
976	Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. 2015 , 36, 273-82	26
975	Effect of active A β immunotherapy on neurons in human Alzheimer's disease. 2015 , 235, 721-30	28
974	Hippocampal volume in older adults at risk of cognitive decline: the role of sleep, vascular risk, and depression. 2015 , 44, 1279-90	37
973	Gray & white matter tissue contrast differentiates Mild Cognitive Impairment converters from non-converters. 2015 , 9, 141-8	17
972	Potential role of antimicrobial peptides in the early onset of Alzheimer's disease. 2015 , 11, 51-7	44
971	Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. 2015 , 11, 58-69	271
970	Divergent CSF β alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy. 2015 , 86, 244-50	77

969	AIImaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study. 2015 , 86, 431-6	63
968	Curcumin derivative with the substitution at C-4 position, but not curcumin, is effective against amyloid pathology in APP/PS1 mice. 2015 , 36, 201-10	52
967	Dual effect of docosahexaenoic acid (attenuation or amplification) on C22:0-, C24:0-, and C26:0-induced mitochondrial dysfunctions and oxidative stress on human neuronal SK-N-BE cells. 2015 , 19, 198-205	8
966	Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia. 2015 , 11, 608-21.e7	121
965	The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey. 2015 , 11, 195-206.e1	45
964	Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies. 2015 , 19, 154-63	34
963	An Emerging Model of Word Retrieval in Preclinical Alzheimer's Disease. 2016 , 06,	
962	Postoperative Cognitive Dysfunction. 2016 , 411-427	2
961	Mild Cognitive Impairment. 2016 ,	
960	Overview of Alzheimer's disease. 2016 ,	
959	Validation of Immunoassay-Based Tools for the Comprehensive Quantification of A β 0 and A β 2 Peptides in Plasma. 2016 , 54, 751-62	19
958	Blood-based Amyloid and Tau Biomarker Tests For Alzheimer's Disease. 2016 , 4, 4-13	
957	Mechanisms underlying Alzheimer's disease. 2016 , 3, 85-92	0
956	Factores de riesgo y precursores del Deterioro Cognitivo Leve (DCL): Una mirada sintética. 2016 , 34, 183-189	5
955	Exploring Biomarkers for Alzheimer's Disease. 2016 , 10, KE01-6	31
954	Imaging Alzheimer's disease pathophysiology with PET. 2016 , 10, 79-90	21
953	Impact of SORL1 genetic variations on MRI markers in non-demented elders. 2016 , 7, 31689-98	7
952	Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer's Disease. 2016 , 13, 809-16	5

951	Acceleration of Amyloidosis by Inflammation in the Amyloid-Beta Marmoset Monkey Model of Alzheimer's Disease. 2017 , 55, 101-113	46
950	Pathophysiological Role of Neuroinflammation in Neurodegenerative Diseases and Psychiatric Disorders. 2016 , 20, S2-7	139
949	Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease. 2016 , 13, 307-16	11
948	Rust on the Brain from Microbleeds and Its Relevance to Alzheimer Studies: Invited Commentary on Cacciottolo Neurobiology of Aging, 2016. 2016 , 6,	5
947	The Aging Mind in Transition. 2016 , 87-103	1
946	Independent and Interactive Influences of the APOE Genotype and Beta-Amyloid Burden on Cognitive Function in Mild Cognitive Impairment. 2016 , 31, 286-95	10
945	Overview of Alzheimer's Disease and Some Therapeutic Approaches Targeting Aβ Using Several Synthetic and Herbal Compounds. 2016 , 2016, 7361613	82
944	Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?. 2016 , 13, 1145-64	36
943	Alterations in Glucose Metabolism in Alzheimer's Disease. 2016 , 10, 31-39	34
942	Subjective cognitive decline: The first clinical manifestation of Alzheimer's disease?. 2016 , 10, 170-177	53
941	Advanced epidemiologic and analytical methods. 2016 , 138, 39-52	1
940	Commentary: Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy. 2016 , 8, 5	2
939	Hippocampal Amyloid Burden with Downstream Fusiform Gyrus Atrophy Correlate with Face Matching Task Scores in Early Stage Alzheimer's Disease. 2016 , 8, 145	14
938	Association of Cerebral Amyloidosis, Blood Pressure, and Neuronal Injury with Late-Life Onset Depression. 2016 , 8, 236	3
937	Amyloid Plaques in Retina for Diagnosis in Alzheimer's Patients: a Meta-Analysis. 2016 , 8, 267	18
936	Amyloid Dysmetabolism Relates to Reduced Glucose Uptake in White Matter Hyperintensities. 2016 , 7, 209	7
935	VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis. 2016 , 10, 20	44
934	Affinity of (nat/68)Ga-Labelled Curcumin and Curcuminoid Complexes for β Amyloid Plaques: Towards the Development of New Metal-Curcumin Based Radiotracers. 2016 , 17,	11

933 Alzheimer's Disease and white matter. 172-184

932	Predicting Progression from Mild Cognitive Impairment to Alzheimer's Dementia Using Clinical, MRI, and Plasma Biomarkers via Probabilistic Pattern Classification. 2016 , 11, e0138866	121
931	Self-Organizing 3D Human Neural Tissue Derived from Induced Pluripotent Stem Cells Recapitulate Alzheimer's Disease Phenotypes. 2016 , 11, e0161969	277
930	Structural MR Imaging in the Diagnosis of Alzheimer's Disease and Other Neurodegenerative Dementia: Current Imaging Approach and Future Perspectives. 2016 , 17, 827-845	38
929	Neuropsychological Profiles in Mild Cognitive Impairment due to Alzheimer's and Parkinson's Diseases. 2016 , 6, 413-21	9
928	What can imaging tell us about cognitive impairment and dementia?. 2016 , 8, 240-54	26
927	Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT. 2016 , 7, 88	20
926	Methods for the Specific Detection and Quantitation of Amyloid- β Oligomers in Cerebrospinal Fluid. 2016 , 53, 53-67	21
925	Plasma Biomarkers in Alzheimer's Disease. 2016 ,	1
924	Composite risk scores for predicting dementia. 2016 , 29, 174-80	18
923	Bioenergetics and metabolism: a bench to bedside perspective. 2016 , 139 Suppl 2, 126-135	26
922	Instantiated mixed effects modeling of Alzheimer's disease markers. 2016 , 142, 113-125	24
921	Expression of familial Alzheimer disease presenilin 1 gene attenuates vesicle traffic and reduces peptide secretion in cultured astrocytes devoid of pathologic tissue environment. 2016 , 64, 317-29	38
920	Application of Machine Learning to Arterial Spin Labeling in Mild Cognitive Impairment and Alzheimer Disease. 2016 , 281, 865-875	44
919	On the early diagnosis of Alzheimer's Disease from multimodal signals: A survey. 2016 , 71, 1-29	76
918	Do we still need positron emission tomography for early Alzheimer's disease diagnosis?. 2016 , 139, e60	4
917	Onset of Mild Cognitive Impairment in Parkinson Disease. 2016 , 30, 127-33	14
916	Reversion From Mild Cognitive Impairment to Normal Cognition: A Meta-Analysis. 2016 , 30, 324-330	92

915	The Effects of Physiological and Methodological Determinants on 18F-FDG Mouse Brain Imaging Exemplified in a Double Transgenic Alzheimer Model. 2016 , 15,	15
914	Elevated C-Reactive Protein Is Associated with Cognitive Decline in Outpatients of a General Hospital: The Project in Sado for Total Health (PROST). 2016 , 6, 10-9	29
913	Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid- β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease. 2017 , 55, 473-484	60
912	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. 2017 , 55, 159-170	19
911	Ten Challenges of the Amyloid Hypothesis of Alzheimer's Disease. 2017 , 55, 447-457	61
910	Segmentation of nuclei in digital pathology images. 2016 ,	7
909	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. 2017 , 55, 19-35	29
908	Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia. 2016 ,	0
907	Brain imaging in dementia. 2016 , 92, 333-40	17
906	Increased functional connectivity common to symptomatic amyotrophic lateral sclerosis and those at genetic risk. 2016 , 87, 580-8	62
905	Interaction Between Midlife Blood Glucose and APOE Genotype Predicts Later Alzheimer's Disease Pathology. 2016 , 53, 1553-62	19
904	Formal Psychiatric Disorders are not Overrepresented in Behavioral Variant Frontotemporal Dementia. 2016 , 51, 1249-56	9
903	The Brain's Structural Connectome Mediates the Relationship between Regional Neuroimaging Biomarkers in Alzheimer's Disease. 2017 , 55, 1639-1657	13
902	Better Objective Sleep Quality in Older Adults with High Subjective Memory Decline. 2016 , 53, 943-53	12
901	Orexin and Alzheimer's Disease. 2017 , 33, 305-322	31
900	Application of the IWG-2 Diagnostic Criteria for Alzheimer's Disease to the ADNI. 2016 , 51, 227-36	10
899	Redox Based-Peripheral Biomarkers in Alzheimer's Disease: Challenges, Limits and Prospects. 2016 , 377-397	1
898	Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease. 2016 , 22, 978-990	13

897	Alterations of the volatile metabolome in mouse models of Alzheimer's disease. 2016 , 6, 19495	24
896	Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration. 2016 , 52, 179-90	26
895	Five-Year Longitudinal Brain Volume Change in Healthy Elders at Genetic Risk for Alzheimer's Disease. 2017 , 55, 1363-1377	30
894	Staging Alzheimer's Disease Risk by Sequencing Brain Function and Structure, Cerebrospinal Fluid, and Cognition Biomarkers. 2016 , 54, 983-993	26
893	Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. 2016 , 8, 369ra178	155
892	Rapid and sustained cognitive recovery in APP/PS1 transgenic mice by co-administration of EPPS and donepezil. 2016 , 6, 34165	11
891	A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimer's Disease. 2017 , 55, 521-537	31
890	Recent advances in cerebrospinal fluid biomarkers for the detection of preclinical Alzheimer's disease. 2016 , 29, 749-755	7
889	Perspective from the Alzheimer's Association: Neuroimaging Professional Interest Area of ISTAART continues impact on the field. 2016 , 5, 1-2	
888	The effect of the top 20 Alzheimer disease risk genes on gray-matter density and FDG PET brain metabolism. 2016 , 5, 53-66	23
887	Brain omega-3 polyunsaturated fatty acids modulate microglia cell number and morphology in response to intracerebroventricular amyloid- β -40 in mice. 2016 , 13, 257	47
886	The limitations of opportunistic epidemiology, pseudopod epidemiology. 2016 , 31, 957-966	2
885	Clinical trials in Alzheimer's disease. 2016 , 153-172	
884	Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine. 2016 , 54, 55-67	22
883	An Overview of Quantitative Magnetic Resonance Imaging Analysis Studies in the Assessment of Alzheimer's Disease. 2016 , 281-286	2
882	MicroRNA-107 prevents amyloid-beta induced blood-brain barrier disruption and endothelial cell dysfunction by targeting Endophilin-1. 2016 , 343, 248-257	35
881	Will You Still Need Me When I'm 64, or 84, or 104? The Importance of Speech-Language Pathologists in Promoting the Quality of Life of Aging Adults in the United States into the Future. 2016 , 37, 185-200	13
880	Amyloid- β peptides time-dependent structural modifications: AFM and voltammetric characterization. 2016 , 926, 36-47	25

879	Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis. 2016 , 39, 99-107	18
878	Regional brain stiffness changes across the Alzheimer's disease spectrum. 2016 , 10, 283-90	104
877	Bis-pyridylethenyl benzene as novel backbone for amyloid-binding compounds. 2016 , 24, 6139-6148	5
876	Decreased hemoglobin levels, cerebral small-vessel disease, and cortical atrophy: among cognitively normal elderly women and men. 2016 , 28, 147-56	10
875	Measuring Cortical Connectivity in Alzheimer's Disease as a Brain Neural Network Pathology: Toward Clinical Applications. 2016 , 22, 138-63	71
874	Combining anatomical, diffusion, and resting state functional magnetic resonance imaging for individual classification of mild and moderate Alzheimer's disease. 2016 , 11, 46-51	69
873	Cerebrospinal fluid analysis detects cerebral amyloid- β accumulation earlier than positron emission tomography. 2016 , 139, 1226-36	229
872	Nuclear Imaging of Dementia. 2016 , 233-240	
871	Differences in cognitive ability and hippocampal volume between Alzheimer's disease, amnesic mild cognitive impairment, and healthy control groups, and their correlation. 2016 , 620, 115-20	13
870	References. 2016 , 353-428	
869	Alzheimer's disease: a mathematical model for onset and progression. 2017 , 34, 193-214	25
868	Diseases of the Brain, Head and Neck, Spine 2016-2019. 2016 ,	1
867	Accelerating rates of cognitive decline and imaging markers associated with β amyloid pathology. 2016 , 86, 1887-96	37
866	Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment. 2016 , 43, 1304-14	32
865	Alzheimer's therapy targeting the β secretase enzyme BACE1: Benefits and potential limitations from the perspective of animal model studies. 2016 , 126, 183-198	31
864	Aberrant functional connectivity differentiates retrosplenial cortex from posterior cingulate cortex in prodromal Alzheimer's disease. 2016 , 44, 114-126	44
863	Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease. 2016 , 43, 1700-9	48
862	Association of Vitamin B12, Folate, and Sulfur Amino Acids With Brain Magnetic Resonance Imaging Measures in Older Adults: A Longitudinal Population-Based Study. 2016 , 73, 606-13	59

861	Inhibitory RNA Aptamers of Tau Oligomerization and Their Neuroprotective Roles against Proteotoxic Stress. 2016 , 13, 2039-48	27
860	βAmyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review. 2016 , 24, 923-39	11
859	Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease. 2016 , 139, 2275-89	48
858	Cortical sources of resting state EEG rhythms are related to brain hypometabolism in subjects with Alzheimer's disease: an EEG-PET study. 2016 , 48, 122-134	36
857	Magnetic Resonance Spectroscopy in Dementia. 2016 , 55-70	
856	Middle age self-report risk score predicts cognitive functioning and dementia in 20-40 years. 2016 , 4, 118-125	12
855	NPT088 reduces both amyloid-β and tau pathologies in transgenic mice. 2016 , 2, 141-155	31
854	Regional tau deposition measured by [¹⁸ F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer's disease. 2016 , 8, 38	35
853	Prefrontal contributions to relational encoding in amnesic mild cognitive impairment. 2016 , 11, 158-166	5
852	Biomimetic ApoE-Reconstituted High Density Lipoprotein Nanocarrier for Blood-Brain Barrier Penetration and Amyloid Beta-Targeting Drug Delivery. 2016 , 13, 3976-3987	61
851	Alzheimer disease: Preclinical Alzheimer disease - the new frontier. 2016 , 12, 620-621	7
850	Adverse brain aging in atrial fibrillation patients. 2016 , 13, 2025-6	
849	Current viewpoints on DSM-5 in Japan. 2016 , 70, 371-93	7
848	Seed-competent high-molecular-weight tau species accumulates in the cerebrospinal fluid of Alzheimer's disease mouse model and human patients. 2016 , 80, 355-67	67
847	Alzheimer Disease and Its Growing Epidemic: Risk Factors, Biomarkers, and the Urgent Need for Therapeutics. 2016 , 34, 941-953	86
846	Advances in neuroimaging in frontotemporal dementia. 2016 , 138 Suppl 1, 193-210	52
845	Multimodality Imaging of Neurodegenerative Processes: Part 1, The Basics and Common Dementias. 2016 , 207, 871-882	15
844	Magnetic Resonance Spectroscopy of Degenerative Brain Diseases. 2016 ,	0

843	The effect of β Amyloid positivity on cerebral metabolism in cognitively normal seniors. 2016 , 12, 1250-1258	8
842	Longitudinal β Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. 2016 , 73, 1192-1200	63
841	Extracellular Mitochondria and Mitochondrial Components Act as Damage-Associated Molecular Pattern Molecules in the Mouse Brain. 2016 , 11, 622-628	21
840	Genome research in pre-dementia stages of Alzheimer's disease. 2016 , 18, e11	12
839	Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review. 2016 , 8, 46	39
838	Inflammation, Antiinflammatory Agents, and Alzheimer's Disease: The Last 22 Years. 2016 , 54, 853-857	127
837	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. 2016 , 52, 51-64	17
836	Alpha band disruption in the AD-continuum starts in the Subjective Cognitive Decline stage: a MEG study. 2016 , 6, 37685	41
835	Tau and tauopathies. 2016 , 126, 238-292	292
834	Tau PET in Alzheimer disease and mild cognitive impairment. 2016 , 87, 375-83	175
833	Genetic and degenerative disorders primarily causing dementia. 2016 , 135, 525-564	3
832	Imaging of neurodegenerative cognitive and behavioral disorders: practical considerations for dementia clinical practice. 2016 , 136, 971-84	13
831	Feasibility and acceptance of simultaneous amyloid PET/MRI. 2016 , 43, 2236-2243	22
830	Viscoelasticity of subcortical gray matter structures. 2016 , 37, 4221-4233	66
829	Cognitive impairment among World Trade Center responders: Long-term implications of re-experiencing the 9/11 terrorist attacks. 2016 , 4, 67-75	41
828	Population imaging in neuroepidemiology. 2016 , 138, 69-90	1
827	Selective Degeneration of Entorhinal-CA1 Synapses in Alzheimer's Disease via Activation of DAPK1. 2016 , 36, 10843-10852	28
826	[Biomarkers for dementia and other neurodegenerative diseases : Current developments]. 2016 , 87, 1305-1309	8

825	Advances in A β plaque detection and the value of knowing: overcoming challenges to improving patient outcomes in Alzheimer's disease. 2016 , 6, 491-497	2
824	Alzheimer's disease severity, objectively determined and measured. 2016 , 4, 159-168	9
823	Age-dependent inverse correlations in CSF and plasma amyloid- β (1-42) concentrations prior to amyloid plaque deposition in the brain of 3xTg-AD mice. 2016 , 6, 20185	24
822	Atrophy of amygdala and abnormal memory-related alpha oscillations over posterior cingulate predict conversion to Alzheimer's disease. 2016 , 6, 31859	13
821	Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology. 2016 , 7, 13249	151
820	Arterial Spin Labeling Perfusion of the Brain: Emerging Clinical Applications. 2016 , 281, 337-356	225
819	The mismatch negativity as an index of cognitive decline for the early detection of Alzheimer's disease. 2016 , 6, 33167	16
818	Simulating the Evolution of Functional Brain Networks in Alzheimer's Disease: Exploring Disease Dynamics from the Perspective of Global Activity. 2016 , 6, 34156	7
817	Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. 2016 , 7, 11934	547
816	Early diagnosis of Alzheimer's disease from elevated olfactory mucosal miR-206 level. 2016 , 6, 20364	36
815	Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer's disease cohorts. 2016 , 6, 26027	32
814	Posterior Ventricular Enlargement to Differentiate Dementia with Lewy Bodies from Alzheimer's Disease. 2016 , 52, 1237-43	4
813	Multimodal Image Analysis in Alzheimer's Disease via Statistical Modelling of Non-local Intensity Correlations. 2016 , 6, 22161	14
812	Poster Abstracts. 2016 , 36, 174-738	2
811	Biochemical and Radiological Markers of Alzheimer's Disease Progression. 2016 , 50, 623-44	2
810	Early Postmenopausal Transdermal 17 β Estradiol Therapy and Amyloid- β Deposition. 2016 , 53, 547-56	70
809	Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab. 2016 , 53, 535-46	4
808	Heterogeneous multimodal biomarkers analysis for Alzheimer's disease via Bayesian network. 2016 , 2016, 12	11

807	Amyloid Plaques Show Binding Capacity of Exogenous Injected Amyloid- β 2017 , 55, 147-157	3
806	The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. 2016 , 139, 2249-60	125
805	Synthesis and evaluation of copper-64 labeled benzofuran derivatives targeting β amyloid aggregates. 2016 , 24, 3618-23	11
804	Molecular Imaging in Alzheimer Clinical Trials. 2016 , 523-563	
803	Prospects and Challenges for Alzheimer Therapeutics. 2016 , 605-637	0
802	The Prion-Like Properties of Amyloid- β Assemblies: Implications for Alzheimer's Disease. 2016 , 6,	49
801	Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies. 2016 , 8, 8	39
800	Exposure to air pollution as a potential contributor to cognitive function, cognitive decline, brain imaging, and dementia: A systematic review of epidemiologic research. 2016 , 56, 235-253	200
799	ACR-ASNR Practice Parameter for Brain PET/CT Imaging Dementia. 2016 , 41, 118-25	10
798	Modulation of glucose metabolism and metabolic connectivity by β amyloid. 2016 , 36, 2058-2071	11
797	Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease?. 2016 , 39, 552-566	226
796	Neurovascular unit impairment in early Alzheimer's disease measured with magnetic resonance imaging. 2016 , 45, 190-196	109
795	Prediction of Alzheimer's disease pathophysiology based on cortical thickness patterns. 2016 , 2, 58-67	48
794	Elucidating novel dysfunctional pathways in Alzheimer's disease by integrating loci identified in genetic and epigenetic studies. 2016 , 6, 32-50	13
793	Quantitative multimodal multiparametric imaging in Alzheimer's disease. 2016 , 3, 29-37	8
792	CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia. 2016 , 42, 124-31	23
791	A brain stress test: Cerebral perfusion during memory encoding in mild cognitive impairment. 2016 , 11, 388-397	20
790	Blood-Brain Barrier Leakage in Patients with Early Alzheimer Disease. 2016 , 281, 527-535	276

789	Relevance of defensin α and defensins (HNP1-3) in Alzheimer's disease. 2016 , 239, 342-5	6
788	Comparative pathobiology of β amyloid and the unique susceptibility of humans to Alzheimer's disease. 2016 , 44, 185-196	31
787	Increased CSF tau level is correlated with decreased lamina cribrosa thickness. 2016 , 8, 6	7
786	Early detection of Alzheimer's disease using MRI hippocampal texture. 2016 , 37, 1148-61	108
785	Cortical phase changes measured using 7-T MRI in subjects with subjective cognitive impairment, and their association with cognitive function. 2016 , 29, 1289-94	9
784	Alzheimer's disease due to loss of function: A new synthesis of the available data. 2016 , 143, 36-60	85
783	SNP Variation in MicroRNA Biogenesis Pathway Genes as a New Innovation Strategy for Alzheimer Disease Diagnostics: A Study of 10 Candidate Genes in an Understudied Population From the Eastern Mediterranean. 2016 , 30, 203-9	8
782	Regional β amyloid burden does not correlate with cognitive or language deficits in Alzheimer's disease presenting as aphasia. 2016 , 23, 313-9	12
781	Brain Events Underlying Episodic Memory Changes in Aging: A Longitudinal Investigation of Structural and Functional Connectivity. 2016 , 26, 1272-1286	67
780	Advances in the development of tau PET radiotracers and their clinical applications. 2016 , 30, 107-13	49
779	Suspected non-Alzheimer disease pathophysiology--concept and controversy. 2016 , 12, 117-24	174
778	Intraneuronal Amyloid Beta Accumulation Disrupts Hippocampal CRT1-Dependent Gene Expression and Cognitive Function in a Rat Model of Alzheimer Disease. 2017 , 27, 1501-1511	33
777	The Impact of UNC5C Genetic Variations on Neuroimaging in Alzheimer's Disease. 2016 , 53, 6759-6767	14
776	Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. 2016 , 16, 69-76	34
775	Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia. 2016 , 46, 57-87	11
774	Cerebral perfusion in the prodementia stages of Alzheimer's disease. 2016 , 26, 506-14	69
773	Combined Plasma and Cerebrospinal Fluid Signature for the Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer Disease. 2016 , 73, 203-212	42
772	A methodological critique of the National Institute of Aging and Alzheimer's Association Guidelines for Alzheimer's disease, dementia, and mild cognitive impairments. 2016 , 15, 239-54	6

771	Instrumental variable approaches to identifying the causal effect of educational attainment on dementia risk. 2016 , 26, 71-6.e1-3	48
770	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. 2016 , 12, 292-323	832
769	Medium-chain plasma acylcarnitines, ketone levels, cognition, and gray matter volumes in healthy elderly, mildly cognitively impaired, or Alzheimer's disease subjects. 2016 , 43, 1-12	40
768	How many amyloid- β peptides can a neuron bind before it dies?. 2016 , 136, 437-9	3
767	Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study. 2016 , 86, 1499-506	27
766	Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. 2016 , 73, 561-71	118
765	Cerebrospinal Biomarkers in Alzheimer Disease-Potential Roles as Markers of Prognosis and Neuroplasticity. 2016 , 73, 508-10	3
764	Alzheimer's Disease, Neural Plasticity, and Functional Recovery. 2021 , 82, S37-S50	4
763	Analyzing Olfactory Neuron Precursors Non-Invasively Isolated through NADH FLIM as a Potential Tool to Study Oxidative Stress in Alzheimer's Disease. 2021 , 22,	2
762	Thiophene-Based Optical Ligands That Selectively Detect A β Pathology in Alzheimer's Disease. 2021 , 22, 2568-2581	1
761	Immunological and hormonal mechanisms in Alzheimer's disease. 2020 , 61, 1033-1038	
760	Specific White Matter Tracts and Diffusion Properties Predict Conversion From Mild Cognitive Impairment to Alzheimer's Disease. 2021 , 13, 711579	2
759	Phage-Derived and Aberrant HaloTag Peptides Immobilized on Magnetic Microbeads for Amperometric Biosensing of Serum Autoantibodies and Alzheimer's Disease Diagnosis.	2
758	The informed road map to prevention of Alzheimer Disease: A call to arms. 2021 , 16, 49	7
757	Parametric imaging of dual-time window [18 F]flutemetamol and [18 F]florbetaben studies. 2021 , 234, 117953	2
756	1700 nm optical coherence microscopy enables minimally invasive, label-free, in vivo optical biopsy deep in the mouse brain. 2021 , 10, 145	5
755	A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation. 2021 , 13, 132	0
754	Combined Model of Aggregation and Network Diffusion Recapitulates Alzheimer's Regional Tau-Positron Emission Tomography. 2021 , 11, 624-638	3

753	Comparing amyloid- β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. 2021 , 142, 689-706	8
752	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. 2021 , 13, 712545	3
751	Entorhinal cortex EWAS meta-analysis highlights four novel loci showing differential methylation in Alzheimer's disease.	1
750	Accumulation of saposin in dystrophic neurites is linked to impaired lysosomal functions in Alzheimer's disease brains. 2021 , 16, 45	5
749	Trajectory patterns of blood pressure change up to six years and the risk of dementia: a nationwide cohort study. 2021 , 13, 17380-17406	0
748	Reproductive period and preclinical cerebrospinal fluid markers for Alzheimer disease: a 25-year study. 2021 , 28, 1099-1107	2
747	The complexity of Alzheimer's disease: an evolving puzzle. 2021 , 101, 1047-1081	7
746	Neuronal α -amylase is important for neuronal activity and glycogenolysis and reduces in presence of amyloid beta pathology. 2021 , 20, e13433	2
745	Long-term running exercise alleviates cognitive dysfunction in APP/PSEN1 transgenic mice via enhancing brain lysosomal function. 2021 ,	0
744	When Does Alzheimer's Disease Really Start? The Role of Biomarkers. 2021 , 19, 355-364	
743	A disease-specific metabolic imaging marker for diagnosis and progression evaluation of semantic variant primary progressive aphasia. 2021 , 28, 2927-2939	1
742	Progressive Brain Degeneration From Subjective Cognitive Decline to Amnesic Mild Cognitive Impairment: Evidence From Large-Scale Anatomical Connection Classification Analysis. 2021 , 13, 687530	0
741	Developing the ATX(N) classification for use across the Alzheimer disease continuum. 2021 , 17, 580-589	25
740	Fine Particulate Matter and Dementia Incidence in the Adult Changes in Thought Study. 2021 , 129, 87001	5
739	Exosomal tau with seeding activity is released from Alzheimer's disease synapses, and seeding potential is associated with amyloid beta. 2021 , 101, 1605-1617	6
738	Longitudinal predictive modeling of tau progression along the structural connectome. 2021 , 237, 118126	1
737	Socioeconomic Position and Late-Onset Dementia: A Nationwide Register-Based Study. 2021 , 8982643211037200	
736	Multi view based imaging genetics analysis on Parkinson disease.	

735	Automatic Diagnosis of Alzheimer's Disease and Mild Cognitive Impairment Based on CNN + SVM Networks with End-to-End Training. 2021 , 2021, 9121770	3
734	Convergent and Discriminant Validity of Default Mode Network and Limbic Network Perfusion in Amnesic Mild Cognitive Impairment Patients. 2021 , 82, 1797-1808	0
733	Predicting brain amyloid- β PET phenotypes with graph convolutional networks based on functional MRI and multi-level functional connectivity.	1
732	¹²³ I-iodoflupane SPECT and ¹⁸ F-FDG PET Combined Use in the Characterization of Movement and Cognitive Associated Disorders in Neurodegenerative Diseases. 2021 , 18, 196-207	0
731	Oral Glucose Tolerance Test Predicts Episodic Memory Decline: A 10-Year Population-Based Follow-up Study. 2021 , 44, 2435-2437	1
730	Brain Network Integrity Changes in Subjective Cognitive Decline: A Possible Physiological Biomarker of Dementia. 2021 , 12, 699014	0
729	Does the Anti-Tau Strategy in Progressive Supranuclear Palsy Need to Be Reconsidered? Yes. 2021 , 8, 1034-1037	0
728	Charting Brain Growth and Aging at High Spatial Precision.	2
727	Advances in Genetic and Molecular Understanding of Alzheimer's Disease. 2021 , 12,	2
726	Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis. 2021 , 22,	9
725	Soluble Amyloid- β Consumption in Alzheimer's Disease. 2021 , 82, 1403-1415	16
724	Anticipatory and Reactive Grip Force Control in Patients with Alzheimer's Disease: A Pilot Study. 2021 , 82, 1651-1665	
723	Lower regional gray matter volume in the absence of higher cortical amyloid burden in late-life depression. 2021 , 11, 15981	3
722	Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease. 2021 ,	5
721	Disease Modelling of Cognitive Outcomes and Biomarkers in the European Prevention of Alzheimer's Dementia Longitudinal Cohort. 2021 , 4, 676168	0
720	A Personalized Computer-Aided Diagnosis System for Mild Cognitive Impairment (MCI) Using Structural MRI (sMRI). 2021 , 21,	0
719	Magnetic Resonance Imaging Findings Among Individuals With Olfactory and Cognitive Impairment. 2021 ,	0
718	Diagnosi clinicolaboratoristica della malattia di Alzheimer. 2021 , 21, 1-15	

717	Neuroticism Is Associated with Tau Pathology in Cognitively Unimpaired Individuals with Autosomal Dominant Alzheimer's Disease. 2021 , 82, 1809-1822	3
716	Multiparametric MRI for the improved diagnostic accuracy of Alzheimer's disease and mild cognitive impairment: Research protocol of a case-control study design. 2021 , 16, e0252883	1
715	Platelet biomarkers identifying mild cognitive impairment in type 2 diabetes patients. 2021 , 20, e13469	1
714	Biomarkers of Alzheimer's Disease and Cerebrovascular Lesions and Clinical Progression in Patients with Subjective Cognitive Decline: A Systematic Review. 2021 , 83, 1089-1111	1
713	Relationship between Cortical Thickness and EEG Alterations during Sleep in the Alzheimer's Disease. 2021 , 11,	0
712	Palmitoylated prolactin-releasing peptide reduced A β plaques and microgliosis in the cerebellum: APP/PS1 mice study. 2021 ,	1
711	Blood-Brain Barrier Permeable and NO-Releasing Multifunctional Nanoparticles for Alzheimer's Disease Treatment: Targeting NO/cGMP/CREB Signaling Pathways. 2021 , 64, 13853-13872	3
710	Apolipoprotein E e4-related effects on cognition are limited to the Alzheimer's disease spectrum. 2021 , 1	
709	Should We Open Fire on Microglia? Depletion Models as Tools to Elucidate Microglial Role in Health and Alzheimer's Disease. 2021 , 22,	2
708	New RNA-Based Breakthroughs in Alzheimer's Disease Diagnosis and Therapeutics. 2021 , 13,	2
707	Age-related episodic memory decline and the role of amyloid- β a systematic review. 2021 , 15, 299-313	1
706	Exploration of Alzheimer's Disease MRI Biomarkers Using APOE4 Carrier Status in the UK Biobank.	0
705	The effects of cerebral amyloidopathy on regional glucose metabolism in older adults with depression and mild cognitive impairment while performing memory tasks. 2021 , 54, 6663-6672	
704	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. 2021 ,	4
703	Content-specific vulnerability of recent episodic memories in Alzheimer's disease. 2021 , 160, 107976	0
702	Perioperative neurocognitive and functional neuroimaging trajectories in older APOE4 carriers compared with non-carriers: secondary analysis of a prospective cohort study. 2021 , 127, 917-928	1
701	Transition from mild cognitive impairment to normal cognition: Determining the predictors of reversion with multi-state Markov models. 2021 ,	2
700	Rates of longitudinal change in F-flortaucipir PET vary by brain region, cognitive impairment, and age in atypical Alzheimer's disease. 2021 ,	0

699	Biomarkers of Neurodegenerative Diseases. 2021 , 7, 341-353	
698	T2 heterogeneity as an in vivo marker of microstructural integrity in medial temporal lobe subfields in ageing and mild cognitive impairment. 2021 , 238, 118214	
697	Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances. 2021 , 92, 1231-1241	14
696	Functional co-activation of the default mode network in APOE ε-carriers: A replication study. 2021 , 240, 118304	2
695	Opportunities and Barriers for Adoption of a Decision-Support Tool for Alzheimer's Disease. 2021 , 2, 1-19	0
694	Thionine-functionalized three-dimensional carbon nanomaterial-based aptasensor for analysis of Aβ oligomers in serum. 2021 , 1183, 338990	2
693	Alzheimer's disease: Is there a role for galectins?. 2021 , 909, 174437	1
692	Relationships between βAmyloid and tau in an elderly population: An accelerated failure time model. 2021 , 242, 118440	1
691	Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [F]-AV-1451 PET data. 2021 , 243, 118553	4
690	Label-free detection of βAmyloid (1-42) in plasma using electrospun SnO2 nanofiber based electro-analytical sensor. 2021 , 346, 130522	5
689	Using big data methods to understand Alzheimer's disease. 2022 , 125-149	0
688	Basolateral amygdala stimulation plus water maze training restore dentate gyrus LTP and improve spatial learning and memory. 2022 , 417, 113589	0
687	Personalized brain models identify neurotransmitter receptor changes in Alzheimer's disease. 2021 , ,	3
686	Regression and Classification of Alzheimers Disease Diagnosis using NMF-TDNet Features from 3D Brain MR Image. 2021 , PP,	4
685	Modeling autosomal dominant Alzheimer's disease with machine learning. 2021 , 17, 1005-1016	5
684	Classification of Mild Cognitive Impairment With Multimodal Data Using Both Labeled and Unlabeled Samples. 2021 , 18, 2281-2290	1
683	Sleep quality and cortical amyloid-β deposition in postmenopausal women of the Kronos early estrogen prevention study. 2021 , 32, 326-331	0
682	Evaluation of the ATN model in a longitudinal memory clinic sample with different underlying disorders. 2021 , 13, e12031	0

681	Training the functionality of daily life. A new neuroscientific paradigm of cognitive training. 2021 , 439-445	
680	Alzheimer's disease: neuropathology, neuropsychological differential diagnosis, and treatment. 2021 , 57-128	
679	Network-constrained technique to characterize pathology progression rate in Alzheimer's disease. 2021 , 3, fcab144	0
678	Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals. 2021 , 13, e12198	
677	Assessment of Leisure Time Physical Activity and Brain Health in a Multiethnic Cohort of Older Adults. 2020 , 3, e2026506	6
676	Drug Development and Alzheimer's Disease. 923-941	0
675	Complex interactions underlie racial disparity in the risk of developing Alzheimer's disease dementia. 2020 , 16, 589-597	6
674	Cognitive indicators of transition to preclinical and prodromal stages of Alzheimer's disease in Down syndrome. 2020 , 12, e12096	9
673	Movement Disorders in Alzheimer's Disease. 2014 , 129-140	1
672	Brain Imaging in People with HIV. 2015 , 745-759	1
671	Nutrition and Cognitive Decline in Older Persons: Bridging the Gap Between Epidemiology and Intervention Studies. 2014 , 395-414	2
670	A Mixed-Effects Model with Time Reparametrization for Longitudinal Univariate Manifold-Valued Data. 2015 , 24, 564-75	9
669	Multiple Orderings of Events in Disease Progression. 2015 , 24, 711-22	18
668	Joint Learning of Multiple Longitudinal Prediction Models by Exploring Internal Relations. 2015 , 330-337	8
667	The Aged Dog as a Natural Model of Alzheimer's Disease Progression. 2017 , 69-92	2
666	A Vertex Clustering Model for Disease Progression: Application to Cortical Thickness Images. 2017 , 134-145	4
665	Prediction of Amyloidosis from Neuropsychological and MRI Data for Cost Effective Inclusion of Pre-symptomatic Subjects in Clinical Trials. 2017 , 357-364	1
664	FreeSurfer Automatic Brain Segmentation Adaptation to Medial Temporal Lobe Structures: Volumetric Assessment and Diagnosis of Mild Cognitive Impairment. 2011 , 112-119	1

663	A Unified Image Registration Framework for ITK. 2012 , 266-275	4
662	Machine Learning Techniques for AD/MCI Diagnosis and Prognosis. 2014 , 147-179	7
661	Neuroimaging Findings in Mild Cognitive Impairment. 2014 , 271-307	1
660	Demenz. 2017 , 1377-1465	1
659	Ginkgo biloba Extract EGb 761 : From an Ancient Asian Plant to a Modern European Herbal Medicinal Product. 2013 , 431-470	13
658	Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease. 2019 , 1184, 145-166	6
657	Amyloid- and Tau at the 'Crossroads of Alzheimer's Disease. 2019 , 1184, 187-203	48
656	Diffusion-weighted imaging (DWI) tractography and Alzheimer's disease. 2020 , 313-325	1
655	Auditory event-related potentials in individuals with subjective and mild cognitive impairment. 2020 , 391, 112700	3
654	Mathematical analysis for stochastic model of Alzheimer's disease. 2020 , 89, 105347	5
653	Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin. 2017 , 8, 131-138	57
652	Development of a histologically validated segmentation protocol for the hippocampal body. 2017 , 157, 219-232	8
651	Associations between reaction time measures and white matter hyperintensities in very old age. 2017 , 96, 249-255	9
650	Alzheimer's disease. 80-108	1
649	How technology is reshaping cognitive assessment: Lessons from the Framingham Heart Study. 2017 , 31, 846-861	23
648	Failure to stop autocorrect errors in reading aloud increases in aging especially with a positive biomarker for Alzheimer's disease. 2020 , 35, 1016-1025	3
647	Mental Disorders Across the Life Span and the Role of Executive Function Networks. 2012 , 245-268	1
646	Brain-behaviour associations and neural representations of emotions in frontotemporal dementia. 2020 , 143, e17	2

645	Mechanical property alterations across the cerebral cortex due to Alzheimer's disease. 2020 , 2, fcz049	23
644	Beyond cardiovascular medicine: potential future uses of icosapent ethyl. 2020 , 22, J54-J64	4
643	From Reproducibility to Translation in Neurodegenerative Disease. 2017 , 58, 106-114	6
642	Modeling Alzheimer Disease Through Functional Independence and Participation. 2017 , 31, 218-224	6
641	Functional Decline and Body Composition Change in Older Adults With Alzheimer Disease: A Retrospective Cohort Study at a Japanese Memory Clinic. 2021 , 35, 36-43	3
640	Anterolateral entorhinal-hippocampal imbalance in older adults disrupts object pattern separation.	1
639	APOE interacts with tau PET to influence memory independently of amyloid PET.	2
638	OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease.	81
637	Amyloid- β /CSF/PET discordance vs tau load 5 years later: It takes two to tangle.	1
636	Whole brain optoacoustic tomography reveals strain-specific regional beta-amyloid densities in Alzheimer's disease amyloidosis models.	8
635	A meta-analysis of epigenome-wide association studies in Alzheimer's disease highlights novel differentially methylated loci across cortex.	8
634	Functional brain age prediction suggests accelerated aging in preclinical familial Alzheimer's disease, irrespective of fibrillar amyloid-beta pathology.	3
633	Single-soma transcriptomics of tangle-bearing neurons in Alzheimer's disease reveals the signatures of tau-associated synaptic dysfunction.	12
632	Alterations in resting-state network dynamics along the Alzheimer's disease continuum: a combined MEG-PET/MR approach.	2
631	Time between milestone events in the Alzheimer's disease amyloid cascade.	1
630	Heightened β adrenergic receptor function in the TgF344-AD rat model drives synaptic potentiation and supports learning and memory.	0
629	Multi-cellular communities are perturbed in the aging human brain and with Alzheimer's disease.	4
628	Diagnosis and Prognosis Using Machine Learning Trained on Brain Morphometry and White Matter Connectomes.	1

627	Multimodal Hippocampal Subfield Grading For Alzheimer’s Disease Classification.	4
626	MRI and cognitive scores complement each other to accurately predict Alzheimer’s dementia 2 to 7 years before clinical onset.	1
625	Predicting Alzheimer’s disease progression using deep recurrent neural networks.	3
624	Amyloid duration is associated with preclinical cognitive decline and tau PET.	3
623	Brain investigation and brain conceptualization. 2013 , 28, 175-90	13
622	Study on discrimination of Alzheimer’s disease states using an ensemble neural network’s model. 2019 ,	1
621	Visual impairment and posterior cortical atrophy preceding rapid progressive dementia. 2013 , 2013,	3
620	Multimodal analysis using [C]PiB-PET/MRI for functional evaluation of patients with Alzheimer’s disease. 2020 , 10, 30	11
619	Longitudinal [F]FDG-PET/CT analysis of the glucose metabolism in ApoE-deficient mice. 2020 , 10, 119	1
618	[C]PiB amyloid quantification: effect of reference region selection. 2020 , 10, 123	4
617	Alzheimer Disease. 2016 , 22, 419-34	62
616	Different Cortical Thinning Patterns Depending on Their Prognosis in Individuals with Subjective Cognitive Decline. 2019 , 18, 113-121	3
615	Investigation of the Correlation between Seoul Neuropsychological Screening Battery Scores and the Gray Matter Volume after Correction of Covariates of the Age, Gender, and Genotypes in Patients with AD and MCI. 2013 , 17, 294	5
614	Selective disruption of the cerebral neocortex in Alzheimer’s disease. 2010 , 5, e12853	60
613	Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer’s disease diagnosis and prognosis. 2011 , 6, e18850	168
612	In vivo detection of amyloid- β deposits using heavy chain antibody fragments in a transgenic mouse model for Alzheimer’s disease. 2012 , 7, e38284	30
611	Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. 2012 , 7, e47905	40
610	Transcriptional alterations related to neuropathology and clinical manifestation of Alzheimer’s disease. 2012 , 7, e48751	27

609	Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials. 2013 , 8, e58816	33
608	Prevalence of Alzheimer's pathologic endophenotypes in asymptomatic and mildly impaired first-degree relatives. 2013 , 8, e60747	13
607	Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. 2013 , 8, e63644	271
606	Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation. 2013 , 8, e64314	31
605	The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study. 2014 , 9, e86558	82
604	Differential white matter connectivity in early mild cognitive impairment according to CSF biomarkers. 2014 , 9, e91400	12
603	Aminostyrylbenzofuran directly reduces oligomeric amyloid- β and reverses cognitive deficits in Alzheimer transgenic mice. 2014 , 9, e95733	9
602	Modeling test and treatment strategies for presymptomatic Alzheimer disease. 2014 , 9, e114339	3
601	Effect of APOE and CD33 on Cognitive Decline. 2015 , 10, e0130419	12
600	A Subset of Cerebrospinal Fluid Proteins from a Multi-Analyte Panel Associated with Brain Atrophy, Disease Classification and Prediction in Alzheimer's Disease. 2015 , 10, e0134368	21
599	Age and Vascular Burden Determinants of Cortical Hemodynamics Underlying Verbal Fluency. 2015 , 10, e0138863	17
598	Learning Biomarker Models for Progression Estimation of Alzheimer's Disease. 2016 , 11, e0153040	16
597	Vocabulary Size in Speech May Be an Early Indicator of Cognitive Impairment. 2016 , 11, e0155195	21
596	The nonlinear relationship between cerebrospinal fluid A β 2 and tau in preclinical Alzheimer's disease. 2018 , 13, e0191240	23
595	Functional connectivity of white matter as a biomarker of cognitive decline in Alzheimer's disease. 2020 , 15, e0240513	9
594	Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force. 2015 , 2, 128-135	24
593	Cognitive/Clinical Endpoints for Pre-Dementia AD Trials. 2015 , 2, 82-84	7
592	EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials. 2017 , 4, 116-124	15

591	Magnetic resonance imaging texture predicts progression to dementia due to Alzheimer disease earlier than hippocampal volume. 2020 , 45, 7-14	15
590	The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease. 2011 , 49, 375-83	66
589	Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease. 2020 , 16, e9356	47
588	Decreased plasmatic spermidine and increased spermine in mild cognitive impairment and Alzheimer's disease patients. 2019 , 46, 120-124	9
587	Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges. 2020 , 42, 431-441	18
586	Sleep and Alzheimer's Disease. 2015 , 6, 1-9	2
585	Neurofilament light chain plasma concentration predicts neurodegeneration and clinical progression in nondemented elderly adults. 2019 , 11, 6904-6914	18
584	Fasting blood glucose and cerebrospinal fluid Alzheimer's biomarkers in non-diabetic cognitively normal elders: the CABLE study. 2020 , 12, 4945-4952	4
583	MiR-340 Reduces the Accumulation of Amyloid- β Through Targeting BACE1 (Bite Amyloid Precursor Protein Cleaving Enzyme 1) in Alzheimer's Disease. 2020 , 17, 86-92	9
582	Structural MRI Predictors of Late-Life Cognition Differ Across African Americans, Hispanics, and Whites. 2015 , 12, 632-9	54
581	Association Between Anemia and Dementia: A Nationwide, Populationbased Cohort Study in Taiwan. 2020 , 17, 196-204	6
580	Exosome and Biomimetic Nanoparticle Therapies for Cardiac Regenerative Medicine. 2020 , 15, 674-684	5
579	Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. 2010 , 9, 140-8	59
578	Cerebrospinal Fluid Markers of Synaptic Injury and Functional Connectivity in Alzheimer Disease: Protocol for a Cross-Sectional Study. 2019 , 8, e14302	1
577	Cut-Off Scores of an Olfactory Function Test for Mild Cognitive Impairment and Dementia. 2020 , 17, 1021-1030	3
576	Cognitive function improvement with astaxanthin and tocotrienol intake: a randomized, double-blind, placebo-controlled study. 2020 , 67, 307-316	11
575	Cognitive Reserve, Brain Reserve, APOE ϵ 4, and Cognition in Individuals with Subjective Cognitive Decline in the SILCODE Study. 2020 , 76, 249-260	5
574	Quality Reporting of Radiomics Analysis in Mild Cognitive Impairment and Alzheimer's Disease: A Roadmap for Moving Forward. 2020 , 21, 1345-1354	9

573	Posterior Cingulate Cortex Network Predicts Alzheimer's Disease Progression. 2020 , 12, 608667	4
572	Relationship between restless legs syndrome and mortality in hemodialysis patients. 2015 , 48, 45-50	1
571	Integrated (18)F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging ((18)F-FDG PET/MRI), a multimodality approach for comprehensive evaluation of dementia patients: A pictorial essay. 2015 , 25, 342-52	6
570	Are Markov and semi-Markov models flexible enough for cognitive panel data?. 2013 , 4,	1
569	Biomarkers for the early diagnosis of Alzheimer's disease: The challenge of XXI century. 2013 , 02, 13-30	8
568	FDG and Amyloid PET in Cognitively Normal Individuals at Risk for Late-Onset Alzheimer's Disease. 2014 , 4, 15-26	23
567	Physical Activity, Mediterranean Diet and Biomarkers-Assessed Risk of Alzheimer's: A Multi-Modality Brain Imaging Study. 2014 , 4, 43-57	41
566	Amyloid positron emission tomography and cognitive reserve. 2015 , 7, 475-83	6
565	Cortical tau deposition follows patterns of entorhinal functional connectivity in aging. 2019 , 8,	38
564	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. 2019 , 8,	27
563	Dendritic complexity change in the triple transgenic mouse model of Alzheimer's disease. 2020 , 8, e8178	3
562	Anti-amyloidogenic indolizino[3,2-]quinolines as imaging probes differentiating dense-core, diffuse, and coronal plaques of amyloid- β . 2021 , 12, 1926-1934	
561	Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease-related declines. 2021 , 13, e12238	0
560	Hippocampus- and Thalamus-Related Fiber-Specific White Matter Reductions in Mild Cognitive Impairment. 2021 ,	0
559	Education as a moderator of middle-age cardiovascular risk factor-old-age cognition relationships: testing cognitive reserve hypothesis in epidemiological study.. 2022 , 51,	0
558	Telephone Interview for Cognitive Status Scores Associate with Cognitive Impairment and Alzheimer's Disease Pathology at Death. 2021 , 84, 609-619	0
557	Mechanism of Cellular Formation and In Vivo Seeding Effects of Hexameric β Amyloid Assemblies. 2021 , 58, 6647-6669	0
556	Premorbid de novo artistic creativity in frontotemporal dementia (FTD) syndromes. 2021 , 128, 1813-1833	2

555 Sequential Pathway Inference for Multimodal Neuroimaging Analysis.. **2022**, 11, e433

554 Revealing the Timeline of Structural MRI Changes in Premanifest to Manifest Huntington Disease. **2021**, 7, e617 2

553 Disturbance of phylogenetic layer-specific adaptation of human brain gene expression in Alzheimer's disease. **2021**, 11, 20200

552 Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious β Secretase (BACE1) Inhibitor for the Prevention of Alzheimer's Disease. **2021**, 64, 15262-15279 2

551 proNGF Measurement in Cerebrospinal Fluid Samples of a Large Cohort of Living Patients With Alzheimer's Disease by a New Automated Immunoassay. **2021**, 13, 741414

550 Identification of early-onset photoreceptor degeneration in transgenic mouse models of Alzheimer's disease. **2021**, 24, 103327 2

549 PET Imaging of Tau Pathology and Amyloid- β and MRI for Alzheimer's Disease Feature Fusion and Multimodal Classification. **2021**, 0

548 Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer's disease. **2021**, 11, 19853 0

547 The Effect of the β Allele on the Cholinergic Circuitry for Subjects With Different Levels of Cognitive Impairment. **2021**, 12, 651388 0

546 Amyloid peptide exerts a rapid induction of Dicer1 protein in neuron via reducing phosphorylation. **2021**, 151, 105210 0

545 Primary Grey Matter Loss. **2011**, 59-135

544 Imaging Biomarkers for Diagnosis, Prognosis and Treatment of Alzheimer's Disease. **2012**, 103-116

543 Alzheimer's Disease and Other Dementias. 293-311

542 Role of Cellular Prion Protein in the Amyloid- β Oligomer Pathophysiology of Alzheimer's Disease. **2013**, 35-48

541 Cholesterol Metabolism and Oxidative Stress in Alzheimer's Disease. **2013**, 119-135

540 Apport de l'imagerie par rsonance magnétique dans la maladie d'Alzheimer. **2013**, 45-61

539 Brain Hypometabolism, Oxidative Stress, Maternal Transmission, and Risk of Late-Onset Alzheimer's Disease. **2013**, 137-157

538 Attivit^ motoria e demenza. **2013**, 483-500

- 537 Changes in cognitive function and functional disability in older adults - Comparison of groups converted and not converted to dementia among cognitively normal older adults -. **2013**, 44, 327-358
- 536 Impact of the IWG/Dubois Criteria for Alzheimer's Disease in Imaging Studies. **2014**, 309-322
- 535 Neural Plasticity and Compensation for Human Brain Damage. **2014**, 10, 101-105 1
- 534 Models for Predicting Risk of Dementia: Predictive Accuracy and Model Complexity. **2014**, 141-159
- 533 PET Imaging of the $\alpha 7$ Nicotinic Acetylcholine Receptors in Alzheimer's Disease. **2014**, 255-269
- 532 Discrete Ladders for Parallel Transport in Transformation Groups with an Affine Connection Structure. **2014**, 243-271
- 531 Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia. **2014**, 131-157
- 530 fMRI in Aging, Alzheimer's Disease and Other Neurodegenerative Conditions. **2014**, 213-254
- 529 Cognitive Decline Associated with Aging, Alzheimer's Disease and Cerebrovascular Risk: Advantages of Dynamic Imaging with MEG. **2014**, 657-676
- 528 Imaging of the Serotonin System: Radiotracers and Applications in Memory Disorders. **2014**, 669-686 0
- 527 Tracking the Progression. **2014**, 23-26
- 526 Aberrant Gray Matter Structure Associated with Sleep Disturbance in the Drug Naïve Subjects with Alzheimer's Disease. **2014**, 5, 43-48
- 525 Alzheimer's Disease and Other Neurodegenerative Disorders. **2015**, 329-351
- 524 Recent Update of Clinical Drug Trials in Alzheimer's Disease. **2015**, 33, 252-258
- 523 Alzheimer Disease. **2016**, 38-43
- 522 Encyclopedia of Geropsychology. **2016**, 1-13
- 521 Demenz. **2016**, 1-89
- 520 Encyclopedia of Clinical Neuropsychology. **2016**, 1-8

- 519 Alzheimer's disease as a neuropathological continuum in clinical practice.. **2016**, 17, 305-309
- 518 Biomarkers of Alzheimer's Disease. **2017**, 1-35
- 517 [Neuroimaging and molecular biomarkers of dementia]. **2017**, 117, 16-22
- 516 Biomarkers of Alzheimer's Disease. **2017**, 105-139
- 515 Effects of Formaldehyde on Protein (Tau) Aggregation and Cytotoxicity. **2017**, 121-142
- 514 Approaches to Brain Tissue Quantification with Comparison on Supporting the Detection of Age-Related Dementia in MRI. **2017**, 78-85
- 513 Verubecestat. **2017**, 204-251
- 512 Encyclopedia of Geropsychology. **2017**, 256-268
- 511 Identifying cognitive impairment in type 2 diabetes with functional connectivity: a multivariate pattern analysis of resting state fMRI data. **2017**,
- 510 Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition.
- 509 Alzheimer's Disease Modelling and Staging Through Independent Gaussian Process Analysis of Spatio-Temporal Brain Changes. **2018**, 3-14
- 508 Biomarqueurs du liquide c brospinal dans la maladie d'Alzheimer. **2018**, 202, 307-320
- 507 Encyclopedia of Clinical Neuropsychology. **2018**, 147-154
- 506 Data-driven models of dominantly-inherited Alzheimer's disease progression.
- 505 Alzheimer Disease. **2018**, 316-321
- 504 Reproducible evaluation of classification methods in Alzheimer's disease: framework and application to MRI and PET data. 2
- 503 Computational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer's Disease. 1
- 502 Longitudinal increase in sleep problems is related to amyloid deposition in cortical regions with high HOMER1 gene expression.

- 501 Diagnosis and Prognosis of Alzheimer’s Disease Using Brain Morphometry and White Matter Connectomes.
- 500 Interpretable classification of Alzheimer’s disease pathologies with a convolutional neural network pipeline.
- 499 Multi-modal Latent Factor Exploration of Atrophy, Cognitive and Tau Heterogeneity in Alzheimer’s Disease. 1
- 498 Cognitive Decline Associated with Aging, Alzheimer’s Disease, and Cerebrovascular Risk: Advantages of Dynamic Imaging with MEG. **2019**, 1099-1119
- 497 Diagnosis of Alzheimer’s Disease Using Brain Imaging: State of the Art. **2019**, 129-149
- 496 Aβ-positivity Predicts Cognitive Decline but Cognition Also Predicts Progression to Aβ-positivity. 1
- 495 Constraining Disease Progression Models Using Subject Specific Connectivity Priors. **2019**, 106-116 1
- 494 Editorial: A Turning Point in Alzheimer’s Research: Harmonized Research Strategies and Novel Investments in Public Health Infrastructure Are Reenergizing the Field, and Rekindling Hope for Those Affected by Alzheimer’s and Related Dementias. **2019**, 6, 214-216
- 493 Disease Knowledge Transfer across Neurodegenerative Diseases. **2019**, 11765, 860-868 2
- 492 Grant Report on PREDICT-AD/FTD: Multimodal Imaging Prediction of AD/FTD and Differential Diagnosis. **2019**, 4, 3
- 491 Radionuclide Imaging for Non-tumor Diseases of the Brain. **2019**, 391-412
- 490 Patient-Tailored, Connectivity-Based Forecasts of Spreading Brain Atrophy. 0
- 489 Cognitive Decline Associated with Aging, Alzheimer’s Disease, and Cerebrovascular Risk: Advantages of Dynamic Imaging with MEG. **2019**, 1-20 1
- 488 Role of imaging in Alzheimer’s disease. **2019**, 12, 106
- 487 A quantitative model of human neurodegenerative diseases involving protein aggregation.
- 486 SNIPE score can capture prodromal Alzheimer’s in cognitively normal subjects. 2
- 485 Modeling longitudinal imaging biomarkers with parametric Bayesian multi-task learning.
- 484 Cerebrospinal Fluid Markers of Synaptic Injury and Functional Connectivity in Alzheimer Disease: Protocol for a Cross-Sectional Study (Preprint).

- 483 Anosognosia como sntoma inicial de la enfermedad de Alzheimer. A propósito de un caso. **2019**, 26, 62-65
- 482 Predicting dysfunctional age-related task activations from resting-state network alterations. 0
- 481 Mathematical model shows how sleep may affect amyloid fibrillization. 0
- 480 Functional connectivity between the entorhinal and posterior cingulate cortices associated with navigation impairment following path integration in at-genetic-risk Alzheimer's disease. 2
- 479 Isolation housing exacerbates Alzheimer's Disease phenotype in aged APP KI mice.
- 478 The Essence of Geriatric Medicine Required for Rehabilitation Medicine. **2019**, 56, 1020-1026
- 477 Transfer Learning for Predicting Conversion from Mild Cognitive Impairment to Dementia of Alzheimer's Type based on 3D-Convolutional Neural Network. 1
- 476 Radial diffusivity is the best global biomarker able to discriminate healthy elders, mild cognitive impairment, and Alzheimer's disease: A diagnostic study of DTI-derived data. **2020**, 68, 427-434 4
- 475 Greater Effect of Polygenic Risk Score for Alzheimer's Disease Among Younger Cases who are Apolipoprotein E- ϵ Carriers.
- 474 Functional connectivity of white matter as a biomarker of cognitive decline in Alzheimer's disease.
- 473 Clinical and biomarker changes in sporadic Alzheimer's disease.
- 472 Causal evidence of network communication in whole-brain dynamics through a multiplexed neural code.
- 471 Clinical Topics in Old Age Psychiatry. **2020**,
- 470 Connectome-mediated prediction of future tau-PET burden in Alzheimer's disease. 1
- 469 Predicting future regional tau accumulation in asymptomatic and early Alzheimer's disease. 1
- 468 Early Diagnosis of Alzheimer's Disease - Blessing or Curse for Patients?. **2021**, 12, 234-236
- 467 The protective impact of education on brain structure and function in Alzheimer's disease. **2021**, 21, 423 0
- 466 Adaptive data-driven selection of sequences of biological and cognitive markers in clinical diagnosis of dementia. 1

465	Analysis of Immune-related Key Genes in Alzheimer's Disease. 2021 ,	1
464	Prediction of Alzheimer's Disease Progression Based on Magnetic Resonance Imaging. 2021 , 12, 4209-4223	2
463	Distance Assessment for Detecting Cognitive Impairment in Older Adults: A Systematic Review of Psychometric Evidence. 2020 , 49, 456-470	7
462	The cross-sectional association between mean corpuscular volume level and cognitive function in Chinese over 45 years old: Evidence from the China Health and Retirement Longitudinal Study. 2020 , 15, e0243227	1
461	Memory precision of object-location binding is unimpaired in APOE ϵ -carriers with spatial navigation deficits.	
460	Comparison of visual criteria for amyloid-PET reading: could criteria merging reduce inter-rater variability?. 2020 , 64, 414-421	3
459	Mild and moderate cognitive impairment and mortality among Brazilian older adults in long-term follow-up: The Bambui Health Aging Study. 2020 , 42, 583-590	2
458	Assessing clinical progression from subjective cognitive decline to mild cognitive impairment with incomplete multi-modal neuroimages. 2021 , 75, 102266	3
457	Alzheimer Dementia and Microvascular Pathology: Blood-Brain Barrier Permeability Imaging. 2020 , 81, 488	2
456	Multivariate Data Analysis and Machine Learning for Prediction of MCI-to-AD Conversion. 2020 , 1194, 81-103	2
455	Multiplex Connectome Changes across the Alzheimer's Disease Spectrum Using Gray Matter and Amyloid Data.. 2022 ,	1
454	HMPAO-SPECT Can Discriminate between Patients with Subjective Cognitive Complaints with and without Cognitive Deficits and those with Mild Cognitive Impairment. 2019 , 16, 843-851	1
453	Centenarians as Models of Resistance and Resilience to Alzheimer's Disease and Related Dementias. 2020 , 2,	3
452	Multimodal magnetic resonance imaging predicts regional amyloid- β burden in the brain.	
451	Linking gradient echo plural contrast imaging metrics of tissue microstructure with Alzheimer disease. 2020 , 507-519	
450	Utility of ALBA screening instrument. 2020 , 411-427	1
449	Revisiting Alzheimer's Disease. 2020 , 137-155	
448	Patterns of glucose hypometabolism in Down syndrome resemble sporadic Alzheimer's disease except for the putamen. 2020 , 12, e12138	2

- 447 Executive Summary of the 2019 International Conference of Korean Dementia Association: Exploring the Novel Concept of Alzheimer's Disease and Other Dementia: a Report from the Academic Committee of the Korean Dementia Association. **2020**, 19, 39-53 1
- 446 A History of Antidementic Drug Development in Japan. **2020**, 34, 152 1
- 445 Treating Medical Comorbidities Associated with Dementia Among Latinos. **2020**, 69-89
- 444 Neuroimaging Outcomes of Cognitively Oriented Treatments in Older Adults Across the Alzheimer's Disease Spectrum. **2020**, 69-89
- 443 Les nouveaux traitements de la maladie d'Alzheimer. **2020**, 204, 237-247 2
- 442 DNA Methylation in Genetic and Sporadic Forms of Neurodegeneration: Lessons from Alzheimer's, Related Tauopathies and Genetic Tauopathies. **2021**, 10, 3
- 441 Brain geometry matters in Alzheimer's disease progression: a simulation study.
- 440 Predicting the future development of mild cognitive impairment in the cognitively healthy elderly.
- 439 Multimodal imaging improves brain age prediction and reveals distinct abnormalities in patients with psychiatric and neurological disorders. 0
- 438 Amyloid imaging in Alzheimer's disease: A literature review.
- 437 AI Imaging in Aging, Alzheimer's Disease, and Other Neurodegenerative Conditions. **2021**, 283-343
- 436 PET Imaging of the $\alpha 7$ * Nicotinic Acetylcholine Receptors in Alzheimer's Disease.
- 435 Impact of the New Conceptual Framework of Alzheimer's Disease in Imaging Studies. **2021**, 427-451
- 434 Imaging of the Serotonin System: Radiotracers and Applications in Memory Disorders. **2021**, 891-910
- 433 Medial Temporal Atrophy Alone is Insufficient to Predict Underlying Alzheimer's Disease Pathology. **2020**, 41, 352-358 1
- 432 T2 heterogeneity as an in vivo marker of microstructural integrity in medial temporal lobe subfields in ageing and mild cognitive impairment.
- 431 Nutrient signaling pathways regulate amyloid clearance and synaptic loss in Alzheimer's disease.
- 430 Identification of novel Alzheimer's disease genes co-expressed with TREM2. 0

- 429 Age-related Changes in Memory for Object and Position-In-Context.
- 428 Voxel-based morphometry focusing on medial temporal lobe structures has a limited capability to detect amyloid β an Alzheimer's disease pathology. **2020**, 12, 19701-19710
- 427 Predicting the Progression of Mild Cognitive Impairment Using Machine Learning: A Systematic, Quantitative and Critical Review.
- 426 FDG- and amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts?. **2011**, 55, 250-64 29
- 425 Plasma acetylcholinesterase activity correlates with intracerebral β amyloid load. **2013**, 10, 48-56 22
- 424 Mediterranean Diet and Magnetic Resonance Imaging-Assessed Brain Atrophy in Cognitively Normal Individuals at Risk for Alzheimer's Disease. **2014**, 1, 23-32 75
- 423 Octodon degus: a strong attractor for Alzheimer research. **2013**, 4, 91-6 11
- 422 Impact of C24:0 on actin-microtubule interaction in human neuronal SK-N-BE cells: evaluation by FRET confocal spectral imaging microscopy after dual staining with rhodamine-phalloidin and tubulin tracker green. **2015**, 30, 33-46 5
- 421 Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores. **2016**, 89, 5-21 57
- 420 Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Emergence of the Solution to an Important Unmet Need. **2013**, 24, 97-104 3
- 419 Alzheimer's Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station. **2017**, 90, 45-61 17
- 418 Tau and Pet/Mri Imaging Biomarkers for Detecting and Diagnosing Early Dementia. **2017**, 2, 2 2
- 417 Detection of Alzheimer's Disease. **2018**, 91, 291-300 17
- 416 Innate Immunity and Cell Death in Alzheimer's Disease. **2021**, 13, 17590914211051908
- 415 The SarcoEndoplasmic Reticulum Calcium ATPase (SERCA) pump: a potential target for intervention in aging and skeletal muscle pathologies. **2021**, 11, 25 3
- 414 A national cohort study (2000-2018) of long-term air pollution exposure and incident dementia in older adults in the United States. **2021**, 12, 6754 6
- 413 Tau Imaging in Neurodegenerative Dementia. **2022**, 111-120
- 412 Loneliness, Not Social Support, Is Associated with Cognitive Decline and Dementia Across Two Longitudinal Population-Based Cohorts. **2021**, 5 5

411	Bioinspired Synthesis of ZnO@polydopamine/Au for Label-Free Photoelectrochemical Immunoassay of Amyloid- β Protein. 2021 , 9, 777344	0
410	Aumento de la confianza en la interpretaci3n del PET con 18F-Florbetaben: 3n machine learning3n basado en la aproximaci3n cuantitativa. 2021 ,	
409	Psychedelic-inspired approaches for treating neurodegenerative disorders. 2021 ,	4
408	Is Amyloid Burden Measured by 18F-Flutemetamol PET Associated with Progression in Clinical Alzheimer's Disease?. 2021 ,	
407	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. 2021 ,	17
406	Mild behavioral impairment correlates of cognitive impairments in older adults without dementia: mediation by amyloid pathology. 2021 , 11, 577	4
405	Urine metabolic profiling of dementia rats with vital energy deficiency using ultra-high-performance liquid chromatography coupled with an orbitrap mass spectrometer. 2021 ,	1
404	Hypothesis: Modulation of microglial phenotype in Alzheimer's disease drives neurodegeneration. 2021 ,	0
403	Pursuit of precision medicine: Systems biology approaches in Alzheimer's disease mouse models. 2021 , 161, 105558	3
402	What can 7T sodium MRI tell us about cellular energy depletion and neurotransmission in Alzheimer's disease?. 2021 , 17, 1843-1854	1
401	Integrating Bio-metabolism and Structural Changes for the Diagnosis of Dementia. 2022 , 169-172	
400	Innate Immunity and Cell Death in Alzheimer's Disease. 2021 , 13, 175909142110519	1
399	Association between serum urate and CSF markers of Alzheimer's disease pathology in a population-based sample of 70-year-olds.. 2021 , 13, e12241	0
398	Toward a Multimodal Computer-Aided Diagnostic Tool for Alzheimer's Disease Conversion.. 2021 , 15, 744190	1
397	A Network-Guided Reaction-Diffusion Model of AT[N] Biomarkers in Alzheimer's Disease. 2020 ,	
396	Chapter 12. The Limits of Biomarkers: Contemporary Re-Phrasings of Canguilhem. 2020 , 469-497	
395	Biomarkers and Precision Medicine in Alzheimer's Disease.. 2021 , 1339, 403-408	0
394	Synapses, Microglia, and Lipids in Alzheimer's Disease.. 2021 , 15, 778822	2

393	Plasma p-tau231, p-tau181, PET biomarkers and cognitive change in older adults.. 2022 ,	3
392	Independent morphological variables correlate with Aging, Mild Cognitive Impairment, and Alzheimer's Disease.	0
391	Association of improved air quality with lower dementia risk in older women.. 2022 , 119,	0
390	Associating Alzheimer's disease pathology with its cerebrospinal fluid biomarkers.. 2022 ,	1
389	Utility of Diffusion Modeling of Cogstate Brief Battery Test Performance in Detecting Mild Cognitive Impairment.. 2022 , 10731911211069089	
388	Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial.. 2022 , 9, 255-261	
387	VGLUT3 neurons in median raphe control the efficacy of spatial memory retrieval via ETV4 regulation of VGLUT3 transcription.. 2022 , 1	0
386	□ 2022 ,	3
385	Multiscale structural mapping of Alzheimer's disease neurodegeneration.. 2022 , 33, 102948	0
384	A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimer's Disease: Towards a More Continuous Approach.. 2022 ,	2
383	Identifying the regional substrates predictive of Alzheimer's disease progression through a convolutional neural network model and occlusion.	
382	Simple Quantification of Surface Uptake in F-18 Florapronol PET/CT Imaging for the Validation of Alzheimer's Disease.. 2022 , 12,	0
381	Quantitative Gradient Echo MRI Identifies Dark Matter as a New Imaging Biomarker of Neurodegeneration that Precedes Tissue Atrophy in Early Alzheimer's Disease.. 2021 ,	0
380	Detection and Quantification of Aβ-40 (APP669-711) in Cerebrospinal Fluid.. 2022 ,	1
379	Application of QPLEX biomarkers in cognitively normal individuals across a broad age range and diverse regions with cerebral amyloid deposition.. 2022 ,	
378	Charting brain growth and aging at high spatial precision.. 2022 , 11,	2
377	Alzheimer's disease susceptibility locus in CD2AP is associated with increased cerebrospinal fluid tau levels in mild cognitive impairment.. 2021 , 136419	
376	Wireless USB-like electrochemical platform for individual electrochemical sensing in microdroplets.. 2022 , 1197, 339526	1

375	Distinctive Temporal Trajectories of Alzheimer’s Disease Biomarkers According to Sex and Genotype: Importance of Striatal Amyloid.. 2022 , 14, 829202	1
374	Stage-Dependent Cerebral Blood Flow and Leukoaraiosis Couplings in Subcortical Ischemic Vascular Disease and Alzheimer’s Disease.. 2022 ,	0
373	Approche clinique des troubles neurocognitifs des pathologies d’égifatives. 2022 , 3, 57-57	
372	Association of Performance on the Financial Capacity InstrumentâShort Form With Brain Amyloid Load and Cortical Thickness in Older Adults. 10.1212/CPJ.0000000000001157	
371	Phosphorylated Neurofilament Heavy Chain: A Potential Diagnostic Biomarker in Amyotrophic Lateral Sclerosis.. 2022 ,	0
370	The spike-and-slab elastic net as a classification tool in Alzheimer’s disease.. 2022 , 17, e0262367	0
369	Orthogonalized Kernel Debiased Machine Learning for Multimodal Data Analysis. 1-15	0
368	Race, sex, and mid-life changes in brain health: Cardia MRI substudy.. 2022 ,	0
367	Artificial Intelligence based Modern Approaches to Diagnose Alzheimer s. 2022 , 2, 1-14	
366	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. 2021 ,	2
365	Amyloid Imaging. 2022 , 161-165	
364	Basic Knowledge of Dementia Treatment required for Neurosurgeons. 2022 , 31, 165-171	
363	Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort.. 2022 , 14, e12298	0
362	The Viability of Treatment Conditioned to the Pathophysiology of Alzheimerâ Disease. 2022 , 31-52	
361	Moderate ethanol consumption interacts with AÎto exacerbate Alzheimerâ-like pathological, behavioral, and metabolic deficits in mice.	
360	Predicting Brain Amyloid-IPET Grades with Graph Convolutional Networks Based on Functional MRI and Multi-Level Functional Connectivity.. 2022 ,	
359	Executive Functions in Alzheimerâ Disease: A Systematic Review. 2022 , 6, 81-99	
358	Image-level trajectory inference of tau pathology using variational autoencoder for Flortaucipir PET.. 2022 , 1	0

357	Alzheimer's disease amyloid- β pathology in the lens of the eye.. 2022 , 108974	1
356	Model of glymphatic clearance of aggregating proteins from the brain interstitium.. 2022 , 105, 024405	0
355	Neural Organoids, a Versatile Model for Neuroscience.. 2022 , 45, 53-64	1
354	Potential Applications of Artificial Intelligence in Clinical Trials for Alzheimer's Disease.. 2022 , 12,	2
353	Operationalising the Centiloid Scale for [18F]florbetapir PET Studies on PET/MR.	
352	The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.. 2022 ,	24
351	An efficient combination of quadruple biomarkers in binary classification using ensemble machine learning technique for early onset of Alzheimer disease.	0
350	Technological Solutions for Diagnosis, Management and Treatment of Alzheimer's Disease-Related Symptoms: A Structured Review of the Recent Scientific Literature.. 2022 , 19,	1
349	Neuropsychiatric Symptoms in Dementia: Considering a Clinical Role for Electroencephalography.. 2022 , appineuropsych21050135	1
348	Neurochemical and cognitive changes precede structural abnormalities in the TgF344-AD rat model.. 2022 , 4, fcac072	0
347	Waste Clearance in the Brain and Neuroinflammation: A Novel Perspective on Biomarker and Drug Target Discovery in Alzheimer's Disease.. 2022 , 11,	0
346	Effect of Denoising and Deblurring F-Fluorodeoxyglucose Positron Emission Tomography Images on a Deep Learning Model's Classification Performance for Alzheimer's Disease.. 2022 , 12,	0
345	Exploring common genetic contributors to neuroprotection from amyloid pathology.. 2022 , 4, fcac066	1
344	Fluid Biomarkers in Alzheimer's Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments.. 2022 , 12,	0
343	Association of Indication for Hospitalization with Subsequent Amyloid PET and MRI Biomarkers.. 2022 ,	
342	A Two-Stage Model for Predicting Mild Cognitive Impairment to Alzheimer's Disease Conversion.. 2022 , 14, 826622	2
341	Investigating the temporal pattern of neuroimaging-based brain age estimation as a biomarker for Alzheimer's Disease related neurodegeneration.	
340	Adverse driving behaviors are associated with sleep apnea severity and age in cognitively normal older adults at risk for Alzheimer's disease.. 2022 ,	0

339	Associations between cerebrospinal fluid markers and cognition in aging and dementia: A systematic review.. 2022,	0
338	Assessment of the In Vivo Relationship Between Cerebral Hypometabolism, Tau Deposition, TSPO Expression, and Synaptic Density in a Tauopathy Mouse Model: a Multi-tracer PET Study.. 2022, 1	0
337	Structural Plasticity of the Hippocampus in Neurodegenerative Diseases.. 2022, 23,	3
336	APOE ϵ , Alzheimer's disease neuropathology and sleep disturbance, in individuals with and without dementia.. 2022, 14, 47	2
335	Metal-Organic Framework Based Drug Delivery for Alzheimer Therapy and Clinical Progress. 2022, 19,	
334	Multicenter F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer's Disease.. 2022, 12,	0
333	Low Subicular Volume as an Indicator of Dementia-Risk Susceptibility in Old Age.. 2022, 14, 811146	1
332	Modifiable lifestyle activities affect cognition in cognitively healthy middle-aged individuals at risk for late-life Alzheimer's Disease.	0
331	Establishing a baseline for human cortical folding morphological variables: a multicenter study.	
330	Immunotherapy for Alzheimer's disease: targeting β amyloid and beyond.. 2022, 11, 18	9
329	Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment.. 2022,	0
328	Development of Alzheimer's Disease Biomarkers: From CSF- to Blood-Based Biomarkers.. 2022, 10,	1
327	Mapping cerebral atrophic trajectory from amnesic mild cognitive impairment to Alzheimer's disease.. 2022,	0
326	Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: an updated instrumental variable meta-analysis.	1
325	The Past, Present and Future of Sleep Measurement in Mild Cognitive Impairment and Early Dementia - Towards a Core Outcome Set: A Scoping Review.. 2022,	0
324	A robust and interpretable machine learning approach using multimodal biological data to predict future pathological tau accumulation.. 2022, 13, 1887	2
323	Biometal Dyshomeostasis in Olfactory Mucosa of Alzheimer's Disease Patients.. 2022, 23,	0
322	Automatic Classification of Subjects of the PSEN1-E280A Family at Risk of Developing Alzheimer's Disease Using Machine Learning and Resting State Electroencephalography.. 2022,	

321	Categorical predictive and disease progression modeling in the early stage of Alzheimer's disease.. 2022 , 109581	0
320	Kinetics of amyloid accumulation in physiological viscosity.. 2022 , 214, 112449	
319	Implementation of Dual Tree Complex Wavelet Transform with Mean Energy Features to detect Alzheimer's Disease. 2021 ,	0
318	Distinct factors drive the spatiotemporal progression of tau pathology in older adults.. 2021 ,	0
317	NRM 2021 Abstract Booklet.. 2021 , 41, 11-309	
316	Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts.	0
315	Validation of Plasma Amyloid- β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.. 2021 ,	7
314	Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in Mild Cognitive Impairment and Alzheimer's Disease: A Meta-Analysis.. 2021 , 8, 757673	0
313	Association of β Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra.. 2021 ,	1
312	Establishing pre-analytical requirements and maximizing peptide recovery in the analytical phase for mass spectrometric quantification of amyloid- β peptides 1-42 and 1-40 in CSF. 2021 ,	0
311	A systematic review on the use of quantitative imaging to detect cancer therapy adverse effects in normal-appearing brain tissue.. 2021 , 35, 163	0
310	Cross-tissue meta-analysis of blood and brain epigenome-wide association studies in Alzheimer's disease.	0
309	Regional A β tau interactions promote onset and acceleration of Alzheimer's disease tau spreading.. 2022 ,	1
308	In-depth insights into Alzheimer's disease by using explainable machine learning approach.. 2022 , 12, 6508	1
307	Plasma Amyloid and in vivo Brain Amyloid in Late Middle-Aged Hispanics.. 2022 ,	
306	Blueberry Supplementation in Midlife for Dementia Risk Reduction.. 2022 , 14,	0
305	Unravelling neural correlates of empathy deficits in Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer's Disease.. 2022 , 113893	1
304	Current trends in blood biomarker detection and imaging for Alzheimer's disease.. 2022 , 210, 114278	1

303 Table_1.docx. **2019,**

302 Table_1.docx. **2018,**

301 Table_1.pdf. **2018,**

300 Table_2.pdf. **2018,**

299 Table_3.pdf. **2018,**

298 Table_4.pdf. **2018,**

297 Table_5.pdf. **2018,**

296 data_sheet_1.xlsx. **2018,**

295 data_sheet_2.xlsx. **2018,**

294 data_sheet_3.xlsx. **2018,**

293 data_sheet_4.xlsx. **2018,**

292 data_sheet_5.xlsx. **2018,**

291 data_sheet_6.xlsx. **2018,**

290 data_sheet_7.xlsx. **2018,**

289 data_sheet_8.xlsx. **2018,**

288 presentation_1.PDF. **2018,**

287 Data_Sheet_1.ZIP. **2019,**

286 Image_1.tif. **2019,**

285 Image_2.tif. **2019**,

284 Image_3.tif. **2019**,

283 Image_4.jpg. **2019**,

282 Table_1.doc. **2019**,

281 Table_2.doc. **2019**,

280 Image_1.JPEG. **2019**,

279 Table_1.DOCX. **2019**,

278 Video_1.AVI. **2020**,

277 Video_2.AVI. **2020**,

276 Table_1.xlsx. **2018**,

275 DataSheet_1.docx. **2020**,

274 Data_Sheet_1.DOCX. **2020**,

273 Image_1.TIF. **2020**,

272 Image_2.TIF. **2020**,

271 Table_1.DOCX. **2020**,

270 Table_2.DOCX. **2020**,

269 Table_1.DOCX. **2020**,

268 Data_Sheet_1.docx. **2019**,

267 Data_Sheet_1.pdf. **2018,**

266 DataSheet1.ZIP. **2018,**

265 Sex- and age-specific associations between cardiometabolic risk and white matter brain age in the UK Biobank cohort.. **2022,** 1

264 A possible blood plasma biomarker for early-stage Alzheimer’s disease.. **2022,** 17, e0267407 0

263 Galantamine nanoparticles outperform oral galantamine in an Alzheimer’s rat model: pharmacokinetics and pharmacodynamics. **2021,** 16, 1281-1296 3

262 Network-wise concordance of multimodal neuroimaging features across the Alzheimer’s disease continuum.. **2022,** 14, e12304 0

261 Sex-Driven Differences in the Effectiveness of Individualized Clinical Management of Alzheimer’s Disease Risk.

260 Nicotinic Acetylcholine Receptors and Microglia as Therapeutic and Imaging Targets in Alzheimer’s Disease.. **2022,** 27, 0

259 Age Related Changes in Muscle Mass and Force Generation in the Triple Transgenic (3xTgAD) Mouse Model of Alzheimer’s Disease.. **2022,** 14, 876816 0

258 Associations Between Dietary Patterns and Neuroimaging Markers: A Systematic Review.. **2022,** 9, 806006 1

257 Effects of a multicomponent day-care program on cerebral blood flow in patients with mild cognitive impairment.. **2022,**

256 PET Imaging of Dementia: Update 2022.. **2022,** 0

255 Increase in Mitochondrial D-Loop Region Methylation Levels in Mild Cognitive Impairment Individuals. **2022,** 23, 5393 0

254 Primitive detection of Alzheimer’s disease using neuroimaging: A progression model for Alzheimer’s disease: Their applications, benefits, and drawbacks. **2022,** 1-14

253 Investigating the Association Between Polygenic Risk Scores for Alzheimer’s Disease With Cognitive Performance and Intrinsic Functional Connectivity in Healthy Adults. **2022,** 14,

252 Molecular insights into cell type-specific roles in alzheimer’s disease: human induced pluripotent stem cell-based disease modeling.. **2022,** 0

251 New PET tracers for dementia evaluation: Coming to your clinic now. 21-29

250 Pratique de l’annonce du diagnostic de la maladie d’Alzheimer. **2022,** 3, 234-234

- 249 Effects of Two Short-Term Aerobic Exercises on Cognitive Function in Healthy Older Adults during COVID-19 Confinement in Japan: A Pilot Randomized Controlled Trial. **2022**, 19, 6202 0
- 248 Association Between Retinal Layer Thickness and Cognitive Decline in Older Adults. 1
- 247 CSF Phosphorylated Tau as an Indicator of Subsequent Tau Accumulation. **2022**, 0
- 246 Targeted Screening for Alzheimer's Disease Clinical Trials Using Data-Driven Disease Progression Models. **2022**, 5, 0
- 245 Patterns of Focal Amyloid Deposition Using 18F-Florbetaben PET in Patients with Cognitive Impairment. **2022**, 12, 1357
- 244 The Relationships Among Metal Homeostasis, Mitochondria, and Locus Coeruleus in Psychiatric and Neurodegenerative Disorders: Potential Pathogenetic Mechanism and Therapeutic Implications. 1
- 243 Neuropsychological Performance Is Correlated With Tau Protein Deposition and Glucose Metabolism in Patients With Alzheimer's Disease. 14, 0
- 242 A History of Senile Plaques: From Alzheimer to Amyloid Imaging. **2022**, 81, 387-413 0
- 241 Annual Trends in the Incidence and Prevalence of Alzheimer's Disease in South Korea: A Nationwide Cohort Study. **2022**, 13, 0
- 240 The revised authorship along with author affiliations. **2022**,
- 239 Genistein effect on cognition in early Alzheimer's disease patients. The GENIAL clinical trial.
- 238 Chemical analysis of amyloid aggregation inhibitors derived from *Geranium thunbergii*. **2022**, 68, 116840
- 237 Histoire naturelle et diagnostic de la maladie d'Alzheimer. **2022**, 143-161
- 236 Some Noncommunicable Diseases of the Central Nervous System with a Possible Infectious Etiology (in Collaboration with V.A. Orlova, I.I. Mikhailova, A.A. Garbuzov, D.A. Khavkina, P.V. Chukhlaev, T.A. Ruzhentsova I. L. Naidenova, A. B. Danilov, A.V. Simonova, E.G. Filatova, I.A. Pavlovsky, O.V. Dystrova, A.M. Zotevalov, S.L. Bezrodny, T.Sh. Sadekov). **2022**, 299-359
- 235 Cerebral A β deposition in an A β precursor protein-transgenic rhesus monkey. **2022**, 2, 100044 1
- 234 Correction of Partial Volume Effect Using CT Images in Brain 18 F-FDG PET. **2022**, 0
- 233 Entorhinal-hippocampal circuit integrity is related to mnemonic discrimination and amyloid- β pathology in older adults. 0
- 232 Non-Communicable Neurological Disorders and Neuroinflammation. 13,

231	Mapping the Genetic-Imaging-Clinical Pathway with Applications to Alzheimer’s Disease. 1-30	0
230	Alterations in protein kinase networks in astrocytes and neurons derived from patients with familial Alzheimer’s Disease.	
229	Functional Connectivity Dynamics Altered of the Resting Brain in Subjective Cognitive Decline. 14,	
228	Effect of the ABCA1 agonist CS-6253 on amyloid- β and lipoprotein metabolism in cynomolgus monkeys. 2022 , 14,	0
227	Multi-Omics-Based Autophagy-Related Untypical Subtypes in Patients with Cerebral Amyloid Pathology. 2201212	0
226	Normalization of MRI T1w between-scan effects for improved longitudinal volumetric estimates.	
225	Posterior cingulate cortex reveals an expression profile of resilience in cognitively intact elders.	0
224	Molecular PET Imaging in Alzheimer’s Disease.	0
223	Differential Diagnosis Between Alzheimer’s Disease-Related Depression and Pseudo-Dementia in Depression: A New Indication for Amyloid- β Imaging?. 2022 , 1-7	
222	Innate Immune Cell Death in Neuroinflammation and Alzheimer’s Disease. 2022 , 11, 1885	3
221	Physical activity is associated with increased resting-state functional connectivity in networks predictive of cognitive decline in clinically unimpaired older adults. 2022 , 14,	
220	Microglia and border-associated macrophages in the central nervous system. 2022 , 181-212	
219	Astragalus mongholicus Bunge (Fabaceae): Bioactive Compounds and Potential Therapeutic Mechanisms Against Alzheimer’s Disease. 13,	0
218	Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer’s Disease: ELISA Development and Clinical Validation. 2022 , 1-10	
217	Horizons in Human Aging Neuroscience: From Normal Neural Aging to Mental (Fr)Agility. 16,	1
216	Traumatic brain injury and post-traumatic stress disorder are not associated with Alzheimer’s disease pathology measured with biomarkers.	1
215	Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer’s Disease Continuum. 14,	1
214	Targeting Microglia in Alzheimer’s Disease: From Molecular Mechanisms to Potential Therapeutic Targets for Small Molecules. 2022 , 27, 4124	1

213	Near-Infrared Fluorescent Probes as Imaging and Theranostic Modalities for Amyloid-Beta and Tau Aggregates in Alzheimer's Disease. 2022 , 65, 8550-8595	0
212	S-EBM: Generalising event-based modelling of disease progression for simultaneous events.	
211	Changes in Biomarkers and Hemodynamics According to Antibiotic Susceptibility in a Model of Bacteremia.	0
210	Apolipoprotein E Genotype e2: Neuroprotection and Its Limits. 14,	0
209	Changes in Brain Metabolism Induced by Metabolic Challenges and Their Beneficial Roles for Brain Aging.	
208	RNASE6 is a novel modifier of APOE- ϵ effects on cognition. 2022 ,	0
207	Brain Amyloid Index as a Probable Marker Bridging Between Subjective Memory Complaint and Objective Cognitive Performance. 16,	
206	Multiscale optical and optoacoustic imaging of amyloid- β deposits in mice.	2
205	White matter microstructural abnormality precedes cortical volumetric decline in Alzheimer's disease: evidence from data-driven disease progression modelling.	0
204	Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia. 2022 , 2022,	0
203	Establishing a Baseline for Human Cortical Folding Morphological Variables: A Multisite Study. 16,	0
202	Effects of aging on functional connectivity in a neurodegenerative risk cohort: resting state versus task measurement using near-infrared spectroscopy. 2022 , 12,	1
201	Does Loss of Integrity of the Cingulum Bundle Link Amyloid- β Accumulation and Neurodegeneration in Alzheimer's Disease?. 2022 , 1-11	
200	Basic lifestyle habits and volume change in total gray matter among community dwelling middle-aged and older Japanese adults. 2022 , 161, 107149	0
199	Mathematical model of Alzheimer's disease with prion proteins interactions and treatment. 2022 , 433, 127377	1
198	Alzheimer diseases. 2023 , 313-336	0
197	The unique effect of TDP-43 on hippocampal subfield morphometry and cognition. 2022 , 103125	
196	A functional connectome signature of blood pressure in >30 000 participants from the UK biobank.	

195	Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts.	4
194	Early alterations in brain glucose metabolism and vascular function in a transgenic rat model of Alzheimer’s disease. 2022 , 102327	0
193	miR-143-3p Inhibits Aberrant Tau Phosphorylation and Amyloidogenic Processing of APP by Directly Targeting DAPK1 in Alzheimer’s Disease. 2022 , 23, 7992	3
192	Molecular signatures underlying neurofibrillary tangle susceptibility in Alzheimer’s disease. 2022 ,	1
191	Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer’s disease: additional results from the AMBAR study.	1
190	Cognitive impact of exposure to airborne particles captured by brain imaging. 2022 , 29-45	
189	From clinical phenotype to proteinopathy: molecular neuroimaging in neurodegenerative dementias. 2022 , 80, 24-35	
188	The fractional amplitude of low-frequency fluctuations signals related to amyloid uptake in high-risk populations—a pilot fMRI study. 14,	
187	Episodic Memory, Hippocampal Volume, and Function for Classification of Mild Cognitive Impairment Patients Regarding Amyloid Pathology. 2022 , 1-12	
186	Consistent Abnormalities in Metabolic Patterns of Lewy Body Dementias.	1
185	Identifying the regional substrates predictive of Alzheimer’s disease progression through a convolutional neural network model and occlusion.	1
184	Cholesterol as a key player in amyloid-mediated toxicity in Alzheimer’s disease. 15,	0
183	The Potential of Small Molecules to Modulate the Mitochondria-Endoplasmic Reticulum Interplay in Alzheimer’s Disease. 10,	0
182	Early diagnosis of Alzheimer’s disease using machine learning: a multi-diagnostic, generalizable approach. 2022 , 14,	1
181	A Mathematical Investigation of Sex Differences in Alzheimer’s Disease. 2022 , 6, 457	
180	Amyloid- β levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy.	0
179	Induction of A Disintegrin and Metalloproteinase with Thrombospondin motifs 1 by a rare variant or cognitive activities reduces hippocampal amyloid- β and consequent Alzheimer’s disease risk. 14,	
178	Effects of Acute Sepsis on Cellular Dynamics and Amyloid Formation in a Mouse Model of Alzheimer’s Disease. 2022 , 44, 3822-3834	0

- 177 Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice. ○
- 176 AT[N]-net. **2022**,
- 175 Cross-tissue analysis of blood and brain epigenome-wide association studies in Alzheimer’s disease. **2022**, 13, ○
- 174 Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan. ○
- 173 Associations of genetic liability for Alzheimer’s disease with cognition and eye movements in a large, population-based cohort study. **2022**, 12, ○
- 172 A systematic review of the validity of non-invasive sleep-measuring devices in mid-to-late life adults: Future utility for Alzheimer’s disease research. **2022**, 101665 ○
- 171 The impact of age-related hearing loss on structural neuroanatomy: A meta-analysis. 13,
- 170 Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint. **2022**, 14,
- 169 Lower Brain Glucose Metabolism in Normal Ageing is Predominantly Frontal and Temporal: A Systematic Review and Pooled Effect Size and Activation Likelihood Estimates Meta-Analyses.
- 168 Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer’s disease.
- 167 Sex differences in patterns of associative memory-related activation in individuals at risk of Alzheimer’s disease. **2022**, 119, 89-101 ○
- 166 Ensemble of convolutional neural networks and multilayer perceptron for the diagnosis of mild cognitive impairment and Alzheimer’s disease. ○
- 165 Enhanced temporal complexity of EEG signals in older individuals with high cognitive functions. 16, ○
- 164 Advances in Alzheimer’s disease research over the past two decades. **2022**, 21, 866-869 ○
- 163 Investigating the temporal pattern of neuroimaging-based brain age estimation as a biomarker for Alzheimer’s Disease related neurodegeneration. **2022**, 263, 119621 ○
- 162 Functional connectivity to the premotor cortex maps onto longitudinal brain neurodegeneration in progressive apraxia of speech. **2022**, 120, 105-116 ○
- 161 Comparison of Cerebral Cortex Transcriptome Profiles in Ischemic Stroke and Alzheimer’s Disease Models. **2022**, 11, 159 ○
- 160 Asymmetric amyloid deposition in preclinical Alzheimer’s disease: A PET study. **2022**, 2, 100048 ○

- 159 Expression of Regional Amyloid Deposition in Centiloid Scale and Used for Quantitative Analysis in Alzheimer's Disease-A Multi-Site Study. ○
- 158 Roadmap for ecosystem-based approach for patients with Alzheimer disease in Russia: current needs, barriers, and possible solutions (resolution of the scientific and practical experts meeting). **2022**, 122, 121 ○
- 157 Potential biomarkers of early diagnosis of Alzheimer's disease. **2022**, 122, 7 ○
- 156 Comparison of Computerized Testing Versus Paper-Based Testing in the Neurocognitive Assessment of Seniors at Risk of Dementia. **2022**, 291-314 ○
- 155 Predicting conversion from mild cognitive impairment to Alzheimer's disease with multimodal latent factors. **2022**, 44, 316-335 ○
- 154 Plasma biomarkers and their correlation in adult children of parents with Alzheimer's disease. 14, ○
- 153 Mapping the association between tau-PET and A β amyloid-PET using deep learning. **2022**, 12, ○
- 152 Screening for preclinical Alzheimer's disease: Deriving optimal policies using a partially observable Markov model. ○
- 151 Fitting Contralateral Neuroanatomical Asymmetry into the Amyloid Cascade Hypothesis. **2022**, 10, 1643 ○
- 150 Enlarged perivascular spaces are associated with decreased brain tau deposition. ○
- 149 Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: An instrumental variable meta-analysis. ○
- 148 Low Plasma Ergothioneine Predicts Cognitive and Functional Decline in an Elderly Cohort Attending Memory Clinics. **2022**, 11, 1717 2
- 147 Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) Study. **2022**, 58, 1179 2
- 146 Diagnostic performance of automated plasma amyloid- β assays combined with pre-analytical immunoprecipitation. **2022**, 14, ○
- 145 Alzheimer's Disease Diagnosis Based on the Amyloid, Tau, and Neurodegeneration Scheme (ATN) in a Real-Life Multicenter Cohort of General Neurological Centers. **2022**, 1-14 ○
- 144 Effectiveness of an integrative medicine approach to improve cognitive dysfunction and dementia: An observational study. **2022**, 101, e30301 ○
- 143 Association between cortisol and aging-related hippocampus volume changes in community-dwelling older adults: a 7-year follow-up study. **2022**, 22, ○
- 142 More than a marker: potential pathogenic functions of MAP2. 15, ○

- 141 Distinct cerebral cortical perfusion patterns in idiopathic normal-pressure hydrocephalus. 0
- 140 Landscape of immune infiltration in entorhinal cortex of patients with Alzheimer's disease. 13, 0
- 139 The relationship between mild cognitive impairment and postoperative delirium undergoing total knee arthroplasty: The PNDABLE study. 14, 0
- 138 How can secondary dementia prevention trials of Alzheimer's disease be clinically meaningful?. 0
- 137 Regulation of microglial physiology by the microbiota. 2022, 14, 0
- 136 In pre-clinical AD small vessel disease is associated with altered hippocampal connectivity and atrophy. 2022, 0
- 135 Association of Alzheimer's disease polygenic risk scores with amyloid accumulation in cognitively intact older adults. 2022, 14, 0
- 134 Synthesizing Images of Tau Pathology from Cross-modal Neuroimaging using Deep Learning. 0
- 133 Mitochondrial DNA variation in Alzheimer's disease reveals a unique microprotein called SHMOOSE. 2
- 132 Neural compensation in manifest neurodegeneration: systems neuroscience evidence from social cognition in frontotemporal dementia. 0
- 131 Multilayer Exponential Family Factor models for integrative analysis and learning disease progression. 0
- 130 Biomarkers Related to Synaptic Dysfunction to Discriminate Alzheimer's Disease from Other Neurological Disorders. 2022, 23, 10831 1
- 129 Mid- and later-life risk factors for predicting neuropathological brain changes associated with Alzheimer's and vascular dementia: The Honolulu Asia Aging Study and the Age, Gene/Environment Susceptibility-Reykjavik Study. 0
- 128 Brain age predicts long-term recovery in post-stroke aphasia. 0
- 127 Müller cell degeneration and microglial dysfunction in the Alzheimer's retina. 2022, 10, 1
- 126 Learning Interpretable Regularized Ordinal Models from 3D Mesh Data for Neurodegenerative Disease Staging. 2022, 115-124 0
- 125 Non-parametric ODE-Based Disease Progression Model of Brain Biomarkers in Alzheimer's Disease. 2022, 95-103 0
- 124 Free water derived by multi-shell diffusion MRI reflects tau/neuroinflammatory pathology in Alzheimer's disease. 2022, 8, 0

123	Correlation of Global and Regional Amyloid Burden by 18F-Florbetaben PET/CT With Cognitive Impairment Profile and Severity. 2022 , 47, 923-930	0
122	In Vivo Detection of Neurofibrillary Tangles by 18F-MK-6240 PET/MR in Patients With Ischemic Stroke. 10.1212/WNL.0000000000201344	0
121	In Vivo Tau Burden Is Associated with Abnormal Brain Functional Connectivity in Alzheimer's Disease: A 18F-Florzolotau Study. 2022 , 12, 1355	1
120	Intensity-dependent gamma electrical stimulation regulates microglial activation, reduces beta-amyloid load, and facilitates memory in a mouse model of Alzheimer's disease.	0
119	Age-linked suppression of lipoxin A4 associates with cognitive deficits in mice and humans. 2022 , 12,	0
118	Retinal Examinations Provides Early Warning of Alzheimer's Disease. 2022 , 1-17	0
117	Deep learning-based diagnosis of Alzheimer's disease using brain magnetic resonance images: an empirical study. 2022 , 12,	1
116	Multi-task Learning with Adaptive Global Temporal Structure for Predicting Alzheimer's Disease Progression. 2022 ,	0
115	Distinct spatiotemporal subtypes of amyloid deposition are associated with diverging disease profiles in cognitively normal and mild cognitive impairment individuals.	0
114	Individual functional parcellation revealed compensation of dynamic limbic network organization in healthy ageing.	0
113	Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates. 2022 , 7,	0
112	Lower brain glucose metabolism in normal ageing is predominantly frontal and temporal: A systematic review and pooled effect size and activation likelihood estimates meta-analyses.	0
111	A Deep Longitudinal Model for Mild Cognitive Impairment to Alzheimer's Disease Conversion Prediction in Low-Income Countries. 2022 , 2022, 1-8	0
110	Cross-sectional and longitudinal association of sleep and Alzheimer biomarkers in cognitively unimpaired adults. 2022 , 4,	0
109	Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE β system.	0
108	A Therapeutic Nanovaccine that Generates Anti-amyloid Antibodies and Amyloid-specific Regulatory T cells for Alzheimer's Disease. 2207719	0
107	Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status. 2022 , 14,	0
106	Plasma P-Tau181 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease. 10.1212/WNL.0000000000201344	0

105	Need for an Update for the Guideline for the Management of Mild Cognitive Impairment. 2022 , 21, 107	0
104	Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer's Disease and Identifying Promising Drug Targets. 2022 , 12, 1676	3
103	Alzheimer's Disease: Treatment Strategies and Their Limitations. 2022 , 23, 13954	0
102	Predictive Power of Cognitive Biomarkers in Neurodegenerative Disease Drug Development: Utility of the P300 Event-Related Potential. 2022 , 2022, 1-13	2
101	Elevated Cortical Tau Positron Emission Tomography Binding in Misery Perfusion: Novel, Puzzling, and Heuristic.	0
100	Brain Aging Among Racially and Ethnically Diverse Middle-Aged and Older Adults.	0
99	Genistein effect on cognition in prodromal Alzheimer's disease patients. The GENIAL clinical trial. 2022 , 14,	1
98	A review on Alzheimer's Disease Classification from Normal Controls and Mild Cognitive Impairment using structural MR Images. 2022 , 109745	1
97	Review of Quantitative Methods for the Detection of Alzheimer's Disease with Positron Emission Tomography. 2022 , 12, 11463	0
96	Association of Longitudinal Cognitive Decline with Diffusion MRI in Gray Matter, Amyloid, and Tau Deposition. 2022 ,	1
95	Hearing impairment is associated with cognitive decline, brain atrophy and tau pathology. 2022 , 86, 104336	2
94	Design, synthesis, and preliminary evaluation of [18F]-aryl flurosulfates PET radiotracers via SuFEX methods for amyloid plaques in Alzheimer's disease. 2022 , 75, 117087	0
93	Herpes simplex virus alters Alzheimer's disease biomarkers - A hypothesis paper.	0
92	Discriminative patterns of white matter changes in Alzheimer's. 2023 , 328, 111576	0
91	Increasing empathic concern relates to salience network hyperconnectivity in cognitively healthy older adults with elevated amyloid-burden. 2023 , 37, 103282	0
90	Alzheimer's disease-like cortical atrophy mediates the effect of air pollution on global cognitive function. 2023 , 171, 107703	0
89	Orthogonal latent space learning with feature weighting and graph learning for multimodal Alzheimer's disease diagnosis. 2023 , 84, 102698	0
88	Functional MRI and ApoE4 genotype for predicting cognitive decline in amyloid-positive individuals. 2022 , 15, 175628642211381	0

87	Longitudinal Changes in Blood Biomarkers of Clinical Alzheimer Disease in a Biracial Population Sample. 10.1212/WNL.0000000000201289	0
86	Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology. 2022 , 2, 1138-1144	2
85	Gut microbiome alterations in preclinical Alzheimer’s disease. 2022 , 17, e0278276	0
84	Association of Klotho Protein Levels and KL-VS Heterozygosity With Alzheimer Disease and Amyloid and Tau Burden. 2022 , 5, e2243232	0
83	Functional network segregation is associated with attenuated tau spreading in Alzheimer’s disease.	0
82	Cerebral Superficial Siderosis.	0
81	Adverse driving behaviors increase over time as a function of preclinical Alzheimer’s disease biomarkers.	0
80	Differential impact of body mass index and leptin on baseline and longitudinal positron emission tomography measurements of the cerebral metabolic rate for glucose in amnesic mild cognitive impairment. 14,	0
79	Impact of Amyloid Pathology in Mild Cognitive Impairment Subjects: The Longitudinal Cognition and Surface Morphometry Data. 2022 , 23, 14635	0
78	Modifiable Lifestyle Activities Affect Cognition in Cognitively Healthy Middle-Aged Individuals at Risk for Late-Life Alzheimer’s Disease. 2022 , 1-14	0
77	Intensity-dependent gamma electrical stimulation regulates microglial activation, reduces beta-amyloid load, and facilitates memory in a mouse model of Alzheimer’s disease.	0
76	Hippocampal subfield volumetry in corticobasal syndrome of diverse underlying pathologies.	0
75	Enlarged perivascular spaces are associated with decreased brain tau deposition.	0
74	Co-alteration Network Architecture of Major Depressive Disorder: A Multi-modal Neuroimaging Assessment of Large-scale Disease Effects.	0
73	Capillary dysfunction correlates with cortical amyloid load in early Alzheimer’s Disease. 2022 ,	0
72	The Early Diagnosis of Alzheimer’s Disease: A Patient-Centred Conversation with the Care Team.	0
71	The use of an individual-based FDG-PET volume of interest approach in mild cognitive impairment: a multi-modality longitudinal follow-up study.	0
70	Oligomer Formation by Amyloid- β 2 in a Membrane-Mimicking Environment in Alzheimer’s Disease. 2022 , 27, 8804	0

- 69 Regression convolutional neural network models implicate peripheral immune regulatory variants in the predisposition to Alzheimer’s disease. ○
- 68 TDP-43 pathology effect on volume and flortaucipir uptake in Alzheimer’s disease. 1
- 67 Recent diagnostic techniques for the detection of Alzheimer’s disease: a short review. ○
- 66 Proteomic clusters underlie heterogeneity in preclinical Alzheimer’s disease progression. ○
- 65 Intraindividual Cognitive Variability and Magnetic Resonance Imaging in Aging American Indians: Data from the Strong Heart Study. **2023**, 1-13 ○
- 64 Increased plasma DYRK1A with aging may protect against neurodegenerative diseases. ○
- 63 Sex differences in the associations between risk for late-life AD, protective lifestyle factors and cognition in mid-life. ○
- 62 A review of biospectroscopy coupled with chemometrics for Alzheimer’s disease diagnosis. 1-39 ○
- 61 Efficacy of Souvenaid® Combined with Acetylcholinesterase Inhibitors in the Treatment of Mild Alzheimer’s Disease. **2023**, 1-11 ○
- 60 Metabotropic glutamate receptor function and regulation of sleep-wake cycles. **2023**, ○
- 59 Ethanol exposure alters Alzheimer’s-related pathology, behavior, and metabolism in APP/PS1 mice. **2023**, 177, 105967 ○
- 58 Towards better interpretable and generalizable AD detection using collective artificial intelligence. **2023**, 104, 102171 ○
- 57 Transcriptome Profile in the Mouse Brain of Hepatic Encephalopathy and Alzheimer’s Disease. **2023**, 24, 675 ○
- 56 Cultivation Factors That Affect Amyloid- β Aggregation Inhibitory Activity in *Perilla frutescens* var. *crispa*. **2023**, 12, 486 ○
- 55 The Role of Lifestyle on Adherence to Treatment in a Sample of Patients with Unipolar and Bipolar Depression. **2023**, 20, 1994 ○
- 54 Robustness of CSF A β 2/40 and A β 2/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes. ○
- 53 Impaired Early Insulin Response to Glucose Load Predicts Episodic Memory Decline: A 10-Year Population-Based Cohort Follow-Up of 45-74-Year-Old Men and Women. **2023**, 1-12 ○
- 52 Computational Investigation of the Interaction Mechanism of Some anti-Alzheimer Drugs with the Acetylcholinesterase Enzyme. **2023**, 8, 11-21 ○

- 51 Individualized network analysis: A novel approach to investigate tau PET using graph theory in the Alzheimer's disease continuum. 17,
- 50 Retinal imaging in animal models: Searching for biomarkers of neurodegeneration. 3,
- 49 Deep brain stimulation for the treatment of Alzheimer's disease: A systematic review and meta-analysis. 17,
- 48 Promotion of astrocyte-neuron glutamate-glutamine shuttle by SCFA contributes to the alleviation of Alzheimer's disease. **2023**, 62, 102690
- 47 The association of dietary and nutrient patterns on neurocognitive decline: A systematic review of MRI and PET studies. **2023**, 87, 101892
- 46 MRI assessment of cerebral perfusion in clinical trials. **2023**, 28, 103506
- 45 MC-RVAE: Multi-channel recurrent variational autoencoder for multimodal Alzheimer's disease progression modelling. **2023**, 268, 119892
- 44 Distinct spatiotemporal subtypes of amyloid deposition are associated with diverging disease profiles in cognitively normal and mild cognitive impairment individuals. **2023**, 13,
- 43 A novel regulator in Alzheimer's disease progression: The astrocyte-derived extracellular vesicles. **2023**, 86, 101871
- 42 A review of the application of three-dimensional convolutional neural networks for the diagnosis of Alzheimer's disease using neuroimaging. **2023**,
- 41 Toxic Tau Aggregation in AD. **2023**, 1-30
- 40 An empirical measure of resilience explains individual differences in the effect of tau pathology on memory change in aging. **2023**, 3, 229-237
- 39 Longitudinal Spatial Relationships Between Atrophy and Hypometabolism Across the Alzheimer's Disease Continuum. **2023**, 92, 513-527
- 38 Pathology vs pathogenesis: Rationale and pitfalls in the clinicopathology model of neurodegeneration. **2023**, 35-55
- 37 Finding the falsification threshold of the toxic proteinopathy hypothesis in neurodegeneration. **2023**, 143-154
- 36 The Alzheimer's Disease Mitochondrial Cascade Hypothesis: A Current Overview. **2023**, 92, 751-768
- 35 The shift to a proteinopenia paradigm in neurodegeneration. **2023**, 23-32
- 34 Distinct CSF biomarker-associated DNA methylation in Alzheimer's disease and cognitively normal subjects.

- 33 Bilateral Hippocampal Volume Mediated the Relationship Between Plasma BACE1 Concentration and Memory Function in the Early Stage of Alzheimer’s Disease: A Cross-Sectional Study. **2023**, 92, 1001-1013 ^o
- 32 A multidimensional ODE-based model of Alzheimer’s disease progression. **2023**, 13, ^o
- 31 Predicting age at Alzheimer’s dementia onset with the cognitive clock. ^o
- 30 Differences between ante mortem Alzheimer’s disease biomarkers in predicting neuropathology at autopsy. ^o
- 29 Selective dysfunction of fast-spiking inhibitory interneurons and disruption of perineuronal nets in a tauopathy mouse model. **2023**, 26, 106342 ^o
- 28 Restless leg syndrome and risk of all-cause dementia: a nationwide retrospective cohort study. **2023**, 15, ^o
- 27 Medicinal Cannabis for Alzheimer’s Disease. **2023**, 1-47 ^o
- 26 Molecular Biomarkers of Neuronal Injury in Epilepsy Shared with Neurodegenerative Diseases. ^o
- 25 Thiophene-based Ligands: Design, Synthesis and Their Utilization for Optical Assignment of Polymorphic Disease Associated Protein Aggregates. ^o
- 24 Beyond the amyloid cascade: An update of Alzheimer’s disease pathophysiology. **2023**, ^o
- 23 Transferability of Alzheimer’s disease progression subtypes to an independent population cohort. **2023**, 271, 120005 ^o
- 22 Low Ankle-Brachial Index Relates to Alzheimer-Signature Cerebral Glucose Metabolism in Cognitively Impaired Older Adults. **2023**, 1-9 ^o
- 21 Multimodality neuroimaging in vascular mild cognitive impairment: A narrative review of current evidence. 15, ^o
- 20 Patient-specific multi-modal modeling uncovers neurotransmitter receptor involvement in motor and non-motor axes of Parkinson’s disease. ^o
- 19 The Future of Cognitive Screening in Neurodegenerative Diseases. **2023**, 1-13 ^o
- 18 A novel method for diagnosing Alzheimer’s disease using deep pyramid CNN based on EEG signals. **2023**, 9, e14858 ^o
- 17 Uncovering heterogeneous cognitive trajectories in mild cognitive impairment: a data-driven approach. **2023**, 15, ^o
- 16 Disease trajectories in elders with suspected non-Alzheimer’s pathophysiology and its comparison with Alzheimer’s disease pathophysiology: a longitudinal study. ^o

- 15 A scoping review of neurodegenerative manifestations in explainable digital phenotyping. **2023**, 9, ○
- 14 Disentangling the distal association between ðAmyloid and tau pathology at varying stages of tau deposition. ○
- 13 Increased plasma DYRK1A with aging may protect against neurodegenerative diseases. **2023**, 13, ○
- 12 Differential involvement of hippocampal subfields in the relationship between Alzheimer’s pathology and memory interference in older adults. **2023**, 15, ○
- 11 Ultra-high field imaging, plasma markers and autopsy data uncover a specific rostral locus coeruleus vulnerability to hyperphosphorylated tau. ○
- 10 Mild Cognitive Impairment in Older Adults. **2023**, 5, 41-53 ○
- 9 Olfactory function reflects episodic memory performance and atrophy in the medial temporal lobe in individuals at risk for Alzheimer’s disease. **2023**, ○
- 8 Distinct CSF biomarker-associated DNA methylation in Alzheimer’s disease and cognitively normal subjects. **2023**, 15, ○
- 7 Accelerated hypometabolism with disease progression associated with faster cognitive decline among amyloid positive patients. 17, ○
- 6 Structural complexity of brain regions in mild cognitive impairment and Alzheimer’s disease. ○
- 5 Adaptive data-driven selection of sequences of biological and cognitive markers in pre-clinical diagnosis of dementia. **2023**, 13, ○
- 4 Large-Scale Integration of Single-Cell RNA-Seq Data Reveals Astrocyte Diversity and Transcriptomic Modules across Six Central Nervous System Disorders. **2023**, 13, 692 ○
- 3 Entorhinal cortex epigenome-wide association study highlights four novel loci showing differential methylation in Alzheimer’s disease. **2023**, 15, ○
- 2 Antibodies Raised Against an AβOligomer Mimic Recognize Pathological Features in Alzheimer’s Disease and Associated Amyloid-Disease Brain Tissue. ○
- 1 Brain function effects of exercise interventions for cognitive decline: a systematic review and meta-analysis. 17, ○